View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
Document And Entity Information - USD ($) $ in Billions	Dec. 31, 2018	Feb. 07, 2019	Jun. 29, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	dhr
Entity Registrant Name	DANAHER CORP /DE/
Entity Central Index Key	0000313616
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 61
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		701,875,340

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and equivalents	$ 787.8	$ 630.3
Trade accounts receivable, less allowance for doubtful accounts of $120.4 and $116.1, respectively	3,489.6	3,521.8
Inventories	1,910.1	1,840.8
Prepaid expenses and other current assets	906.3	857.1
Total current assets	7,093.8	6,850.0
Property, plant and equipment, net	2,511.2	2,454.6
Other long-term assets	648.4	538.3
Goodwill	25,906.0	25,138.6
Other intangible assets, net	11,673.1	11,667.1
Total assets	47,832.5	46,648.6
Current liabilities:
Notes payable and current portion of long-term debt	51.8	194.7
Trade accounts payable	1,712.8	1,509.9
Accrued expenses and other liabilities	3,076.9	3,087.7
Total current liabilities	4,841.5	4,792.3
Other long-term liabilities	5,075.8	5,161.1
Long-term debt	9,688.5	10,327.4
Stockholders’ equity:
Common stock - $0.01 par value, 2.0 billion shares authorized; 817.9 and 812.5 issued; 701.5 and 696.6 outstanding, respectively	8.2	8.1
Additional paid-in capital	5,834.3	5,538.2
Retained earnings	25,163.0	22,806.1
Accumulated other comprehensive income (loss)	(2,791.1)	(1,994.2)
Total Danaher stockholders’ equity	28,214.4	26,358.2
Noncontrolling interests	12.3	9.6
Total stockholders’ equity	28,226.7	26,367.8
Total liabilities and stockholders’ equity	$ 47,832.5	$ 46,648.6

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Trade accounts receivable allowance	$ 120.4	$ 116.1
Common stock par value	$ 0.01	$ 0.01
Common stock shares authorized	2,000.0	2,000.0
Common stock shares issued	817.9	812.5
Common stock shares outstanding	701.5	696.6

Consolidated Statements Of Earnings - USD ($)
shares in Millions, $ in Millions

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Income Statement [Abstract]

Sales

$ 19,893.0

$ 18,329.7

$ 16,882.4

Cost of sales

(8,785.9)

(8,137.2)

(7,547.8)

Gross profit

11,107.1

10,192.5

9,334.6

Operating costs:

Selling, general and administrative expenses

(6,472.1)

(6,073.3)

(5,624.3)

Research and development expenses

(1,231.2)

(1,128.8)

(975.1)

Operating profit

3,403.8

2,990.4

2,735.2

Nonoperating income (expense):

Other income, net

37.2

103.6

239.1

Loss on early extinguishment of borrowings

0.0

(178.8)

Interest expense

(157.4)

(162.7)

(184.4)

Interest income

9.2

7.5

0.2

Earnings from continuing operations before income taxes

3,292.8

2,938.8

2,611.3

Income taxes

(641.9)

(469.0)

(457.9)

Net earnings from continuing operations

2,650.9

2,469.8

2,153.4

Earnings from discontinued operations, net of income taxes

0.0

22.3

400.3

Net earnings

$ 2,650.9

$ 2,492.1

$ 2,553.7

Net earnings per share:

Net earnings per share from continuing operations, basic

$ 3.78

$ 3.55

$ 3.12

Net earnings per share from continuing operations, diluted

3.74

3.50

3.08

Net earnings per share from discontinued operations, basic

0.00

0.03

0.58

Net earnings per share from discontinued operations, diluted

0.00

0.03

0.57

Net earnings per share, basic

3.78

3.58

3.69

^[1]

Net earnings per share, diluted

$ 3.74

$ 3.53

$ 3.65

Average common stock and common equivalent shares outstanding:

Basic

700.6

695.8

691.2

Diluted

710.2

706.1

699.8

[1]	*Net earnings per share amount does not add due to rounding.

Consolidated Statements Of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net earnings	$ 2,650.9	$ 2,492.1	$ 2,553.7
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(632.2)	976.1	(517.3)
Pension and postretirement plan benefit adjustments	(12.7)	71.0	(58.2)
Unrealized loss on available-for-sale securities	(0.8)	(19.6)	(114.8)
Total other comprehensive income (loss), net of income taxes	(645.7)	1,027.5	(690.3)
Comprehensive income	$ 2,005.2	$ 3,519.6	$ 1,863.4

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements Of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Balance at beginning of period, shares at Dec. 31, 2015		801.6
Balance at beginning of period, value at Dec. 31, 2015		$ 8.0	$ 4,981.2	$ 21,012.3	$ (2,311.2)	$ 73.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the year	$ 2,553.7			2,553.7
Other comprehensive income (loss)	(690.3)				(690.3)
Dividends declared				(393.6)
Common stock-based award activity, shares		5.8
Common stock-based award activity, value		$ 0.1	322.6
Common stock issued in connection with LYONs' conversions, shares		0.3
Common stock issued in connection with LYONs' conversions, value		$ 0.0	9.1
Distribution of Fortive Corporation				(2,468.9)	(20.2)
Change in noncontrolling interests						0.3
Balance at ending of period, shares at Dec. 31, 2016		807.7
Balance at ending of period, value at Dec. 31, 2016		$ 8.1	5,312.9	20,703.5	(3,021.7)	74.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the year	2,492.1			2,492.1
Other comprehensive income (loss)	1,027.5				1,027.5
Dividends declared				(389.5)
Common stock-based award activity, shares		4.8
Common stock-based award activity, value		$ 0.0	214.1
Common stock issued in connection with LYONs' conversions, shares		0.0
Common stock issued in connection with LYONs' conversions, value		$ 0.0	12.4
Change in noncontrolling interests			(1.2)			(64.4)
Balance at ending of period, shares at Dec. 31, 2017		812.5
Balance at ending of period, value at Dec. 31, 2017	26,367.8	$ 8.1	5,538.2	22,806.1	(1,994.2)	9.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standards				154.5	(151.2)
Adjusted balance, January 1, 2018, amount		$ 8.1	5,538.2	22,960.6	(2,145.4)	9.6
Net earnings for the year	2,650.9			2,650.9
Other comprehensive income (loss)	(645.7)				(645.7)
Dividends declared				(448.5)
Common stock-based award activity, shares		4.6
Common stock-based award activity, value		$ 0.1	252.8
Common stock issued in connection with acquisitions, shares		0.2
Common stock issued in connection with acquisitions, value		$ 0.0	23.9
Common stock issued in connection with LYONs' conversions, shares		0.6
Common stock issued in connection with LYONs' conversions, value		$ 0.0	19.4
Change in noncontrolling interests						2.7
Balance at ending of period, shares at Dec. 31, 2018		817.9
Balance at ending of period, value at Dec. 31, 2018	$ 28,226.7	$ 8.2	$ 5,834.3	$ 25,163.0	$ (2,791.1)	$ 12.3

Consolidated Statements Of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net earnings	$ 2,650.9	$ 2,492.1	$ 2,553.7
Less: earnings from discontinued operations, net of income taxes	0.0	22.3	400.3
Net earnings from continuing operations	2,650.9	2,469.8	2,153.4
Noncash items:
Depreciation	601.5	577.8	545.0
Amortization	706.2	660.5	583.1
Stock-based compensation expense	151.4	139.4	129.8
Restructuring and impairment charges	2.1	56.1	12.0
Pretax loss on early extinguishment of borrowings	0.0	0.0	178.8
Pretax gain on sales of investments	0.0	(72.8)	(223.4)
Change in deferred income taxes	(195.1)	(426.9)	(383.9)
Change in trade accounts receivable, net	(58.3)	(161.4)	(183.1)
Change in inventories	(143.3)	(27.4)	9.4
Change in trade accounts payable	225.8	(54.4)	78.1
Change in prepaid expenses and other assets	89.7	4.4	(62.4)
Change in accrued expenses and other liabilities	(8.9)	312.7	250.7
Total operating cash provided by continuing operations	4,022.0	3,477.8	3,087.5
Total operating cash provided by discontinued operations	0.0	0.0	434.3
Net cash provided by operating activities	4,022.0	3,477.8	3,521.8
Cash flows from investing activities:
Cash paid for acquisitions	(2,173.3)	(385.8)	(4,880.1)
Payments for additions to property, plant and equipment	(655.7)	(619.6)	(589.6)
Proceeds from sales of property, plant and equipment	6.3	32.6	9.8
Payments for purchases of investments	(148.9)	0.0	0.0
Proceeds from sales of investments	22.2	137.9	264.8
All other investing activities	0.0	(8.5)	21.9
Total investing cash used in continuing operations	(2,949.4)	(843.4)	(5,173.2)
Total investing cash used in discontinued operations	0.0	0.0	(69.8)
Net cash used in investing activities	(2,949.4)	(843.4)	(5,243.0)
Cash flows from financing activities:
Proceeds from the issuance of common stock	96.0	68.8	164.5
Payment of dividends	(433.4)	(378.3)	(399.8)
Payment for purchase of noncontrolling interest	0.0	(64.4)	0.0
Make-whole premiums to redeem borrowings prior to maturity	0.0	0.0	(188.1)
Net proceeds from (repayments of) borrowings (maturities of 90 days or less)	65.7	(3,778.5)	2,218.1
Proceeds from borrowings (maturities longer than 90 days)	0.0	1,782.1	3,240.9
Repayments of borrowings (maturities longer than 90 days)	(507.8)	(668.4)	(2,480.6)
All other financing activities	(17.9)	(59.8)	(27.0)
Total financing cash (used in) provided by continuing operations	(797.4)	(3,098.5)	2,528.0
Cash distributions to Fortive Corporation, net	0.0	0.0	(485.3)
Net cash (used in) provided by financing activities	(797.4)	(3,098.5)	2,042.7
Effect of exchange rate changes on cash and equivalents	(117.7)	130.7	(148.6)
Net change in cash and equivalents	157.5	(333.4)	172.9
Beginning balance of cash and equivalents	630.3	963.7	790.8
Ending balance of cash and equivalents	787.8	630.3	963.7
Supplemental disclosure:
Distribution of noncash net assets to Fortive Corporation	$ 0.0	$ 0.0	$ (1,983.6)

Business And Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business And Summary Of Significant Accounting Policies

BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business—Danaher Corporation (“Danaher” or the “Company”) designs, manufactures and markets professional, medical, industrial and commercial products and services, which are typically characterized by strong brand names, innovative technology and major market positions. The Company operates in four business segments: Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions.

The Company’s Life Sciences segment offers a broad range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The segment is also a leading provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial sectors.

The Company’s Diagnostics segment offers analytical instruments, reagents, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

The Company’s Dental segment offers products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. With leading brand names, innovative technology and significant market positions, the Company is a leading worldwide provider of a broad range of dental consumables, equipment and services, and is dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity.

The Company’s Environmental & Applied Solutions segment offers products and services that help protect important resources and keep global food and water supplies safe. The Company’s water quality business provides instrumentation, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. The Company’s product identification business provides equipment, software, services and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding and traceability applications for consumer, pharmaceutical and industrial products.

Refer to Notes 3 and 4 for a discussion of significant acquisitions and discontinued operations.

Accounting Principles—The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. The Consolidated Financial Statements also reflect the impact of noncontrolling interests. Noncontrolling interests do not have a significant impact on the Company’s consolidated results of operations, therefore earnings attributable to noncontrolling interests are not presented separately in the Company’s Consolidated Statements of Earnings. Earnings attributable to noncontrolling interests have been reflected in selling, general and administrative expenses and were insignificant in all periods presented. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.

Use of Estimates—The preparation of these financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company bases these estimates on historical experience, the current economic environment and on various other assumptions that are believed to be reasonable under the circumstances. However, uncertainties associated with these estimates exist and actual results may differ materially from these estimates.

Cash and Equivalents—The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.

Accounts Receivable and Allowances for Doubtful Accounts—All trade accounts, contract and finance receivables are reported on the accompanying Consolidated Balance Sheets adjusted for any write-offs and net of allowances for doubtful accounts. The allowances for doubtful accounts represent management’s best estimate of the credit losses expected from the Company’s trade accounts, contract and finance receivable portfolios. Determination of the allowances requires management to exercise judgment about the timing, frequency and severity of credit losses that could materially affect the provision for credit losses and, therefore, net earnings. The Company regularly performs detailed reviews of its portfolios to determine if an impairment has occurred and evaluates the collectability of receivables based on a combination of various financial and qualitative factors that may affect customers’ ability to pay, including customers’ financial condition, collateral, debt-servicing ability, past payment experience and credit bureau information. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations, a specific reserve is recorded against amounts due to reduce the recognized receivable to the amount reasonably expected to be collected. Additions to the allowances for doubtful accounts are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional reserves would be required. The Company does not believe that trade accounts receivable represent significant concentrations of credit risk because of the diversified portfolio of individual customers and geographical areas. The Company recorded $36 million, $33 million and $33 million of expense associated with doubtful accounts for the years ended December 31, 2018, 2017 and 2016, respectively.

Included in the Company’s trade accounts receivable and other long-term assets as of December 31, 2018 and 2017 are $219 million and $213 million of net aggregate financing receivables, respectively. All financing receivables are evaluated for impairment based on individual customer credit profiles.

Inventory Valuation—Inventories include the costs of material, labor and overhead. Domestic inventories are stated at the lower of cost or market primarily using the first-in, first-out (“FIFO”) method with certain businesses applying the last-in, first-out method (“LIFO”) to value inventory. Inventories held outside the United States are stated at the lower of cost or market primarily using the FIFO method.

Property, Plant and Equipment—Property, plant and equipment are carried at cost. The provision for depreciation has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets as follows:



Category		Useful Life
Buildings		30 years
Leased assets and leasehold improvements		Amortized over the lesser of the economic life of the asset or the term of the lease
Machinery and equipment		3 – 10 years
Customer-leased instruments		5 – 7 years

Estimated useful lives are periodically reviewed and, when appropriate, changes to estimates are made prospectively.

Investments—Investments over which the Company has a significant influence but not a controlling interest, are accounted for using the equity method of accounting which requires the Company to record its initial investment at cost and adjust the balance each period for the Company’s share of the investee’s income or loss and dividends paid. The Company also invests in innovative start-up companies where the Company has neither control of nor significant influence over the investee. Beginning in 2018 with the adoption of Accounting Standards Update (“ASU”) No. 2016-01, the Company measures these non-marketable equity securities at fair value and recognizes changes in fair value in net earnings. For securities without readily available fair values, the Company has elected the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). Additionally, the Company is a limited partner in a partnership that invests in start-up companies. While the partnership records these investments at fair value, the Company’s investment in the partnership is accounted for under the equity method of accounting. The Company made minority investments in non-marketable equity securities and equity method investments totaling $149 million in 2018. No significant realized or unrealized gains or losses were recorded in 2018 with respect to these investments.

Other Assets—Other assets principally include noncurrent financing receivables, noncurrent deferred tax assets and other investments.

Fair Value of Financial Instruments—The Company’s financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, investments in equity securities, available-for-sale debt securities, nonqualified deferred compensation plans, obligations under trade accounts payable and short and long-term debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable and trade accounts payable approximate fair value. Refer to Note 8 for the fair values of the Company’s investments in equity securities, available-for-sale debt securities and other obligations.

Goodwill and Other Intangible Assets—Goodwill and other intangible assets result from the Company’s acquisition of existing businesses. In accordance with accounting standards related to business combinations, goodwill is not amortized; however, certain finite-lived identifiable intangible assets, primarily customer relationships and acquired technology, are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized. In-process research and development (“IPR&D”) is initially capitalized at fair value and when the IPR&D project is complete, the asset is considered a finite-lived intangible asset and amortized over its estimated useful life. If an IPR&D project is abandoned, an impairment loss equal to the value of the intangible asset is recorded in the period of abandonment. The Company reviews identified intangible assets and goodwill for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company also tests intangible assets with indefinite lives and goodwill at least annually for impairment. Refer to Notes 3 and 7 for additional information about the Company’s goodwill and other intangible assets.

Revenue Recognition—On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, using the modified retrospective method for all contracts. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 605, Revenue Recognition.

The Company recorded a net increase to beginning retained earnings of $3 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings was primarily driven by the capitalization of certain costs to obtain a contract, primarily sales-related commissions, partially offset by the deferral of revenue for unfulfilled performance obligations. The adoption of ASC 606 did not have a significant impact on the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2018 and, as a result, comparisons of revenues and operating profit performance between periods are not affected by the adoption of this standard. Refer to Note 2 for additional disclosures required by ASC 606.

The Company derives revenues primarily from the sale of Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions products and services. Revenue is recognized when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For equipment, consumables, spare parts and most software licenses sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. The Company’s principal terms of sale are FOB Shipping Point, or equivalent, and, as such, the Company primarily transfers control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB Shipping Point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. Returns for products sold are estimated and recorded as a reduction of revenue at the time of sale. Customer allowances and rebates, consisting primarily of volume discounts and other short-term incentive programs, are recorded as a reduction of revenue at the time of sale because these allowances reflect a reduction in the transaction price. Product returns, customer allowances and rebates are estimated based on historical experience and known trends. For extended warranty, service, post contract support (“PCS”), software-as-a-service (“SaaS”) and other long-term contracts, control transfers to the customer over the term of the arrangement. Revenue for extended warranty, service, PCS, SaaS and certain software licenses is recognized based upon the period of time elapsed under the arrangement. Revenue for other long-term contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.

Certain of the Company’s revenues relate to operating-type lease (“OTL”) arrangements. Leases are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Equipment lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the cost of customer-leased equipment is recorded within property, plant and equipment in the accompanying Consolidated Balance Sheets and depreciated over the equipment’s estimated useful life. The depreciation expense is reflected in cost of sales in the accompanying Consolidated Statements of Earnings. The OTLs are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of consumables or tests throughout the contract term. Certain of the Company’s lease contracts are customized for larger customers and often result in complex terms and conditions that typically require significant judgment in applying the criteria used to evaluate whether the arrangement should be considered an OTL or a sales-type lease (“STL”). An STL results in earlier recognition of equipment revenue as compared to an OTL.

For a contract with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers; however, when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts’ inception. The Company does not adjust transaction price for the effects of a significant financing component when the period between the transfer of the promised good or service to the customer and payment for that good or service by the customer is expected to be one year or less. This allocation approach also applies to contracts that include a lease component.

Shipping and Handling—Shipping and handling costs are included as a component of cost of sales. Revenue derived from shipping and handling costs billed to customers is included in sales.

Advertising—Advertising costs are expensed as incurred.

Research and Development—The Company conducts research and development activities for the purpose of developing new products, enhancing the functionality, effectiveness, ease of use and reliability of the Company’s existing products and expanding the applications for which uses of the Company’s products are appropriate. Research and development costs are expensed as incurred.

Income Taxes—The Company’s income tax expense represents the tax liability for the current year, the tax benefit or expense for the net change in deferred tax liabilities and assets during the year, as well as reserves for unrecognized tax benefits and return to provision adjustments. Deferred tax liabilities and assets are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted rates expected to be in effect during the year in which the differences reverse. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the Company’s tax return in future years for which the tax benefit has already been reflected on the Company’s Consolidated Statements of Earnings. The Company establishes valuation allowances for its deferred tax assets if it is more likely than not that some or all of the deferred tax asset will not be realized. Deferred tax liabilities generally represent items that have already been taken as a deduction on the Company’s tax return but have not yet been recognized as an expense in the Company’s Consolidated Statements of Earnings. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in income tax expense in the period that includes the enactment date. The Company provides for unrecognized tax benefits when, based upon the technical merits, it is “more likely than not” that an uncertain tax position will not be sustained upon examination. Judgment is required in evaluating tax positions and determining income tax provisions. The Company re-evaluates the technical merits of its tax positions and may recognize an uncertain tax benefit in certain circumstances, including when: (1) a tax audit is completed; (2) applicable tax laws change, including a tax case ruling or legislative guidance; or (3) the applicable statute of limitations expires. The Company recognizes potential accrued interest and penalties associated with unrecognized tax positions in income tax expense. Refer to Note 13 for additional information and discussion of the impact of the enactment of the Tax Cuts and Jobs Act (“TCJA”) in the United States.

Productivity Improvement and Restructuring—The Company periodically initiates productivity improvement and restructuring activities to appropriately position the Company’s cost base relative to prevailing economic conditions and associated customer demand as well as in connection with certain acquisitions. Costs associated with productivity improvement and restructuring actions can include one-time termination benefits and related charges in addition to facility closure, contract termination and other related activities. The Company records the cost of the productivity improvement and restructuring activities when the associated liability is incurred. Refer to Note 15 for additional information.

Foreign Currency Translation—Exchange rate adjustments resulting from foreign currency transactions are recognized in net earnings, whereas effects resulting from the translation of financial statements are reflected as a component of accumulated other comprehensive income (loss) within stockholders’ equity. Assets and liabilities of subsidiaries operating outside the United States with a functional currency other than U.S. dollars are translated into U.S. dollars using year-end exchange rates and income statement accounts are translated at weighted average rates. Net foreign currency transaction gains or losses were not material in any of the years presented. The Company uses its foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. In January 2019, the Company entered into cross-currency swap arrangements whereby existing U.S. dollar-denominated borrowings were effectively converted to foreign currency borrowings to partially hedge additional amounts of its net investments in foreign operations against adverse movements in exchange rates.

Derivative Financial Instruments—The Company is neither a dealer nor a trader in derivative instruments. The Company has generally accepted the exposure to transactional exchange rate movements without using derivative instruments to manage this risk, although the Company from time to time partially hedges its net investments in foreign operations against adverse movements in exchange rates through foreign currency-denominated debt and cross-currency swaps. The Company will periodically enter into foreign currency forward contracts not exceeding 12 months to mitigate a portion of its foreign currency exchange risk and forward starting swaps to mitigate interest rate risk related to the Company’s debt. When utilized, the derivative instruments are recorded on the Consolidated Balance Sheets as either an asset or liability measured at fair value. To the extent the foreign currency forward contract or forward starting swap qualifies as an effective hedge, changes in fair value are recognized in accumulated other comprehensive income (loss) in stockholders’ equity. Changes in the value of the foreign currency denominated debt and cross-currency swaps designated as hedges of the Company’s net investment in foreign operations based on spot rates are recognized in accumulated other comprehensive income (loss) in stockholders’ equity and offset changes in the value of the Company’s foreign currency denominated operations. The Company’s use of foreign currency forward contracts and forward starting swaps during 2018, 2017 and 2016 and as of the years then ended was not significant. In January 2019, the Company entered into approximately $1.9 billion of cross-currency swap derivative contracts on its U.S. dollar-denominated bonds to effectively convert the Company’s U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc.

Accumulated Other Comprehensive Income (Loss)—Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions):



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments				Total
Balance, January 1, 2016	$	(1,797.4	)	$	(647.3	)		$	133.5			$	(2,311.2	)
Other comprehensive income (loss) before reclassifications:
(Decrease) increase	(517.3		)	(115.4		)		39.6				(593.1		)
Income tax impact	—			38.9				(14.8		)		24.1
Other comprehensive income (loss) before reclassifications, net of income taxes	(517.3		)	(76.5		)		24.8				(569.0		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	—			28.0			(a)	(223.4		)	(b)	(195.4		)
Income tax impact	—			(9.7		)		83.8				74.1
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			18.3				(139.6		)		(121.3		)
Net current period other comprehensive income (loss), net of income taxes	(517.3		)	(58.2		)		(114.8		)		(690.3		)
Distribution of Fortive Corporation	(83.5		)	63.3			(c)	—				(20.2		)
Balance, December 31, 2016	(2,398.2		)	(642.2		)		18.7				(3,021.7		)
Other comprehensive income (loss) before reclassifications:
Increase	976.1			62.4				41.7				1,080.2
Income tax impact	—			(13.4		)		(15.7		)		(29.1		)
Other comprehensive income (loss) before reclassifications, net of income taxes	976.1			49.0				26.0				1,051.1
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	—			28.7			(a)	(72.8		)	(b)	(44.1		)
Income tax impact	—			(6.7		)		27.2				20.5
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			22.0				(45.6		)		(23.6		)
Net current period other comprehensive income (loss), net of income taxes	976.1			71.0				(19.6		)		1,027.5
Balance, December 31, 2017	(1,422.1		)	(571.2		)		(0.9		)		(1,994.2		)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)		(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)		(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Decrease	(632.2		)	(44.9		)		(1.1		)		(678.2		)
Income tax impact	—			9.2				0.3				9.5
Other comprehensive income (loss) before reclassifications, net of income taxes	(632.2		)	(35.7		)		(0.8		)		(668.7		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			30.3			(a)	—				30.3
Income tax impact	—			(7.3		)		—				(7.3		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			23.0				—				23.0
Net current period other comprehensive income (loss), net of income taxes	(632.2		)	(12.7		)		(0.8		)		(645.7		)
Balance, December 31, 2018	$	(2,098.1	)	$	(691.1	)		$	(1.9	)		$	(2,791.1	)


^(a)	This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension and postretirement cost (refer to Notes 11 and 12 for additional details).


^(b)	Included in other income in the accompanying Consolidated Statements of Earnings (refer to Note 14 for additional details).


^(c)	This accumulated other comprehensive income (loss) component included an income tax impact of $21 million.

Accounting for Stock-Based Compensation—The Company accounts for stock-based compensation by measuring the cost of employee services received in exchange for all equity awards granted, including stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”), based on the fair value of the award as of the grant date. Equity-based compensation expense is recognized net of an estimated forfeiture rate on a straight-line basis over the requisite service period of the award, except that in the case of RSUs, compensation expense is recognized using an accelerated attribution method. Refer to Note 18 for additional information on the stock-based compensation plans in which certain employees of the Company participate.

Pension and Postretirement Benefit Plans—The Company measures its pension and postretirement plans’ assets and its obligations that determine the respective plan’s funded status as of the end of the Company’s fiscal year, and recognizes an asset for a plan’s overfunded status or a liability for a plan’s underfunded status in its balance sheet. Changes in the funded status of the plans are recognized in the year in which the changes occur and reported in comprehensive income (loss). Refer to Notes 11 and 12 for additional information on the Company’s pension and postretirement plans including a discussion of the actuarial assumptions, the Company’s policy for recognizing the associated gains and losses and the method used to estimate service and interest cost components.

Accounting Standards Recently Adopted—In March 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the TCJA. The Company recognized the estimated income tax effects of the TCJA in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 (“SAB No. 118”). The provisional amounts recorded in 2017 were adjusted to final estimates in 2018 in connection with filing tax returns for 2017. Refer to Note 13 for further information regarding the impact of these provisions for both 2017 and 2018.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to address a specific consequence of the TCJA by allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the TCJA’s reduction of the U.S. federal corporate income tax rate. The ASU is effective for all entities for annual periods beginning after December 15, 2018, with early adoption permitted, and is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company early adopted this ASU on January 1, 2018 and as a result recorded a net increase to beginning retained earnings and decrease to accumulated other comprehensive income (loss) of $151 million to reclassify the income tax effects of the TCJA on the Company’s U.S. pension plans, available-for-sale debt securities and certain foreign currency losses. The ASU also requires the Company to disclose its policy on accounting for income tax effects in accumulated other comprehensive income (loss). In general, the Company applies the individual item approach with respect to available-for-sale debt securities and the portfolio approach with respect to pension, postretirement benefit plan obligations and currency translation matters.

In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which provided clarity on which changes to the terms or conditions of share-based payment awards require an entity to apply the modification accounting provisions required in Topic 718. The adoption of this ASU on January 1, 2018 did not have a significant impact on the Company’s Consolidated Financial Statements.

In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (“ASU No. 2017-07”), which requires employers to disaggregate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The standard requires employers to report the service cost component in the same line item as other compensation costs and to report the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. The service cost component of net periodic pension cost is included in cost of sales and selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings and the other components of net periodic pension cost are included in nonoperating income (expense). The income statement guidance requires application on a retrospective basis. The ASU was adopted by the Company on January 1, 2018 and as a result, operating profit decreased and other income, net increased by $31 million and $16 million for the years ended December 31, 2017 and 2016, respectively. Refer to Notes 11 and 12 for further information on the implementation of this ASU.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the Fair Value Alternative is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income (loss) to retained earnings. In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10), which clarified certain aspects of the previously issued ASU. The ASU was adopted by the Company on January 1, 2018 and did not have a material effect on the Company’s Consolidated Financial Statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes nearly all existing revenue recognition guidance. The core principle of the ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of the standard by one year which resulted in the new standard being effective for the Company at the beginning of its first quarter of fiscal year 2018. In addition, during March, April, May and December 2016 and September and November 2017, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), and ASU No. 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) respectively, which clarified the guidance on certain items such as reporting revenue as a principal versus agent, identifying performance obligations, accounting for intellectual property licenses, assessing collectability, presentation of sales taxes, impairment testing for contract costs, disclosure of performance obligations, and provided additional implementation guidance. Refer to the discussion above in “—Revenue Recognition” and to Note 2 for additional disclosures required by ASC 606.

Accounting Standards Not Yet Adopted—In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, which amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosures on fair value measurements by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income (loss). The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements.

In August 2017, the FASB issued No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which expands and refines hedge accounting for both financial and non-financial risk components, aligns the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements, and includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The ASU is effective for public entities for fiscal years beginning after December 15, 2018. In January 2019, the Company entered into approximately $1.9 billion of cross-currency swap derivative contracts to hedge its net investment in foreign operations against adverse changes in the exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and the Swiss franc.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use (“ROU”) asset and a lease liability for all leases with terms greater than 12 months. The standard also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. In September 2017, January 2018, July 2018 and December 2018, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), ASU No. 2018-01, Leases (Topic 842), Land Easement Practical Expedient for Transition to Topic 842, ASU No. 2018-10, Codification Improvements to Topic 842, Leases, ASU No. 2018-11, Leases (Topic 842), Targeted Improvements and ASU No. 2018-20, Leases (Topic 842), Narrow-Scope Improvements for Lessors, which provided additional implementation guidance on the previously issued ASU. The Company has implemented a new lease system and the related processes and controls for the accounting for leases in accordance with the ASU. On January 1, 2019, the Company adopted this ASU using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 will be presented under ASC 842, while prior period amounts will not be adjusted and will continue to be reported in accordance with the Company’s historic accounting under ASC 840, Leases. As of January 1, 2019, the standard had a material impact on the Company’s Consolidated Balance Sheet, but is expected to have an insignificant impact on the Company’s consolidated net earnings and cash flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for finance leases remained substantially unchanged. For leases that commenced before the effective date of Topic 842, the Company elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) capitalization of initial direct costs for any existing leases.

As a result of the cumulative impact of adopting ASC 842, the Company will record operating lease ROU assets of approximately $1.0 billion and operating lease liabilities of approximately $1.0 billion as of January 1, 2019, primarily related to real estate and automobile leases.

Revenue

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer

REVENUE

The following table presents the Company’s revenues disaggregated by geographical region and revenue type for the year ended December 31, 2018 ($ in millions). Sales taxes and other usage-based taxes are excluded from revenues. The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not high-growth markets.



	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	2,295.6	$	2,403.4	$	1,350.4	$	1,770.7	$	7,820.1
Western Europe	1,846.7		1,155.4		659.6		1,059.1		4,720.8
Other developed markets	570.0		379.1		179.9		125.7		1,254.7
High-growth markets	1,759.1		2,319.7		654.6		1,364.0		6,097.4
Total	$	6,471.4	$	6,257.6	$	2,844.5	$	4,319.5	$	19,893.0

Revenue type:
Recurring	$	4,131.8	$	5,272.0	$	2,039.8	$	2,280.0	$	13,723.6
Nonrecurring	2,339.6		985.6		804.7		2,039.5		6,169.4
Total	$	6,471.4	$	6,257.6	$	2,844.5	$	4,319.5	$	19,893.0

The Company sells equipment to customers as well as consumables, spare parts, software licenses and services, some of which customers purchase on a recurring basis. Consumables are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as dental implants and water treatment solutions. The Company separates its goods and services between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services, spare parts, software licenses recognized over time, SaaS licenses, sales-and-usage based royalties and OTLs. Nonrecurring revenue includes sales from equipment, software licenses recognized at a point in time and STLs. OTLs and STLs are included in the above revenue amounts. For the year ended December 31, 2018, revenue accounted for under Topic 840, Leases was $402 million.

Remaining Performance Obligations

ASC 606 requires disclosure of remaining performance obligations that represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term consumable supply arrangements, extended warranty, service and PCS contracts, SaaS and other long-term contracts. These remaining performance obligations do not include revenue from contracts with customers with an original term of one year or less, revenue from long-term consumable supply arrangements with no minimum purchase requirements or revenue expected from purchases made in excess of the minimum purchase requirements or revenue from equipment leased to customers. While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote. Additionally, the Company has elected to exclude contracts with customers with an original term of one year or less from remaining performance obligations while these contracts are included within backlog.

As of December 31, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $1.9 billion. The Company expects to recognize revenue on approximately 43% of the remaining performance obligations over the next 12 months, 27% recognized over the subsequent 12 months, and the remainder recognized thereafter.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed trade accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets. In addition, the Company defers certain costs incurred to obtain a contract (contract costs).

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Balance Sheet. The balance of contract assets as of December 31, 2018 and at the date of adoption of ASC 606 were $82 million and $114 million, respectively.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize revenue. As of December 31, 2018 and at the date of adoption of ASC 606, contract liabilities were $799 million and $783 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Balance Sheet. The increase in the contract liability balance during the year ended December 31, 2018 is primarily as a result of cash payments received in advance of satisfying performance obligations and acquisitions, partially offset by revenue recognized during the period that was included in the contract liability balance at the date of adoption and foreign currency exchange. Revenue recognized during the year ended December 31, 2018 that was included in the contract liability balance at the date of adoption was $657 million.

Contract costs—The Company capitalizes certain direct incremental costs incurred to obtain a contract, typically sales-related commissions, where the amortization period for the related asset is greater than one year. These costs are amortized over the contract term or a longer period, generally the expected life of the customer relationship if renewals are expected and the renewal commission is not commensurate with the initial commission. Contract costs are classified as current or long-term other assets in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the expense and are generally amortized into earnings on a straight-line basis (which is consistent with the transfer of control for the related goods or services). Management assesses these costs for impairment at least quarterly and as “triggering” events occur that indicate it is more likely than not that an impairment exists. The balance of contract costs as of December 31, 2018 and at the date of adoption were not significant. Amortization expense for the year ended December 31, 2018, was also not significant. The costs to obtain a contract where the amortization period for the related asset is one year or less are expensed as incurred and recorded within selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings.

Contract assets, liabilities and costs are reported on the accompanying Consolidated Balance Sheet on a contract-by-contract basis.

Acquisitions

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s Consolidated Financial Statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, the avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.

The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with certain of its 2018 acquisitions and is also in the process of obtaining valuations of certain property, plant and equipment, acquired intangible assets and certain acquisition-related liabilities in connection with these acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.

The following briefly describes the Company’s acquisition activity for the three years ended December 31, 2018.

On April 13, 2018, the Company acquired Integrated DNA Technologies, Inc. (“IDT”), a privately-held manufacturer of custom DNA and RNA oligonucleotides serving customers in the academic and biopharmaceutical research, biotechnology, agriculture, clinical diagnostics and pharmaceutical development end-markets, for a purchase price of approximately $2.1 billion, net of cash acquired. IDT had revenues of approximately $260 million in 2017, and is now part of the Company’s Life Sciences segment.

The Company financed the acquisition of IDT with available cash and proceeds from the issuance of commercial paper. The Company preliminarily recorded approximately $1.2 billion of goodwill related to the IDT acquisition. The acquisition of IDT provides additional sales and earnings growth opportunities for the Company’s Life Sciences segment by expanding the segment’s product line diversity, including new product and service offerings in the area of genomics consumables, and through the potential future acquisition of complementary businesses.

In addition to the IDT acquisition, during 2018, the Company acquired one other business for total consideration of $95 million in cash, net of cash acquired. The business acquired complements an existing unit of the Environmental & Applied Solutions segment. The aggregate annual sales of this business at the time of its acquisition, based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $53 million. The Company preliminarily recorded an aggregate of $63 million of goodwill related to this acquisition.

During 2017, the Company acquired ten businesses for total consideration of $386 million in cash, net of cash acquired. The businesses acquired complement existing units of the Life Sciences, Dental and Environmental & Applied Solutions segments. The aggregate annual sales of these ten businesses at the time of their respective acquisitions, in each case based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $160 million. The Company recorded an aggregate of $268 million of goodwill related to these acquisitions.

On November 4, 2016, Copper Merger Sub, Inc., a California corporation and an indirect, wholly-owned subsidiary of the Company acquired all of the outstanding shares of common stock of Cepheid, a California corporation, for $53.00 per share in cash, for a total purchase price of approximately $4.0 billion, net of assumed debt and acquired cash (the “Cepheid Acquisition”). Cepheid is a leading global molecular diagnostics company that develops, manufactures and markets accurate and easy to use molecular systems and tests and is now part of the Company’s Diagnostics segment. Cepheid generated revenues of $539 million in 2015.

The Company initially financed the Cepheid acquisition price with available cash and proceeds from the issuance of U.S. dollar and euro-denominated commercial paper. The Company recorded approximately $2.6 billion of goodwill related to the Cepheid Acquisition. As Cepheid is integrated into the Company, a process that will continue over the next several years, the Company expects to realize significant cost synergies through the application of the Danaher Business System (“DBS”) and the combined purchasing power of the Company and Cepheid.

In addition to the Cepheid Acquisition, during 2016 the Company acquired seven businesses for total consideration of $882 million in cash, net of cash acquired. The businesses acquired complement existing units of each of the Company’s four segments. The aggregate annual sales of these seven businesses at the time of their respective acquisitions, in each case based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $237 million. The Company recorded an aggregate of $478 million of goodwill related to these acquisitions.

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition ($ in millions):



	2018			2017			2016
Trade accounts receivable	$	41.1		$	21.6		$	97.8
Inventories	14.8			21.3			204.8
Property, plant and equipment	88.4			9.1			161.8
Goodwill	1,275.4			267.6			3,061.8
Other intangible assets, primarily customer relationships, trade names and technology	850.7			155.1			1,867.0
In-process research and development	—			—			65.0
Trade accounts payable	(6.7		)	(9.9		)	(50.7		)
Other assets and liabilities, net	(66.5		)	(75.0		)	(518.0		)
Assumed debt	—			—			(1.0		)
Attributable to noncontrolling interest	—			(4.0		)	—
Net assets acquired	2,197.2			385.8			4,888.5
Less: noncash consideration	(23.9		)	—			(8.4		)
Net cash consideration	$	2,173.3		$	385.8		$	4,880.1

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2018 discussed above, and the other 2018 acquisitions separately ($ in millions):



	IDT			Other			Total
Trade accounts receivable	$	36.0		$	5.1		$	41.1
Inventories	14.8			—			14.8
Property, plant and equipment	88.2			0.2			88.4
Goodwill	1,212.6			62.8			1,275.4
Other intangible assets, primarily customer relationships, trade names and technology	811.0			39.7			850.7
Trade accounts payable	(5.5		)	(1.2		)	(6.7		)
Other assets and liabilities, net	(55.0		)	(11.5		)	(66.5		)
Net assets acquired	2,102.1			95.1			2,197.2
Less: noncash consideration	(23.9		)	—			(23.9		)
Net cash consideration	$	2,078.2		$	95.1		$	2,173.3

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2016 discussed above, and all of the other 2016 acquisitions as a group ($ in millions):



	Cepheid			Others			Total
Trade accounts receivable	$	61.4		$	36.4		$	97.8
Inventories	165.8			39.0			204.8
Property, plant and equipment	144.5			17.3			161.8
Goodwill	2,584.0			477.8			3,061.8
Other intangible assets, primarily customer relationships, trade names and technology	1,480.0			387.0			1,867.0
In-process research and development	65.0			—			65.0
Trade accounts payable	(41.2		)	(9.5		)	(50.7		)
Other assets and liabilities, net	(452.4		)	(65.6		)	(518.0		)
Assumed debt	(1.0		)	—			(1.0		)
Net assets acquired	4,006.1			882.4			4,888.5
Less: noncash consideration	(8.4		)	—			(8.4		)
Net cash consideration	$	3,997.7		$	882.4		$	4,880.1

During 2018, the Company incurred acquisition-related transaction costs and change in control payments of $15 million associated with the IDT acquisition. In addition, the Company’s earnings for 2018 reflect the pretax impact of $1 million of nonrecurring acquisition date fair value adjustments to inventory related to the IDT acquisition.

During 2016, primarily in connection with the Cepheid Acquisition, the Company incurred $61 million of pretax transaction-related costs, primarily banking fees, legal fees, amounts paid to other third-party advisers and change in control costs. In addition, the Company’s earnings for 2016 reflect the impact of additional pretax charges of $23 million associated with fair value adjustments to acquired inventory and deferred revenue primarily related to the Cepheid Acquisition.

Transaction-related costs and acquisition-related fair value adjustments attributable to other acquisitions were not material for the years ended December 31, 2018, 2017 and 2016.

Acquisition of Noncontrolling Interest

In the first quarter of 2017, Danaher acquired the remaining noncontrolling interest associated with one of its prior business combinations for consideration of $64 million. Danaher recorded the increase in ownership interests as a transaction within stockholders’ equity. As a result of this transaction, noncontrolling interests were reduced by $63 million reflecting the carrying value of the interest with the $1 million difference charged to additional paid-in capital.

Pro Forma Financial Information (Unaudited)

The unaudited pro forma information for the periods set forth below gives effect to the 2018 and 2017 acquisitions as if they had occurred as of January 1, 2017. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions except per share amounts):



	2018		2017
Sales	$	19,995.7	$	18,744.7
Net earnings from continuing operations	2,652.9		2,449.8
Diluted net earnings per share from continuing operations	3.74		3.47

The 2018 unaudited pro forma earnings set forth above were adjusted to exclude the $1 million pretax impact of nonrecurring acquisition date fair value adjustments to inventory related to the 2018 acquisition of IDT and 2017 unaudited pro forma earnings set forth above were adjusted to include the impact of this same fair value adjustment as if the acquisition had occurred on January 1, 2017.

In addition, the acquisition-related transaction costs and change in control payments of $15 million in 2018 associated with the IDT acquisition were excluded from pro forma earnings in both 2018 and 2017.

Discontinued Operations

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS AND DENTAL SEPARATION

Fortive Corporation Separation

On July 2, 2016 (the “Distribution Date”), Danaher completed the separation (the “Fortive Separation”) of its former Test & Measurement segment, Industrial Technologies segment (excluding the product identification businesses) and retail/commercial petroleum business by distributing to Danaher stockholders on a pro rata basis all of the issued and outstanding common stock of Fortive Corporation (“Fortive”), the entity Danaher incorporated to hold such businesses. To effect the Fortive Separation, Danaher distributed to its stockholders one share of Fortive common stock for every two shares of Danaher common stock outstanding as of June 15, 2016, the record date for the distribution. Fractional shares of Fortive common stock that otherwise would have been distributed were aggregated and sold into the public market and the proceeds distributed to Danaher stockholders.

In preparation for the Fortive Separation, in June 2016 Fortive issued approximately $3.4 billion in debt securities (refer to Note 10). The proceeds from these borrowings were used to fund the approximately $3.0 billion net cash distributions Fortive made to Danaher prior to the Distribution Date (“Fortive Distribution”). Danaher used a portion of the cash distribution proceeds to repay the $500 million aggregate principal amount of 2.3% senior unsecured notes that matured in June 2016 and to redeem approximately $1.9 billion in aggregate principal amount of outstanding indebtedness in August 2016 (consisting of the Company’s 5.625% senior unsecured notes due 2018, 5.4% senior unsecured notes due 2019 and 3.9% senior unsecured notes due 2021, collectively the “Redeemed Notes”). Danaher also paid an aggregate of $188 million in make-whole premiums in connection with the August 2016 redemptions, plus accrued and unpaid interest. The Company used the balance of the Fortive Distribution to fund certain of the Company’s regular, quarterly cash dividends to shareholders.

The accounting requirements for reporting the Fortive Separation as a discontinued operation were met when the separation was completed. Accordingly, the accompanying Consolidated Financial Statements for all periods presented reflect this business as a discontinued operation. The Company allocated a portion of the consolidated interest expense and income to discontinued operations based on the ratio of the discontinued business’ net assets to the Company’s consolidated net assets. Fortive had revenues of approximately $3.0 billion in 2016 prior to the Fortive Separation.

As a result of the Fortive Separation, the Company incurred $48 million in Fortive Separation-related costs during the year ended December 31, 2016 which are included in earnings from discontinued operations, net of income taxes in the accompanying Consolidated Statement of Earnings. These Fortive Separation costs primarily relate to professional fees associated with preparation of regulatory filings and Separation activities within finance, tax, legal and information system functions as well as certain investment banking fees incurred upon the Fortive Separation.

In connection with the Fortive Separation, Danaher and Fortive entered into various agreements to effect the Fortive Separation and provide a framework for their relationship after the Fortive Separation, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement and a DBS license agreement. These agreements provide for the allocation between Danaher and Fortive of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after Fortive’s separation from Danaher and govern certain relationships between Danaher and Fortive after the Fortive Separation. In addition, Danaher is also party to various commercial agreements with Fortive entities. The amount billed for transition services provided under the above agreements as well as sales and purchases to and from Fortive were not material to the Company’s results of operations for the years ended December 31, 2018, 2017 and 2016.

In 2017, Danaher recorded a $22 million income tax benefit related to the release of previously provided reserves associated with uncertain tax positions on certain Danaher tax returns which were jointly filed with Fortive entities. These reserves were released due to the expiration of statutes of limitations for those returns. All Fortive entity-related balances were included in the income tax benefit related to discontinued operations.

The key components of income from discontinued operations for the years ended December 31 were as follows ($ in millions):



	2017		2016
Sales	$	—	$	3,029.8
Cost of sales	—		(1,566.4		)
Selling, general and administrative expenses	—		(696.0		)
Research and development expenses	—		(190.4		)
Interest expense	—		(19.7		)
Income from discontinued operations before income taxes	—		557.3
Income taxes	22.3		(157.0		)
Earnings from discontinued operations, net of income taxes	$	22.3	$	400.3

Dental Separation

In July 2018, the Company announced its intention to spin-off its Dental business into an independent publicly-traded company (the “Dental Separation”). The Dental business had sales for the year ended December 31, 2018 of approximately $2.8 billion. The transaction is expected to be tax-free to the Company’s shareholders. The Company is targeting to complete the Dental Separation in the second half of 2019, subject to the satisfaction of certain conditions, including obtaining final approval from the Danaher Board of Directors, satisfactory completion of financing, receipt of tax opinions, receipt of favorable rulings from the Internal Revenue Service (“IRS”) and receipt of other regulatory approvals.

Inventories

12 Months Ended

Dec. 31, 2018

Inventory, Net [Abstract]

Inventories

INVENTORIES

The classes of inventory as of December 31 are summarized as follows ($ in millions):



	2018		2017
Finished goods	$	1,031.2	$	982.5
Work in process	313.9		309.7
Raw materials	565.0		548.6
Total	$	1,910.1	$	1,840.8

As of December 31, 2018 and 2017, the difference between inventories valued at LIFO and the value of that same inventory if the FIFO method had been used was not significant. The liquidation of LIFO inventory did not have a significant impact on the Company’s results of operations in any period presented.

Property, Plant And Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant And Equipment

PROPERTY, PLANT AND EQUIPMENT

The classes of property, plant and equipment as of December 31 are summarized as follows ($ in millions):



	2018			2017
Land and improvements	$	176.5		$	155.6
Buildings	1,047.8			1,009.5
Machinery and equipment	2,482.3			2,239.5
Customer-leased equipment	1,632.9			1,569.4
Gross property, plant and equipment	5,339.5			4,974.0
Less: accumulated depreciation	(2,828.3		)	(2,519.4		)
Property, plant and equipment, net	$	2,511.2		$	2,454.6

Goodwill And Other Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS

As discussed in Note 3, goodwill arises from the purchase price for acquired businesses exceeding the fair value of tangible and intangible assets acquired less assumed liabilities and noncontrolling interests. Management assesses the goodwill of each of its reporting units for impairment at least annually at the beginning of the fourth quarter and as “triggering” events occur that indicate that it is more likely than not that an impairment exists. The Company elected to bypass the optional qualitative goodwill assessment allowed by applicable accounting standards and performed a quantitative impairment test for all reporting units as this was determined to be the most effective method to assess for impairment across a large spectrum of reporting units.

The Company estimates the fair value of its reporting units primarily using a market approach, based on current trading multiples of earnings before interest, taxes, depreciation and amortization (“EBITDA”) for companies operating in businesses similar to each of the Company’s reporting units, in addition to recent available market sale transactions of comparable businesses. In certain circumstances the Company also estimates fair value utilizing a discounted cash flow analysis (i.e., an income approach) in order to validate the results of the market approach. If the estimated fair value of the reporting unit is less than its carrying value, the Company must perform additional analysis to determine if the reporting unit’s goodwill has been impaired.

As of December 31, 2018, the Company had eight reporting units for goodwill impairment testing. As of the date of the 2018 annual impairment test, the carrying value of the goodwill included in each individual reporting unit ranged from $511 million to approximately $13.3 billion. No goodwill impairment charges were recorded for the years ended December 31, 2018, 2017 and 2016 and no “triggering” events have occurred subsequent to the performance of the 2018 annual impairment test. The factors used by management in its impairment analysis are inherently subject to uncertainty. If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may be overstated and a charge would need to be taken against net earnings.

The following is a rollforward of the Company’s goodwill by segment ($ in millions):



	Life Sciences			Diagnostics				Dental			Environmental & Applied Solutions			Total
Balance, January 1, 2017	$	11,610.3		$	6,903.0			$	3,215.6		$	2,098.0		$	23,826.9
Attributable to 2017 acquisitions	95.5			—				2.8			169.3			267.6
Adjustments due to finalization of purchase price allocations	(19.1		)	(39.6		)	^(a)	8.8			—			(49.9		)
Foreign currency translation and other	648.8			216.1				142.8			86.3			1,094.0
Balance, December 31, 2017	12,335.5			7,079.5				3,370.0			2,353.6			25,138.6
Attributable to 2018 acquisitions	1,212.6			—				—			62.8			1,275.4
Adjustments due to finalization of purchase price allocations	2.8			—				—			4.7			7.5
Foreign currency translation and other	(239.9		)	(153.9		)		(44.5		)	(77.2		)	(515.5		)
Balance, December 31, 2018	$	13,311.0		$	6,925.6			$	3,325.5		$	2,343.9		$	25,906.0


^(a)	This adjustment is primarily related to finalization of the Cepheid purchase price allocations.

Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets as of December 31 ($ in millions):



	2018					2017
	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived intangibles:
Patents and technology	$	2,985.3	$	(945.2	)	$	2,363.5	$	(783.7	)
Customer relationships and other intangibles	7,302.8		(2,661.3		)	7,354.9		(2,203.6		)
Trademarks and trade names	190.7		(28.0		)	23.9		(14.0		)
Total finite-lived intangibles	10,478.8		(3,634.5		)	9,742.3		(3,001.3		)
Indefinite-lived intangibles:
Trademarks and trade names	4,828.8		—			4,926.1		—
Total intangibles	$	15,307.6	$	(3,634.5	)	$	14,668.4	$	(3,001.3	)

During 2018, the Company acquired finite-lived intangible assets, consisting primarily of technology, with a weighted average life of 18 years. During 2017, the Company acquired finite-lived intangible assets, consisting primarily of customer relationships, with a weighted average life of nine years. Refer to Note 3 for additional information on the intangible assets acquired.

Total intangible amortization expense in 2018, 2017 and 2016 was $706 million, $661 million and $583 million, respectively. Based on the intangible assets recorded as of December 31, 2018, amortization expense is estimated to be $720 million during 2019, $709 million during 2020, $694 million during 2021, $673 million during 2022 and $665 million during 2023.

Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
December 31, 2018:
Assets:
Available-for-sale debt securities	$	—	$	38.3	$	—	$	38.3
Investment in equity securities	—		—		148.9		148.9
Liabilities:
Deferred compensation plans	—		60.9		—		60.9
December 31, 2017:
Assets:
Available-for-sale debt securities	$	—	$	45.4	$	—	$	45.4
Liabilities:
Deferred compensation plans	—		62.9		—		62.9

Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. As of December 31, 2018, available-for-sale debt securities primarily include U.S. Treasury Notes and corporate debt securities, which are valued based on the terms of the instruments in comparison with similar terms on the active market.

The Company has established nonqualified deferred compensation programs that permit officers, directors and certain management employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment (or board service, as applicable). All amounts deferred under such plans are unfunded, unsecured obligations of the Company and are presented as a component of the Company’s compensation and benefits accrual included in other long-term liabilities in the accompanying Consolidated Balance Sheets (refer to Note 9). Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates. Amounts unilaterally contributed to participant accounts by the Company are deemed invested in the Company’s common stock and future distributions of such contributions will be made solely in shares of common stock. As a result, Company contributions to this program are not reflected in the above amounts.

The Company’s investments in equity securities are measured at fair value and are adjusted for observable transactions for identical or similar investments of the same issuer or impairment. These securities are classified as Level 3 in the fair value hierarchy because the Company estimates the fair value based on the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The investments in equity securities includes investments that the Company has made as a limited partner in a partnership for which the underlying investments are recorded on a fair value basis.

Fair Value of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments as of December 31 were as follows ($ in millions):



	2018				2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	38.3	$	38.3	$	45.4	$	45.4
Investment in equity securities	148.9		148.9		—		—
Liabilities:
Notes payable and current portion of long-term debt	51.8		51.8		194.7		194.7
Long-term debt	9,688.5		9,990.6		10,327.4		10,847.1

As of December 31, 2018 investments in non-marketable equity securities were categorized as Level 3. As of December 31, 2018 and 2017, available-for-sale debt securities were categorized as Level 2 and short and long-term borrowings were categorized as Level 1.

The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings (other than the Company’s Liquid Yield Option Notes due 2021 (the “LYONs”)) is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. In the case of the LYONs, differences in the fair value from the carrying value are attributable to changes in the price of the Company’s common stock due to the LYONs’ conversion features. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable approximate their carrying amounts due to the short-term maturities of these instruments.

Refer to Note 11 for information related to the fair value of the Company sponsored defined benefit pension plan assets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Expenses And Other Liabilities

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Accrued Expenses And Other Liabilities

ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities as of December 31 were as follows ($ in millions):



	2018				2017
	Current		Noncurrent		Current		Noncurrent
Compensation and benefits	$	1,026.8	$	236.9	$	961.0	$	236.2
Pension and postretirement benefits	75.2		961.9		95.8		1,052.0
Taxes, income and other	292.4		3,577.7		386.4		3,543.6
Deferred revenue	685.2		113.8		666.0		104.9
Sales and product allowances	167.8		2.0		155.7		2.0
Other	829.5		183.5		822.8		222.4
Total	$	3,076.9	$	5,075.8	$	3,087.7	$	5,161.1

Financing

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Financing

FINANCING

The components of the Company’s debt as of December 31 were as follows ($ in millions):



	2018		2017
U.S. dollar-denominated commercial paper	$	72.8	$	436.9
Euro-denominated commercial paper (€2.1 billion and €1.7 billion, respectively)	2,377.5		1,993.9
1.65% senior unsecured notes due 2018 (the “2018 U.S. Notes”)	—		499.2
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	687.0		718.4
2.4% senior unsecured notes due 2020 (the “2020 U.S. Notes”)	498.5		497.7
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	386.7		394.6
Zero-coupon LYONs due 2021	56.2		69.1
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	273.2		265.5
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	913.2		955.6
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the "Floating Rate 2022 Euronotes")	285.7		299.1
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	550.7		555.5
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	912.6		955.6
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	496.8		496.3
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	279.9		272.2
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	682.0		714.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	218.1		220.3
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	483.4		470.2
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.3		499.3
Other	66.7		208.6
Total debt	9,740.3		10,522.1
Less: currently payable	51.8		194.7
Long-term debt	$	9,688.5	$	10,327.4

Debt discounts, premiums and debt issuance costs totaled $19 million and $25 million as of December 31, 2018 and 2017, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above.

Commercial Paper Programs and Credit Facilities

In 2015, the Company entered into a $4.0 billion unsecured multi-year revolving credit facility with a syndicate of banks that expires on July 10, 2020, subject to a one-year extension option at the request of the Company with the consent of the lenders (the “Credit Facility”). In 2018, the Company also entered into a $1.0 billion 364-day unsecured revolving credit facility with a syndicate of banks that was scheduled to expire in March 2019 (the “364-Day Facility”), to provide additional liquidity support for issuances under the Company’s U.S. and euro-denominated commercial paper programs. The increase in the size of the Company’s commercial paper programs provided necessary capacity for the Company to use proceeds from the issuance of commercial paper to fund the purchase price for the IDT acquisition. The Company terminated the 364-Day Facility on November 6, 2018. No borrowings were outstanding under the 364-Day Facility at any time, nor under the Credit Facility at any time from inception through December 31, 2018. Total fees incurred by the Company related to the 364-Day Facility and its termination were not significant.

Under the Company’s U.S. and euro-denominated commercial paper programs, the Company or a subsidiary of the Company, as applicable, may issue and sell unsecured, short-term promissory notes. The notes are typically issued at a discount from par, generally based on the ratings assigned to the Company by credit rating agencies at the time of the issuance and prevailing market rates measured by reference to LIBOR or EURIBOR. The Credit Facility provides liquidity support for issuances under the Company’s commercial paper programs, and can also be used for working capital and other general corporate purposes. The availability of the Credit Facility as a standby liquidity facility to repay maturing commercial paper is an important factor in maintaining the existing credit ratings of the Company’s commercial paper programs. The Company expects to limit any borrowings under the Credit Facility to amounts that would leave sufficient available borrowing capacity under such facility to allow the Company to borrow, if needed, to repay all of the outstanding commercial paper as it matures. As commercial paper obligations mature, the Company may issue additional short-term commercial paper obligations to refinance all or part of these borrowings. As of December 31, 2018, borrowings outstanding under the Company’s U.S. and euro commercial paper programs had a weighted average annual interest rate of negative 0.2% and a weighted average remaining maturity of approximately 37 days. As of December 31, 2018, the Company has classified approximately $2.5 billion of its borrowings outstanding under the commercial paper programs as well as the 2019 Euronotes as long-term debt in the accompanying Consolidated Balance Sheet as the Company had the intent and ability, as supported by availability under the Credit Facility referenced above, to refinance these borrowings for at least one year from the balance sheet date.

Under the Credit Facility, borrowings (other than bid loans) bear interest at a rate equal to (at the Company’s option) either (1) a LIBOR-based rate (the “LIBOR-Based Rate”), or (2) the highest of (a) the Federal funds rate plus 0.5%, (b) the prime rate and (c) the LIBOR-Based Rate plus 1%, plus a specified margin that varies according to the Company’s long-term debt credit rating. In addition to certain initial fees the Company paid with respect to the Credit Facility at inception of the facility, the Company is obligated to pay an annual commitment or facility fee under the Credit Facility that varies according to the Company’s long-term debt credit rating. The Credit Facility requires the Company to maintain a consolidated leverage ratio (as defined in the respective facility) of 0.65 to 1.00 or less, and also contains customary representations, warranties, conditions precedent, events of default, indemnities and affirmative and negative covenants. As of December 31, 2018, no borrowings were outstanding under the Credit Facility and the Company was in compliance with all covenants under the facility. The nonperformance by any member of the Credit Facility syndicate would reduce the maximum capacity of the Credit Facility by such member’s commitment amount.

The Company’s ability to access the commercial paper market, and the related costs of these borrowings, is affected by the strength of the Company’s credit rating and market conditions. Any downgrade in the Company’s credit rating would increase the cost of borrowings under the Company’s commercial paper program and the Credit Facility, and could limit or preclude the Company’s ability to issue commercial paper. If the Company’s access to the commercial paper market is adversely affected due to a credit downgrade, change in market conditions or otherwise, the Company expects it would rely on a combination of available cash, operating cash flow and the Credit Facility to provide short-term funding. In such event, the cost of borrowings under the Credit Facility could be higher than the cost of commercial paper borrowings.

In addition to the Credit Facility, the Company has also entered into reimbursement agreements with various commercial banks to support the issuance of letters of credit.

Long-Term Indebtedness

The following summarizes the key terms for the Company’s long-term debt as of December 31, 2018:



	Outstanding Balance as of December 31, 2018		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Issue Date	Maturity Date	Interest Payment Dates (in arrears)
2019 Euronotes ⁽¹⁾	$	687.0	1.0	%	99.696	%	July 8, 2015	July 8, 2019	July 8
2020 U.S. Notes ⁽³⁾	498.5		2.4	%	99.757	%	September 15, 2015	September 15, 2020	March 15 and September 15
2020 Assumed Pall Notes ⁽⁵⁾	386.7		5.0	%	not applicable		not applicable	June 15, 2020	June 15 and December 15
2021 LYONs	56.2		see below		not applicable		January 22, 2001	January 22, 2021	January 22 and July 22
2021 Yen Notes ⁽⁴⁾	273.2		0.352	%	100	%	February 28, 2016	March 16, 2021	September 16
2022 Euronotes ⁽¹⁾	913.2		1.7	%	99.651	%	July 8, 2015	January 4, 2022	January 4
Floating Rate 2022 Euronotes ⁽⁶⁾	285.7		three-month EURIBOR + 0.3%		100.147	%	June 30, 2017	June 30, 2022	March 30, June 30, September 30 and December 31
2023 CHF Bonds⁽²⁾	550.7		0.5	%	100.924	%	December 8, 2015	December 8, 2023	December 8
2025 Euronotes ⁽¹⁾	912.6		2.5	%	99.878	%	July 8, 2015	July 8, 2025	July 8
2025 U.S. Notes ⁽³⁾	496.8		3.35	%	99.857	%	September 15, 2015	September 15, 2025	March 15 and September 15
2027 Yen Notes ⁽⁷⁾	279.9		0.3	%	100	%	May 11, 2017	May 11, 2027	May 11 and November 11
2027 Euronotes ⁽⁶⁾	682.0		1.2	%	99.682	%	June 30, 2017	June 30, 2027	June 30
2028 CHF Bonds⁽²⁾	218.1		1.125	%	102.870	%	December 8, 2015 and December 8, 2017	December 8, 2028	December 8
2032 Yen Notes ⁽⁷⁾	483.4		0.65	%	100	%	May 11, 2017	May 11, 2032	May 11 and November 11
2045 U.S. Notes ⁽³⁾	499.3		4.375	%	99.784	%	September 15, 2015	September 15, 2045	March 15 and September 15
U.S. dollar and euro-denominated commercial paper	2,450.3		various		various		various	various	various
Other	66.7		various		various		various	various	various
Total debt	$	9,740.3


⁽¹⁾	The net proceeds, after underwriting discounts and commissions and offering expenses, of approximately €2.2 billion (approximately $2.4 billion based on currency exchange rates as of the date of issuance) from these notes were used to pay a portion of the purchase price for the acquisition of Pall Corporation in 2015 (the “Pall Acquisition”).

⁽²⁾

The net proceeds, including the related premium, and after underwriting discounts and commissions and offering expenses, of CHF 758 million ($739 million based on currency exchange rates as of date of pricing) from these bonds were used to repay a portion of the commercial paper issued to finance the Pall Acquisition and the CHF 100 million aggregate principal amount of the 0.0% senior unsecured bonds (the “2017 CHF Bonds”) that matured in December 2017.


⁽³⁾	The net proceeds, after underwriting discounts and commissions and offering expenses, of approximately $2.0 billion from these notes were used to repay a portion of the commercial paper issued to finance the Pall Acquisition.


⁽⁴⁾	The net proceeds, after offering expenses, of approximately ¥29.9 billion ($262 million based on currency exchange rates as of the date of issuance) from these notes were used to repay a portion of the commercial paper borrowings issued to finance the Pall Acquisition.

⁽⁵⁾

In connection with the Pall Acquisition, the Company acquired senior unsecured notes previously issued by Pall with an aggregate principal amount of $375 million. In accordance with accounting for business combinations, these notes were recorded at their fair value of $417 million on the date of acquisition and for accounting purposes, interest charges on these notes recorded in the Company’s Consolidated Statement of Earnings reflect an effective interest rate of approximately 2.9% per year.


⁽⁶⁾	The net proceeds at issuance, after offering expenses, of €843 million ($940 million based on currency exchange rates as of the date of pricing) from these notes were used to partially repay commercial paper borrowings.


⁽⁷⁾	The net proceeds at issuance, after offering expenses, of approximately ¥83.6 billion ($744 million based on currency exchange rates as of the date of pricing) from these notes were used to partially repay commercial paper borrowings.

LYONs

In 2001, the Company issued $830 million (value at maturity) in LYONs. The net proceeds to the Company were $505 million, of which approximately $100 million was used to pay down debt and the balance was used for general corporate purposes, including acquisitions. The LYONs originally carry a yield to maturity of 2.375% (with contingent interest payable as described below). Pursuant to the terms of the indenture that governs the Company’s LYONs, effective as of the record date of the distribution of the Fortive shares, the conversion ratio of the LYONs was adjusted so that each $1,000 of principal amount at maturity may be converted into 38.1998 shares of Danaher common stock at any time on or before the maturity date of January 22, 2021.

During the year ended December 31, 2018, holders of certain of the Company’s LYONs converted such LYONs into an aggregate of approximately 585 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax liability associated with the book and tax basis difference in the converted LYONs of $5 million was transferred to additional paid-in capital as a result of the conversions.

As of December 31, 2018, an aggregate of approximately 22 million shares of the Company’s common stock had been issued upon conversion of LYONs. As of December 31, 2018, the accreted value of the outstanding LYONs was lower than the traded market value of the underlying common stock issuable upon conversion. The Company may redeem all or a portion of the LYONs for cash at any time at scheduled redemption prices.

Under the terms of the LYONs, the Company pays contingent interest to the holders of LYONs during any six-month period from January 23 to July 22 and from July 23 to January 22 if the average market price of a LYON for a specified measurement period equals 120% or more of the sum of the issue price and accrued original issue discount for such LYON. The amount of contingent interest to be paid with respect to any quarterly period is equal to the higher of either 0.0315% of the bonds’ average market price during the specified measurement period or the amount of the cash dividend paid on Danaher’s common stock during such quarterly period multiplied by the number of shares issuable upon conversion of a LYON. The Company paid $2 million, $2 million and $1 million of contingent interest on the LYONs for each of the years ended December 31, 2018, 2017 and 2016, respectively. Except for the contingent interest described above, the Company will not pay interest on the LYONs prior to maturity.

Long-Term Debt Repayments

The $500 million aggregate principal amount of 2018 U.S. Notes were repaid with accrued interest upon their maturity in September 2018 using available cash and proceeds from commercial paper borrowings.

The €500 million aggregate principal amount of the floating rate senior unsecured notes due 2017 were repaid with accrued interest upon their maturity in June 2017 and the 2017 CHF Bonds were repaid upon their maturity in December 2017.

Covenants and Redemption Provisions Applicable to Notes

With respect to the 2020 Assumed Pall Notes; the 2027 and 2032 Yen Notes; the 2019, 2022, 2025 and 2027 Euronotes; and the 2020, 2025 and 2045 U.S. Notes, at any time prior to the applicable maturity date (or in certain cases three months prior to the maturity date), the Company may redeem the applicable series of notes in whole or in part, by paying the principal amount and the “make-whole” premium specified in the applicable indenture or comparable governing document, plus accrued and unpaid interest (and in the case of the Yen Notes, net of certain swap-related gains or losses as applicable). With respect to each of the 2023 and 2028 CHF Bonds at any time after 85% or more of the applicable bonds have been redeemed or purchased and canceled, the Company may redeem some or all of the remaining bonds for their principal amount plus accrued and unpaid interest. With respect to the 2021, 2027 and 2032 Yen Notes; the 2019, 2022, Floating Rate 2022, 2025 and 2027 Euronotes; and the 2023 and 2028 CHF Bonds, the Company may redeem such notes and bonds upon the occurrence of specified, adverse changes in tax laws, or interpretations under such laws, at a redemption price equal to the principal amount of the bonds to be redeemed.

If a change of control triggering event occurs with respect to any of the 2020 Assumed Pall Notes; the 2021, 2027 and 2032 Yen Notes; the 2019, 2022, Floating Rate 2022, 2025 and 2027 Euronotes; the 2020, 2025 and 2045 U.S. Notes; or the 2023 and 2028 CHF Bonds, each holder of such notes may require the Company to repurchase some or all of such notes and bonds at a purchase price equal to 101% (100% in the case of the 2027 and 2032 Yen Notes) of the principal amount of the notes and bonds, plus accrued and unpaid interest (and in the case of the Yen Notes, certain swap-related losses as applicable). A change of control triggering event means the occurrence of both a change of control and a rating event, each as defined in the applicable indenture or comparable governing document. Except in connection with a change of control triggering event, the Company does not have any credit rating downgrade triggers that would accelerate the maturity of a material amount of outstanding debt. Each holder of the 2027 and 2032 Yen Notes may also require the Company to repurchase some or all of its notes at a purchase price equal to 100% of the principal amount of the notes, plus accrued and unpaid interest and certain swap-related losses as applicable, in certain circumstances whereby such holder comes into violation of economic sanctions laws as a result of holding such notes.

The respective indentures or comparable governing documents under which the above-described notes and bonds were issued contain customary covenants including, for example, limits on the incurrence of secured debt and sale/leaseback transactions. None of these covenants are considered restrictive to the Company’s operations and as of December 31, 2018, the Company was in compliance with all of its debt covenants.

Guarantors of Debt

The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The 2019 Euronotes, 2022 Euronotes, Floating Rate 2022 Euronotes, 2025 Euronotes and 2027 Euronotes were issued by DH Europe Finance S.A. (“Danaher International”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2021 Yen Notes, 2027 Yen Notes and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the securities issued by each of these entities, as well as the 2020 Assumed Pall Notes, are fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness.

Other

The Company’s minimum principal payments for the next five years are as follows ($ in millions):



2019	$	51.8
2020	4,021.8
2021	327.5
2022	1,211.9
2023	548.1
Thereafter	3,579.2

The Company made interest payments of $140 million, $130 million and $212 million in 2018, 2017 and 2016, respectively.

Pension Benefit Plans

12 Months Ended

Dec. 31, 2018

Pension benefit plans

Defined Benefit Plans and Other Post-Retirement Benefit Plans [Line Items]

Pension Benefit Plans

PENSION BENEFIT PLANS

The Company has noncontributory defined benefit pension plans which cover certain of its U.S. employees. During 2012, all remaining benefit accruals under the U.S. plans ceased. Defined benefit plans from acquisitions subsequent to 2012 are ceased as soon as practical. The Company also has noncontributory defined benefit pension plans which cover certain of its non-U.S. employees, and under certain of these plans, benefit accruals continue. In general, the Company’s policy is to fund these plans based on considerations relating to legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors.

The following sets forth the funded status of the U.S. and non-U.S. plans as of the most recent actuarial valuations using measurement dates of December 31 ($ in millions):



	U.S. Pension Benefits						Non-U.S. Pension Benefits
	2018			2017			2018			2017
Change in pension benefit obligation:
Benefit obligation at beginning of year	$	(2,612.9	)	$	(2,558.1	)	$	(1,571.8	)	$	(1,493.0	)
Service cost	(6.7		)	(7.3		)	(35.5		)	(32.7		)
Interest cost	(81.0		)	(82.3		)	(25.1		)	(25.5		)
Employee contributions	—			—			(9.3		)	(8.2		)
Benefits and other expenses paid	179.0			181.8			51.4			58.3
Acquisitions and other	—			—			(3.6		)	—
Actuarial gain (loss)	145.2			(139.9		)	68.9			51.4
Amendments, settlements and curtailments	31.4			(7.1		)	26.5			10.5
Foreign exchange rate impact	—			—			56.2			(132.6		)
Benefit obligation at end of year	(2,345.0		)	(2,612.9		)	(1,442.3		)	(1,571.8		)
Change in plan assets:
Fair value of plan assets at beginning of year	2,004.9			1,868.2			1,199.3			1,042.9
Actual (loss) return on plan assets	(72.1		)	265.3			(19.9		)	74.6
Employer contributions	55.1			53.2			52.4			44.7
Employee contributions	—			—			9.3			8.2
Amendments and settlements	(30.6		)	—			(28.2		)	(3.7		)
Benefits and other expenses paid	(179.0		)	(181.8		)	(51.4		)	(58.3		)
Acquisitions and other	—			—			1.9			—
Foreign exchange rate impact	—			—			(45.0		)	90.9
Fair value of plan assets at end of year	1,778.3			2,004.9			1,118.4			1,199.3
Funded status	$	(566.7	)	$	(608.0	)	$	(323.9	)	$	(372.5	)

Weighted average assumptions used to determine benefit obligations at date of measurement:



	U.S. Plans				Non-U.S. Plans
	2018		2017		2018		2017
Discount rate	4.3	%	3.6	%	2.0	%	1.8	%
Rate of compensation increase	4.0	%	4.0	%	2.3	%	2.2	%

Components of net periodic pension benefit (cost):



	U.S. Pension Benefits						Non-U.S. Pension Benefits
($ in millions)	2018			2017			2018			2017
Service cost	$	(6.7	)	$	(7.3	)	$	(35.5	)	$	(32.7	)
Interest cost	(81.0		)	(82.3		)	(25.1		)	(25.5		)
Expected return on plan assets	132.0			130.5			46.9			42.4
Amortization of prior service (cost) credit	(0.9		)	—			0.5			0.3
Amortization of net loss	(31.3		)	(24.9		)	(6.0		)	(7.8		)
Curtailment and settlement gains recognized	—			—			4.9			0.5
Net periodic pension benefit (cost)	$	12.1		$	16.0		$	(14.3	)	$	(22.8	)

In the first quarter of 2018, the Company adopted ASU No. 2017-07, which requires the Company to disaggregate the service cost component from other components of net periodic benefit costs and report the service cost component in the same line item as other compensation costs and the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. As this ASU requires application on a retrospective basis, the Company reclassified the prior period presentation of the noncontributory defined benefit pension plans for the adoption of this ASU, resulting in a decrease in operating profit and an increase in other income, net of $33 million and $19 million for the years ended December 31, 2017 and 2016, respectively. The net periodic benefit cost of the noncontributory defined benefit pension plans incurred during the years ended December 31, 2018 and 2017 are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):



	Year Ended December 31
	2018			2017			2016
Service cost:
Cost of sales	$	(11.4	)	$	(8.2	)	$	(9.8	)
Selling, general and administrative expenses	(30.8		)	(31.8		)	(35.6		)
Total service cost	(42.2		)	(40.0		)	(45.4		)
Other net periodic pension costs:
Nonoperating income (expense), net	40.0			33.2			19.2
Total	$	(2.2	)	$	(6.8	)	$	(26.2	)

Weighted average assumptions used to determine net periodic pension (cost) benefit at date of measurement:



	U.S. Plans				Non-U.S. Plans
	2018		2017		2018		2017
Discount rate	3.6	%	4.1	%	1.8	%	1.8	%
Expected long-term return on plan assets	7.0	%	7.0	%	3.9	%	3.9	%
Rate of compensation increase	4.0	%	4.0	%	2.3	%	2.9	%

The discount rate reflects the market rate on December 31 of the prior year for high-quality fixed-income investments with maturities corresponding to the Company’s benefit obligations and is subject to change each year. For non-U.S. plans, rates appropriate for each plan are determined based on investment-grade instruments with maturities approximately equal to the average expected benefit payout under the plan. During 2018, the Company updated the mortality assumptions used to estimate the projected benefit obligation to reflect updated mortality tables.

Included in accumulated other comprehensive income (loss) as of December 31, 2018 are the following amounts that have not yet been recognized in net periodic pension cost: unrecognized prior service cost of $7 million ($5 million, net of tax) and unrecognized actuarial losses of approximately $919 million ($695 million, net of tax). The unrecognized losses and prior service cost, net, is calculated as the difference between the actuarially determined projected benefit obligation and the value of the plan assets less accrued pension costs as of December 31, 2018. The prior service cost and actuarial losses included in accumulated other comprehensive income (loss) and expected to be recognized in net periodic pension costs during the year ending December 31, 2019 is $0.7 million ($0.5 million, net of tax) and $30 million ($23 million, net of tax), respectively. No plan assets are expected to be returned to the Company during the year ending December 31, 2019.

Selection of Expected Rate of Return on Assets

For the years ended December 31, 2018, 2017 and 2016, the Company used an expected long-term rate of return assumption of 7.0% for its U.S. defined benefit pension plan. The Company intends to use an expected long-term rate of return assumption of 7.0% for 2019 for its U.S. plan. This expected rate of return reflects the asset allocation of the plan, and is based primarily on broad, publicly-traded equity and fixed-income indices and forward-looking estimates of active portfolio and investment management. Long-term rate of return on asset assumptions for the non-U.S. plans were determined on a plan-by-plan basis based on the composition of assets and ranged from 1.0% to 5.8% in both 2018 and 2017, with a weighted average rate of return assumption of 3.9% in both 2018 and 2017.

Plan Assets

The U.S. plan’s goal is to maintain between 60% and 70% of its assets in equity portfolios, which are invested in individual equity securities or funds that are expected to mirror broad market returns for equity securities or in assets with characteristics similar to equity investments, such as venture capital funds and partnerships. Asset holdings are periodically rebalanced when equity holdings are outside this range. The balance of the U.S. plan asset portfolio is invested in bond funds, real estate funds, various absolute and real return funds and private equity funds. Non-U.S. plan assets are invested in various insurance contracts, equity and debt securities as determined by the administrator of each plan. The value of the plan assets directly affects the funded status of the Company’s pension plans recorded in the Consolidated Financial Statements.

The Company has some investments that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient have limits on their redemption to monthly, quarterly, semiannually or annually and require up to 90 days prior written notice. These investments valued using NAV consist of mutual funds, common collective trusts, venture capital funds, partnerships, and other private investments, which allow the Company to allocate investments across a broad array of types of funds and diversify the portfolio.

The fair values of the Company’s pension plan assets for both the U.S. and non-U.S. plans as of December 31, 2018, by asset category were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Cash and equivalents	$	29.7	$	—	$	—	$	29.7
Equity securities:
Common stock	355.7		—		—		355.7
Preferred stock	4.6		—		—		4.6
Fixed income securities:
Corporate bonds	—		76.8		—		76.8
Government issued	—		32.8		—		32.8
Mutual funds	284.6		205.2		—		489.8
Insurance contracts	—		168.7		—		168.7
Total	$	674.6	$	483.5	$	—	1,158.1
Investments measured at NAV ^(a):
Mutual funds							179.8
Insurance contracts							209.1
Common collective trusts							957.8
Venture capital, partnerships and other private investments							391.9
Total assets at fair value							$	2,896.7


^(a)	The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

The fair values of the Company’s pension plan assets for both the U.S. and non-U.S. plans as of December 31, 2017, by asset category were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Cash and equivalents	$	36.0	$	—	$	—	$	36.0
Equity securities:
Common stock	444.8		—		—		444.8
Preferred stock	6.7		—		—		6.7
Fixed income securities:
Corporate bonds	—		113.3		—		113.3
Government issued	—		37.5		—		37.5
Mutual funds	341.5		147.0		—		488.5
Insurance contracts	—		299.4		—		299.4
Total	$	829.0	$	597.2	$	—	1,426.2
Investments measured at NAV ^(a):
Mutual funds							232.4
Insurance contracts							72.1
Common collective trusts							1,089.8
Venture capital, partnerships and other private investments							383.7
Total assets at fair value							$	3,204.2


^(a)	The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

Preferred stock and common stock traded on an active market, as well as mutual funds are valued at the quoted closing price reported on the active market on which the individual securities are traded. Preferred stock, common stock, corporate bonds, U.S. government securities and mutual funds that are not traded on an active market are valued at quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. Insurance contracts are valued based upon the quoted prices of the underlying investments with the insurance company.

Common/collective trusts are valued based on the plan’s interest, represented by investment units, in the underlying investments held within the trust that are traded in an active market by the trustee.

Venture capital, partnerships and other private investments are valued using the NAV based on the information provided by the asset fund managers, which reflects the plan’s share of the fair value of the net assets of the investment. Depending on the nature of the assets, the underlying investments are valued using a combination of either discounted cash flows, earnings and market multiples, third-party appraisals or through reference to the quoted market prices of the underlying investments held by the venture, partnership or private entity where available. Valuation adjustments reflect changes in operating results, financial condition, or prospects of the applicable portfolio company.

The methods described above may produce a fair value estimate that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes the valuation methods are appropriate and consistent with the methods used by other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Expected Contributions

During 2018, the Company contributed $55 million to its U.S. defined benefit pension plan and $52 million to its non-U.S. defined benefit pension plans. During 2019, the Company’s cash contribution requirements for its U.S. and its non-U.S. defined benefit pension plans are expected to be approximately $10 million and $50 million, respectively.

The following sets forth benefit payments, which reflect expected future service, as appropriate, expected to be paid by the plans in the periods indicated ($ in millions):



	U.S. Pension Plans		Non-U.S. Pension Plans		All Pension Plans
2019	$	172.3	$	50.2	$	222.5
2020	174.1		52.4		226.5
2021	174.8		51.1		225.9
2022	174.3		54.1		228.4
2023	174.2		56.3		230.5
2024 - 2028	814.7		308.7		1,123.4

Other Matters

Substantially all employees not covered by defined benefit plans are covered by defined contribution plans, which generally provide for Company funding based on a percentage of compensation.

A limited number of the Company’s subsidiaries participate in multiemployer defined benefit and contribution plans, primarily outside of the United States, that require the Company to periodically contribute funds to the plan. The risks of participating in a multiemployer plan differ from the risks of participating in a single-employer plan in the following respects: (1) assets contributed to the multiemployer plan by one employer may be used to provide benefits to employees of other participating employers, (2) if a participating employer ceases contributing to the plan, the unfunded obligations of the plan may be required to be borne by the remaining participating employers and (3) if the Company elects to stop participating in the plan, the Company may be required to pay the plan an amount based on the unfunded status of the plan. None of the multiemployer plans in which the Company’s subsidiaries participate are considered to be quantitatively or qualitatively significant, either individually or in the aggregate. In addition, contributions made to these plans during 2018, 2017 and 2016 were not considered significant, either individually or in the aggregate.

Expense for all defined benefit and defined contribution pension plans amounted to $187 million, $177 million and $177 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Other Postretirement Employee Benefit Plans

12 Months Ended

Dec. 31, 2018

Defined Contribution Plan [Abstract]

Other Postretirement Employee Benefit Plans

OTHER POSTRETIREMENT EMPLOYEE BENEFIT PLANS

In addition to providing pension benefits, the Company provides certain health care and life insurance benefits for some of its retired employees in the United States. Certain employees may become eligible for these benefits as they reach normal retirement age while working for the Company.

The following sets forth the funded status of the domestic plans as of the most recent actuarial valuations using measurement dates of December 31 ($ in millions):



	2018			2017
Change in benefit obligation:
Benefit obligation at beginning of year	$	(167.3	)	$	(174.6	)
Service cost	(0.5		)	(0.7		)
Interest cost	(5.3		)	(5.6		)
Amendments, curtailments and other	1.1			(0.4		)
Actuarial gain (loss)	9.5			(1.5		)
Retiree contributions	(2.6		)	(2.9		)
Benefits paid	18.6			18.4
Benefit obligation at end of year	(146.5		)	(167.3		)
Change in plan assets:
Fair value of plan assets	—			—
Funded status	$	(146.5	)	$	(167.3	)

As of December 31, 2018 and 2017, $131 million and $152 million, respectively, of the total underfunded status of the plan was recognized as long-term accrued postretirement liability since it was not expected to be funded within one year.

Weighted average assumptions used to determine benefit obligations at date of measurement:



	2018		2017
Discount rate	4.2	%	3.5	%
Medical trend rate – initial	6.0	%	6.3	%
Medical trend rate – grading period	19 years		20 years
Medical trend rate – ultimate	4.5	%	4.5	%

Effect of a one-percentage-point change in assumed health care cost trend rates:



($ in millions)	1% Increase		1% Decrease
Effect on the total of service and interest cost components	$	0.3	$	(0.2	)
Effect on postretirement medical benefit obligation	4.4		(3.7		)

The medical trend rate used to determine the postretirement benefit obligation was 6.0% for 2018. The rate decreases gradually to an ultimate rate of 4.5% in 2037 and remains at that level thereafter. The trend rate is a significant factor in determining the amounts reported.

Components of net periodic benefit cost:



($ in millions)	2018			2017
Service cost	$	(0.5	)	$	(0.7	)
Interest cost	(5.3		)	(5.6		)
Amortization of net gain	—			0.1
Amortization of prior service credit	2.5			3.1
Net periodic benefit cost	$	(3.3	)	$	(3.1	)

In the first quarter of 2018, the Company adopted ASU No. 2017-07, which requires the Company to disaggregate the service cost component from other components of net periodic benefit costs and report the service cost component in the same line item as other compensation costs and the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. As this ASU requires application on a retrospective basis, the Company reclassified the prior period presentation of the other postretirement employee benefit plans for the adoption of this ASU, resulting in an increase in operating profit and a decrease in other income, net of $2 million and $3 million for the years ended December 31, 2017 and 2016, respectively. The net periodic benefit cost of the other postretirement employee benefit plans incurred during the years ended December 31, 2018 and 2017 are reflected in the following captions in the accompanying Consolidated Condensed Statements of Earnings ($ in millions):



	Year Ended December 31
	2018			2017			2016
Service cost:
Cost of sales	$	(0.1	)	$	(0.1	)	$	(0.2	)
Selling, general and administrative expenses	(0.4		)	(0.6		)	(0.5		)
Total service cost	(0.5		)	(0.7		)	(0.7		)
Other net periodic pension costs:
Nonoperating income (expense), net	(2.8		)	(2.4		)	(3.5		)
Total	$	(3.3	)	$	(3.1	)	$	(4.2	)

Included in accumulated other comprehensive income (loss) as of December 31, 2018 are the following amounts that have not yet been recognized in net periodic benefit cost: unrecognized prior service credits of $19 million ($14 million, net of tax) and unrecognized actuarial losses of $6 million ($5 million, net of tax). The unrecognized losses and prior service credits, net, is calculated as the difference between the actuarially determined projected benefit obligation and the value of the plan assets less accrued benefit costs as of December 31, 2018. The prior service credits included in accumulated other comprehensive income (loss) and expected to be recognized in net periodic benefit costs during the year ending December 31, 2019 are $2 million ($2 million, net of tax). The actuarial losses included in accumulated other comprehensive income (loss) and expected to be recognized in net periodic benefit costs during the year ending December 31, 2019 are not material.

The following sets forth benefit payments, which reflect expected future service, as appropriate, expected to be paid in the periods indicated ($ in millions):



2019	$	15.2
2020	14.5
2021	13.8
2022	13.1
2023	12.3
2024 - 2028	54.1

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

Earnings from continuing operations before income taxes for the years ended December 31 were as follows ($ in millions):



	2018		2017		2016
United States	$	914.2	$	927.2	$	647.7
International	2,378.6		2,011.6		1,963.6
Total	$	3,292.8	$	2,938.8	$	2,611.3

The provision for income taxes from continuing operations for the years ended December 31 were as follows ($ in millions):



	2018			2017			2016
Current:
Federal U.S.	$	278.8		$	448.3		$	237.2
Non-U.S.	494.3			457.2			542.9
State and local	63.9			(9.6		)	61.7
Deferred:
Federal U.S.	(157.2		)	(424.7		)	(237.5		)
Non-U.S.	(6.8		)	(61.5		)	(104.2		)
State and local	(31.1		)	59.3			(42.2		)
Income tax provision	$	641.9		$	469.0		$	457.9

Noncurrent deferred tax assets and noncurrent deferred tax liabilities are included in other assets and other long-term liabilities, respectively, in the accompanying Consolidated Balance Sheets. Deferred income tax assets and liabilities as of December 31 were as follows ($ in millions):



	2018			2017
Deferred tax assets:
Allowance for doubtful accounts	$	19.7		$	18.6
Inventories	81.2			95.9
Pension and postretirement benefits	222.7			250.6
Environmental and regulatory compliance	22.4			26.8
Other accruals and prepayments	223.7			345.8
Stock-based compensation expense	64.7			63.9
Tax credit and loss carryforwards	894.5			673.4
Valuation allowances	(389.6		)	(324.6		)
Total deferred tax asset	1,139.3			1,150.4
Deferred tax liabilities:
Property, plant and equipment	(90.0		)	(63.4		)
Insurance, including self-insurance	(564.0		)	(696.2		)
Basis difference in LYONs	(21.6		)	(12.9		)
Goodwill and other intangibles	(2,774.9		)	(2,711.2		)
Total deferred tax liability	(3,450.5		)	(3,483.7		)
Net deferred tax liability	$	(2,311.2	)	$	(2,333.3	)

The Company evaluates the future realizability of tax credits and loss carryforwards considering the anticipated future earnings of the Company’s subsidiaries as well as tax planning strategies in the associated jurisdictions. Deferred taxes associated with U.S. entities consist of net deferred tax liabilities of approximately $2.0 billion as of December 31, 2018 and 2017. Deferred taxes associated with non-U.S. entities consist of net deferred tax liabilities of $277 million and $301 million as of December 31, 2018 and 2017, respectively. During 2018, the Company’s valuation allowance increased by $65 million through the tax provision primarily due to changes resulting from additional TCJA guidance and certain tax benefits recognized in 2018 that are not expected to be realized, partially offset by release of valuation allowance in a certain foreign jurisdiction. As of December 31, 2018, the total amount of the basis difference in investments outside the United States for which deferred taxes have not been provided is approximately $9.5 billion. As of December 31, 2018, the Company had no plans which would subject these basis differences to income taxes in the United States or elsewhere.

On December 22, 2017, the TCJA was enacted, substantially changing the U.S. tax system and affecting the Company in a number of ways. Notably, the TCJA:


•	established a flat corporate income tax rate of 21.0% on U.S. earnings;


•	imposed a one-time tax on unremitted cumulative non-U.S. earnings of foreign subsidiaries (“Transition Tax”);


•	imposes a new minimum tax on certain non-U.S. earnings, irrespective of the territorial system of taxation, and generally allows for the repatriation of future earnings of foreign subsidiaries without incurring additional U.S. taxes by transitioning to a territorial system of taxation;


•	subjects certain payments made by a U.S. company to a related foreign company to certain minimum taxes (Base Erosion Anti-Abuse Tax);


•	eliminated certain prior tax incentives for manufacturing in the United States and creates an incentive for U.S. companies to sell, lease or license goods and services abroad by allowing for a reduction in taxes owed on earnings related to such sales;


•	allows the cost of investments in certain depreciable assets acquired and placed in service after September 27, 2017 to be immediately expensed; and


•	reduces deductions with respect to certain compensation paid to specified executive officers.

While the changes from the TCJA were generally effective beginning in 2018, GAAP accounting for income taxes requires the effect of a change in tax laws or rates to be recognized in income from continuing operations for the period that includes the enactment date. Due to the complexities involved in accounting for the enactment of the TCJA, SAB No. 118 allowed the Company to record provisional amounts in earnings for the year ended December 31, 2017. Where reasonable estimates could be made, the provisional accounting was based on such estimates. When no reasonable estimate could be made, SAB No. 118 required the accounting to be based on the tax law in effect before the TCJA. The Company was required to complete its tax accounting for the TCJA when it had obtained, prepared and analyzed the information to complete the income tax accounting but no later than December 22, 2018.

Accordingly, during 2018, the Company completed its accounting for the tax effects of the enactment of the TCJA based on the Company’s interpretation of the new tax regulations and related guidance issued by the U.S. Department of the Treasury and the IRS.

•

The Transition Tax is based on the Company’s post-1986 earnings and profits that were previously deferred from U.S. income taxes. In the year ended December 31, 2017, the Company recorded a provision amount for the Transition Tax expense resulting in an increase in income tax expense of approximately $1.2 billion. During 2018, the Company finalized the calculations of the Transition Tax liability and increased the provisional amount recorded in 2017 by $40 million, with the increase included as a component of income tax expense from continuing operations in 2018. Regulations allow the Company to reduce the Transition Tax payable by applying available foreign tax credits and other tax attributes. The Company has elected to pay the net Transition Tax payable over an eight-year period as permitted by the TCJA. As of December 31, 2018, the remaining Transition Tax balance to be paid over the next seven years is approximately $180 million.


•	In connection with finalizing the calculation of tax credits available to reduce the Transition Tax and other U.S. taxable income, the Company recorded an additional provision of $13 million related to net unrealizable credits which is included as a component of income tax expense from continuing operations in 2018.

•

U.S. deferred tax assets and liabilities were remeasured as of December 31, 2017 based upon the tax rates at which the assets and liabilities are expected to reverse in the future, which is generally 21.0%, resulting in an income tax benefit of approximately $1.2 billion in 2017. Upon finalizing the provisional accounting for the remeasurement of U.S. deferred tax assets and liabilities in 2018, the Company recorded an additional tax benefit of $47 million, which is included as a component of income tax expense from continuing operations.

•

The TCJA imposes tax on U.S. shareholders for global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The Company is required to make an accounting policy election of either: (1) treating taxes due on future amounts included in U.S. taxable income related to GILTI as a current period tax expense when incurred (the “period cost method”); or (2) factoring such amounts into the Company’s measurement of its deferred tax expense (the “deferred method”). As of December 31, 2017, the Company was still analyzing its global income and did not record a GILTI-related deferred tax amount. In 2018, the Company elected the period cost method for its accounting for GILTI.

Due to the complexity and recent issuance of these tax regulations, management’s interpretations of the impact of these rules could be subject to challenge by the taxing authorities.

The effective income tax rate from continuing operations for the years ended December 31 varies from the U.S. statutory federal income tax rate as follows:



	Percentage of Pretax Earnings
	2018		2017		2016
Statutory federal income tax rate	21.0	%	35.0	%	35.0	%
Increase (decrease) in tax rate resulting from:
State income taxes (net of federal income tax benefit)	0.9	%	0.8	%	0.6	%
Foreign rate differential	(0.3	)%	(11.6	)%	(10.2	)%
Resolution and expiration of statutes of limitation of uncertain tax positions	(1.7	)%	(6.5	)%	(3.1	)%
Permanent foreign exchange losses	—	%	(0.6	)%	(8.2	)%
Research credits, uncertain tax positions and other	(0.6	)%	(1.0	)%	3.4	%
TCJA - revaluation of U.S. deferred income taxes	(1.4	)%	(41.5	)%	—	%
TCJA - Transition Tax	1.6	%	41.4	%	—	%
Effective income tax rate	19.5	%	16.0	%	17.5	%

The Company’s effective tax rate for 2018, 2017 and 2016 differs from the U.S. federal statutory rates of 21.0% in 2018 and 35.0% in 2017 and 2016, due principally to the Company’s earnings outside the United States that are indefinitely reinvested and taxed at rates different than the U.S. federal statutory rate. In addition:

•

The effective tax rate of 19.5% in 2018 includes 70 basis points of tax benefits primarily related to the release of reserves upon the expiration of statutes of limitation, audit settlements and release of valuation allowance in a certain foreign tax jurisdiction. These tax benefits were partially offset by additional provisions related to completing the accounting for the enactment of the TCJA as summarized above and tax costs directly related to reorganization activities associated with preparing for the Dental Separation.

•

The effective tax rate of 16.0% in 2017 includes 500 basis points of net tax benefits due to the revaluation of deferred tax liabilities from 35.0% to 21.0% due to the TCJA and the release of reserves upon statute of limitation expiration, partially offset by income tax expense related to the Transition Tax on foreign earnings due to the TCJA and changes in estimates associated with prior period uncertain tax positions.

•

The effective tax rate of 17.5% in 2016 includes 350 basis points of net tax benefits from permanent foreign exchange losses and the release of reserves upon the expiration of statutes of limitation and audit settlements, partially offset by income tax expense related to repatriation of earnings and legal entity realignments associated with the Fortive Separation and changes in estimates associated with prior period uncertain tax positions.

The Company made income tax payments related to both continuing and discontinued operations of $673 million, $689 million and $767 million in 2018, 2017 and 2016, respectively. Current income taxes payable related to both continuing and discontinued operations has been reduced by $57 million, $85 million, and $99 million in 2018, 2017 and 2016, respectively, for tax deductions attributable to stock-based compensation, of which, the excess tax benefit over the amount recorded for financial reporting purposes for both continuing and discontinued operations was $38 million, $55 million and $50 million, respectively. The excess tax benefit realized has been recorded as an increase to additional paid-in capital for the year ended December 31, 2016 and is reflected as a financing cash inflow in the accompanying Consolidated Statement of Cash Flows. As a result of the adoption of ASU 2016-09, Compensation—Stock Compensation, the excess tax benefits for the years ended December 31, 2018 and 2017 have been recorded as reductions to the current income tax provision and are reflected as operating cash inflows in the accompanying Consolidated Statements of Cash Flows.

Included in deferred income taxes related to continuing operations as of December 31, 2018 are tax benefits for U.S. and non-U.S. net operating loss carryforwards totaling $653 million ($252 million of which the Company does not expect to realize and have corresponding valuation allowances). Certain of the losses can be carried forward indefinitely and others can be carried forward to various dates from 2019 through 2038. In addition, the Company had general business and foreign tax credit carryforwards related to continuing operations of $241 million ($89 million of which the Company does not expect to realize and have corresponding valuation allowances) as of December 31, 2018, which can be carried forward to various dates from 2019 to 2028. In addition, as of December 31, 2018, the Company had $49 million of valuation allowances related to other deferred tax asset balances that are not more likely than not of being realized.

As of December 31, 2018, gross unrecognized tax benefits related to continuing operations totaled $986 million ($988 million, net of the impact of $117 million of indirect tax benefits offset by $119 million associated with potential interest and penalties). As of December 31, 2017, gross unrecognized tax benefits related to continuing operations totaled $737 million ($736 million, net of the impact of $104 million of indirect tax benefits offset by $103 million associated with potential interest and penalties). The Company recognized approximately $41 million, $41 million and $47 million in potential interest and penalties related to both continuing and discontinued operations associated with uncertain tax positions during 2018, 2017 and 2016, respectively. To the extent unrecognized tax benefits (including interest and penalties) are recognized with respect to uncertain tax positions, $936 million would reduce the tax expense and effective tax rate in future periods. The Company recognized interest and penalties related to unrecognized tax benefits within income taxes in the accompanying Consolidated Statements of Earnings. Unrecognized tax benefits and associated accrued interest and penalties are included in taxes, income and other accrued expenses as detailed in Note 9.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding amounts accrued for potential interest and penalties related to both continuing and discontinued operations, is as follows ($ in millions):



	2018			2017			2016
Unrecognized tax benefits, beginning of year	$	736.8		$	992.2		$	990.2
Additions based on tax positions related to the current year	43.1			53.0			80.0
Additions for tax positions of prior years	324.3			39.8			154.3
Reductions for tax positions of prior years	(21.9		)	(14.5		)	(7.0		)
Acquisitions, divestitures and other	9.4			13.4			(41.5		)
Lapse of statute of limitations	(52.9		)	(246.7		)	(124.0		)
Settlements	(41.8		)	(124.8		)	(45.3		)
Effect of foreign currency translation	(11.0		)	24.4			(14.5		)
Unrecognized tax benefits, end of year	$	986.0		$	736.8		$	992.2

The Company conducts business globally, and files numerous consolidated and separate income tax returns in the U.S. federal, state and foreign jurisdictions. The non-U.S. countries in which the Company has a significant presence include China, Denmark, Germany, Singapore, Switzerland and the United Kingdom. The Company believes that a change in the statutory tax rate of any individual foreign country would not have a material effect on the Company’s Consolidated Financial Statements given the geographic dispersion of the Company’s taxable income.

The Company and its subsidiaries are routinely examined by various domestic and international taxing authorities. The IRS has completed substantially all of the examinations of the Company’s federal income tax returns through 2011 and is currently examining certain of the Company’s federal income tax returns for 2012 through 2015. In addition, the Company has subsidiaries in Austria, Belgium, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Italy, Japan, New Zealand, Sweden, Switzerland, the United Kingdom and various other countries, states and provinces that are currently under audit for years ranging from 2004 through 2017.

In the fourth quarter of 2018, the IRS proposed significant adjustments to the Company’s taxable income for the years 2012 through 2015 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs. The proposed adjustments would increase the Company’s taxable income over the 2012 through 2015 period by approximately $960 million. In addition, as of December 31, 2018, the IRS has notified the Company that it is considering additional taxable income adjustments related to other aspects of the Company’s self-insurance programs for the years 2012 through 2015. These additional proposed adjustments would increase the Company’s taxable income by approximately $1.7 billion. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws, intends to vigorously defend these positions and is currently considering all of its alternatives. Due to the enactment of the TCJA in 2017 and the resulting reduction in the U.S. corporate tax rate for years after 2017, the Company revalued its deferred tax liabilities related to the temporary differences associated with this deferred premium income from 35.0% to 21.0%. If the Company is not successful in defending these assessments, the taxes owed to the IRS may be computed under the previous 35.0% statutory tax rate and the Company may be required to revalue the related deferred tax liabilities from 21.0% to 35.0%, which in addition to any interest due on the amounts assessed, would require a charge to future earnings. The ultimate resolution of this matter is uncertain, could take many years and could result in a material adverse impact to the Company’s Consolidated Financial Statements, including its cash flows and effective tax rate.

Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries. On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) totaling approximately DKK 1.6 billion (approximately $247 million based on exchange rates as of December 31, 2018) including interest through December 31, 2018, imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the Company’s subsidiaries for the years 2004 through 2009. The Company is currently in discussions with SKAT and anticipates receiving an assessment for years 2010 through 2012 totaling approximately DKK 954 million (approximately $146 million based on exchange rates as of December 31, 2018) including interest through December 31, 2018. Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is vigorously defending its positions. The Company appealed these assessments with the National Tax Tribunal in 2014 and intends on pursuing this matter through the European Court of Justice should this appeal be unsuccessful. The ultimate resolution of this matter is uncertain, could take many years, and could result in a material adverse impact to the Company’s Consolidated Financial Statements, including its cash flows and effective tax rate.

Management estimates that it is reasonably possible that the amount of unrecognized tax benefits related to continuing operations may be reduced by approximately $134 million within 12 months as a result of resolution of worldwide tax matters, payments of tax audit settlements and/or statute of limitations expirations. Future resolution of uncertain tax positions related to discontinued operations may result in additional charges or credits to earnings from discontinued operations in the Consolidated Statements of Earnings (refer to Note 4).

The Company operates in various non-U.S. jurisdictions where income tax incentives and rulings have been granted for specific periods of time. In Switzerland, the Company has various tax rulings and tax holiday arrangements which reduce the overall effective tax rate of the Company. The tax holidays expire between 2019 and 2022. In Singapore, the Company operates under various tax incentive agreements that provide for reduced tax rates. Subject to the Company satisfying certain requirements, the agreements expire in 2022. The Company has satisfied the conditions enumerated in these agreements to date. Included in the accompanying Consolidated Financial Statements are tax benefits of $70 million, $62 million, and $61 million for 2018, 2017, and 2016, respectively, from these rulings and tax holidays.

Nonoperating Income (Expense)	12 Months Ended
Nonoperating Income (Expense)	Dec. 31, 2018
Other Income and Expenses [Abstract]
Nonoperating Income (Expense)	NONOPERATING INCOME (EXPENSE) As described in Notes 1, 11 and 12, in the first quarter of 2018, the Company adopted ASU No. 2017-07. The ASU requires the Company to disaggregate the service cost component from the other components of net periodic benefit costs and requires the Company to present the other components of net periodic benefit cost in other income, net. The ASU also requires application on a retrospective basis. As a result of adopting this ASU, the Company classified $37 million, $31 million and $16 million of net pension and postretirement benefits as other income as of December 31, 2018, 2017 and 2016, respectively. The Company received $138 million of cash proceeds and recorded $22 million in short-term other receivables from the sale of certain marketable equity securities during 2017. The Company recorded a pretax gain related to this sale of $73 million ($46 million after-tax or $0.06 per diluted share). During 2016, the Company received cash proceeds of $265 million from the sale of certain marketable equity securities and recorded a pretax gain related to this sale of $223 million ($140 million after-tax or $0.20 per diluted share). During 2016, the Company also paid $188 million of make-whole premiums associated with the early extinguishment of the Redeemed Notes. The Company recorded a loss on extinguishment of these borrowings, net of certain deferred gains, of $179 million ($112 million after-tax or $0.16 per diluted share).

Productivity Improvement And Restructuring Initiatives

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Productivity Improvement And Restructuring Initiatives

PRODUCTIVITY IMPROVEMENT AND RESTRUCTURING INITIATIVES

During 2018, the Company recorded pretax productivity improvement and restructuring related charges of $70 million. Substantially all the activities initiated in 2018 were completed by December 31, 2018, resulting in $59 million of employee severance and related charges and $11 million of facility exit and other related charges. The Company expects substantially all cash payments associated with remaining termination benefits will be paid during 2019.

During 2017, the Company made the strategic decision to discontinue a molecular diagnostic product line in its Diagnostics segment. As a result, the Company recorded $76 million of pretax restructuring, impairment and other related charges ($51 million after-tax or $0.07 per diluted share). These charges included $49 million of noncash charges for the impairment of certain technology-related intangible assets as well as related inventory and property, plant and equipment with no further use. In addition, the Company incurred $27 million of cash restructuring costs primarily related to employee severance and related charges. Substantially all restructuring activities related to this discontinued product line were completed in 2017.

In addition to the molecular diagnostic product line discontinuation noted above, during 2017 the Company recorded pretax productivity improvement and restructuring related charges of $83 million, for a total of $159 million of pretax productivity improvement and restructuring related charges in 2017. Substantially all of the planned activities related to the 2017 plans were completed by December 31, 2017 resulting in approximately $78 million of employee severance and related charges and $81 million of facility exit and other related charges (including noncash charges for the impairment of certain technology-related intangibles as well as related inventory and property, plant and equipment with no further use).

During 2016, the Company recorded pretax productivity improvement and restructuring related charges totaling $152 million. Substantially all of the planned activities related to the 2016 plans were completed by December 31, 2016 resulting in approximately $111 million of employee severance and related charges, $30 million of facility exit and other related charges and $11 million of charges related to an impairment of a trade name within the Dental segment.

Excluding the discontinuation of the molecular diagnostic product line, the nature of the Company’s productivity improvement and restructuring related activities initiated in 2018, 2017 and 2016 were broadly consistent throughout the Company’s reportable segments and focused on improvements in operational efficiency through targeted workforce reductions and facility consolidations and closures. These costs were incurred to position the Company to provide superior products and services to its customers in a cost efficient manner, and taking into consideration broad economic considerations.

In conjunction with the closing of facilities, certain inventory was written off as unusable in future operating locations. This inventory consisted primarily of component parts and raw materials, which were either redundant to inventory at the facilities being merged or were not economically feasible to relocate since the inventory was purchased to operate on equipment and tooling which was not being relocated. In addition, asset impairment charges have been recorded to reduce the carrying amounts of the long-lived assets that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.

Productivity improvement and restructuring related charges, including those related to the discontinuation of the molecular diagnostics product line, recorded for the years ended December 31 by segment were as follows ($ in millions):



	2018		2017		2016
Life Sciences	$	11.4	$	25.4	$	40.5
Diagnostics	14.9		85.4		62.2
Dental	23.7		35.8		34.3
Environmental & Applied Solutions	20.0		12.5		15.4
Total	$	70.0	$	159.1	$	152.4

The table below summarizes the Company’s accrual balance and utilization by type of productivity improvement and restructuring costs associated with the 2018 and 2017 actions ($ in millions):



	Employee Severance & Related			Facility Exit & Related			Total
Balance, January 1, 2017	$	45.3		$	11.8		$	57.1
Costs incurred	77.7			81.4			159.1
Paid/settled	(74.0		)	(75.9		)	(149.9		)
Balance, December 31, 2017	49.0			17.3			66.3
Costs incurred	59.4			10.6			70.0
Paid/settled	(68.8		)	(20.3		)	(89.1		)
Balance, December 31, 2018	$	39.6		$	7.6		$	47.2

The productivity improvement and restructuring related charges incurred during 2018 include cash charges of $68 million and $2 million of noncash charges. The productivity improvement and restructuring related charges incurred during 2017 and 2016 include cash charges of $103 million and $140 million and $56 million and $12 million of noncash charges, respectively. These charges are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):



	2018		2017		2016
Cost of sales	$	16.8	$	38.0	$	25.4
Selling, general and administrative expenses	53.2		121.1		127.0
Total	$	70.0	$	159.1	$	152.4

Leases And Commitments

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Leases And Commitments

LEASES AND COMMITMENTS

The Company’s operating leases extend for varying periods of time up to 20 years and, in some cases, contain renewal options that would extend existing terms beyond 20 years. Total rent expense for all operating leases was $282 million, $249 million and $220 million for the years ended December 31, 2018, 2017 and 2016, respectively.

As discussed in Note 1, the Company adopted ASC 842 related to lease accounting on January 1, 2019. Future minimum lease payments differ from the future lease liability recognized under ASC 842, as the lease liability recognized under ASC 842 discounts the lease payments while the minimum lease payments presented below are not discounted. Additionally, ASC 842 allows a lessee to elect to combine or separate any non-lease components in an arrangement with the lease components for the calculation of the lease liability while the minimum lease payments exclude any non-lease components. The Company’s future minimum rental payments for all operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows ($ in millions):



2019	$	203.0
2020	167.7
2021	133.3
2022	116.8
2023	101.9
Thereafter	287.2

The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known.

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



	2018			2017
Balance, January 1	$	79.0		$	75.8
Accruals for warranties issued during the year	60.6			54.5
Settlements made	(60.0		)	(56.6		)
Additions due to acquisitions	—			1.7
Effect of foreign currency translation	(2.2		)	3.6
Balance, December 31	$	77.4		$	79.0

Litigation And Contingencies	12 Months Ended
Litigation And Contingencies	Dec. 31, 2018
Loss Contingency [Abstract]
Litigation And Contingencies	LITIGATION AND CONTINGENCIES The Company is subject to a variety of litigation and other legal and regulatory proceedings incidental to its business (or the business operations of previously owned entities), including claims or counterclaims for damages arising out of the use of products or services and claims relating to intellectual property matters, employment matters, tax matters, commercial disputes, breach of contract claims, competition and sales and trading practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters, as well as regulatory subpoenas, requests for information, investigations and enforcement. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. The types of claims made in lawsuits include claims for compensatory damages, punitive and consequential damages (and in some cases, treble damages) and/or injunctive relief. Based upon the Company’s experience, current information and applicable law, it does not believe it is reasonably possible that any amounts it may be required to pay in connection with litigation and other legal and regulatory proceedings in excess of its reserves as of December 31, 2018 will have a material effect on its Consolidated Financial Statements. While the Company maintains general, products, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance (and has acquired rights under similar policies in connection with certain acquisitions) up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. For general, products and property liability and most other insured risks, the Company purchases outside insurance coverage only for severe losses and must establish and maintain reserves with respect to amounts within the self-insured retention. In addition, while the Company believes it is entitled to indemnification from third-parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses. The Company records a liability in the Consolidated Financial Statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss does not meet the known or probable level but is reasonably possible it is disclosed and if the loss or range of loss can be reasonably estimated, the estimated loss or range of loss is disclosed. The Company’s reserves consist of specific reserves for individual claims and additional amounts for anticipated developments of these claims as well as for incurred but not yet reported claims. The specific reserves for individual known claims are quantified with the assistance of legal counsel and outside risk professionals where appropriate. In addition, outside risk professionals assist in the determination of reserves for incurred but not yet reported claims through evaluation of the Company’s specific loss history, actual claims reported and industry trends among statistical and other factors. Reserve estimates may be adjusted as additional information regarding a claim becomes known. Because most contingencies are resolved over long periods of time, liabilities may change in the future due to new developments (including litigation developments, the discovery of new facts, changes in legislation and outcomes of similar cases), changes in assumptions or changes in the Company’s strategy. While the Company actively pursues financial recoveries from insurance providers and indemnifying parties, it does not recognize any recoveries until realized or until such time as a sustained pattern of collections is established related to historical matters of a similar nature and magnitude. If the Company’s self-insurance and litigation reserves prove inadequate, it would be required to incur an expense equal to the amount of the loss incurred in excess of the reserves, which would adversely affect the Company’s Consolidated Financial Statements. In addition, the Company’s operations, products and services are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the environment, establish standards for the use, generation, treatment, storage and disposal of hazardous and nonhazardous wastes and impose end-of-life disposal and take-back programs. A number of the Company’s operations involve the handling, manufacturing, use or sale of substances that are or could be classified as hazardous materials within the meaning of applicable laws. The Company must also comply with various health and safety regulations in both the United States and abroad in connection with the Company’s operations. Compliance with these laws and regulations has not had and, based on current information and the applicable laws and regulations currently in effect, is not expected to have a material effect on the Company’s capital expenditures, earnings or competitive position, and the Company does not anticipate material capital expenditures for environmental control facilities. In addition to environmental compliance costs, the Company from time to time incurs costs related to alleged damages associated with past or current waste disposal practices or other hazardous materials handling practices. For example, generators of hazardous substances found in disposal sites at which environmental problems are alleged to exist, as well as the current and former owners of those sites and certain other classes of persons, are subject to claims brought by state and federal regulatory agencies pursuant to statutory authority. The Company has received notification from the U.S. Environmental Protection Agency, and from state and non-U.S. environmental agencies, that conditions at certain sites where the Company and others previously disposed of hazardous wastes and/or are or were property owners require clean-up and other possible remedial action, including sites where the Company has been identified as a potentially responsible party under U.S. federal and state environmental laws. The Company has projects underway at a number of current and former facilities, in both the United States and abroad, to investigate and remediate environmental contamination resulting from past operations. Remediation activities generally relate to soil and/or groundwater contamination and may include pre-remedial activities such as fact-finding and investigation, risk assessment, feasibility study and/or design, as well as remediation actions such as contaminant removal, monitoring and/or installation, operation and maintenance of longer-term remediation systems. The Company is also from time to time party to personal injury or other claims brought by private parties alleging injury due to the presence of, or exposure to, hazardous substances. The Company has recorded a provision for environmental investigation and remediation and environmental-related claims with respect to sites owned or formerly owned by the Company and its subsidiaries and third-party sites where the Company has been determined to be a potentially responsible party. The Company generally makes an assessment of the costs involved for its remediation efforts based on environmental studies, as well as its prior experience with similar sites. The ultimate cost of site cleanup is difficult to predict given the uncertainties of the Company’s involvement in certain sites, uncertainties regarding the extent of the required cleanup, the availability of alternative cleanup methods, variations in the interpretation of applicable laws and regulations, the possibility of insurance recoveries with respect to certain sites and the fact that imposition of joint and several liability with right of contribution is possible under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 and other environmental laws and regulations. If the Company determines that potential liability for a particular site or with respect to a personal injury claim is known or considered probable and reasonably estimable, the Company accrues the total estimated loss, including investigation and remediation costs, associated with the site or claim. As of December 31, 2018, the Company had a reserve of $147 million for environmental matters which are known or considered probable and reasonably estimable (of which $110 million are noncurrent), which reflects the Company’s best estimate of the costs to be incurred with respect to such matters. All reserves have been recorded without giving effect to any possible future third-party recoveries. While the Company actively pursues insurance recoveries, as well as recoveries from other potentially responsible parties, it does not recognize any insurance recoveries for environmental liability claims until realized or until such time as a sustained pattern of collections is established related to historical matters of a similar nature and magnitude. The Company’s Restated Certificate of Incorporation requires it to indemnify to the full extent authorized or permitted by law any person made, or threatened to be made a party to any action or proceeding by reason of his or her service as a director or officer of the Company, or by reason of serving at the request of the Company as a director or officer of any other entity, subject to limited exceptions. Danaher’s Amended and Restated By-laws provide for similar indemnification rights. In addition, Danaher has executed with each director and executive officer of Danaher Corporation an indemnification agreement which provides for substantially similar indemnification rights and under which Danaher has agreed to pay expenses in advance of the final disposition of any such indemnifiable proceeding. While the Company maintains insurance for this type of liability, a significant deductible applies to this coverage and any such liability could exceed the amount of the insurance coverage. As of December 31, 2018, the Company had approximately $668 million of guarantees consisting primarily of outstanding standby letters of credit, bank guarantees and performance and bid bonds. These guarantees have been provided in connection with certain arrangements with vendors, customers, insurance providers, financing counterparties and governmental entities to secure the Company’s obligations and/or performance requirements related to specific transactions. The Company believes that if the obligations under these instruments were triggered, it would not have a material effect on its Consolidated Financial Statements.

Stock Transactions And Stock-Based Compensation

12 Months Ended

Dec. 31, 2018

Share-based Compensation [Abstract]

Stock Transactions and Stock-Based Compensation

STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION

On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. There is no expiration date for the Repurchase Program, and the timing and amount of any shares repurchased under the program will be determined by the Company’s management based on its evaluation of market conditions and other factors. The Repurchase Program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with the Company’s equity compensation plans (or any successor plan) and for other corporate purposes. As of December 31, 2018, 20 million shares remained available for repurchase pursuant to the Repurchase Program. The Company expects to fund any future stock repurchases using the Company’s available cash balances or proceeds from the issuance of debt.

Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during 2018, 2017 or 2016.

Stock options, RSUs and PSUs have been issued to directors, officers and other employees under the Company’s 2007 Omnibus Incentive Plan. In addition, in connection with the 2016 Cepheid Acquisition, the Company assumed certain outstanding stock options and RSUs, as applicable, that had been awarded under the stock compensation plan of the acquired business. This plan (the “Assumed Plan”) operates in a similar manner to the Company’s 2007 Omnibus Incentive Plan, and no further equity awards will be issued under the Assumed Plan. The 2007 Omnibus Incentive Plan provides for the grant of stock options, stock appreciation rights, RSUs, restricted stock, PSUs or any other stock-based award and cash based awards. A total of approximately 127 million shares of Danaher common stock have been authorized for issuance under the 2007 Omnibus Incentive Plan. As of December 31, 2018, approximately 58 million shares of the Company’s common stock remain available for issuance under the 2007 Omnibus Incentive Plan.

Stock options granted under the 2007 Omnibus Incentive Plan generally vest pro rata over a five-year period and terminate ten years from the grant date, though the specific terms of each grant are determined by the Compensation Committee of the Company’s Board (the “Compensation Committee”). The Company’s executive officers and certain other employees have been awarded options with different vesting criteria, and options granted to outside directors are fully vested as of the grant date. Option exercise prices for options granted by the Company equal the closing price of the Company’s common stock on the NYSE on the date of grant. In connection with the Company’s assumption of options issued pursuant to the Assumed Plan, the number of shares underlying each option and exercise price of each option were adjusted to reflect the substitution of the Company’s stock for the stock of the applicable acquired company.

RSUs issued under the 2007 Omnibus Incentive Plan provide for the issuance of a share of the Company’s common stock at no cost to the holder. The RSUs that have been granted to employees under the 2007 Omnibus Incentive Plan generally provide for time-based vesting over a five-year period, although executive officers and certain other employees have been awarded RSUs with different time-based vesting criteria, and RSUs granted to members of the Company’s senior management have also been subject to performance-based vesting criteria. The RSUs that have been granted to directors under the 2007 Omnibus Incentive Plan vest on the earlier of the first anniversary of the grant date or the date of, and immediately prior to, the next annual meeting of the Company’s shareholders following the grant date, but the underlying shares are not issued until the earlier of the director’s death or the first day of the seventh month following the director’s retirement from the Board. Prior to vesting, RSUs granted under the 2007 Omnibus Incentive Plan do not have dividend equivalent rights, do not have voting rights and the shares underlying the RSUs are not considered issued and outstanding. With respect to RSUs granted under the Assumed Plan, in connection with the Company’s assumption of these RSUs the number of shares underlying each RSU were adjusted to reflect the substitution of the Company’s stock for the stock of the applicable acquired company, and certain of these RSUs have dividend equivalent rights.

In 2015, the Company introduced into its executive officer equity compensation program PSUs that vest based on the Company’s total shareholder return ranking relative to the S&P 500 Index over a three-year performance period and are subject to an additional two-year holding period, and are entitled to dividend equivalent rights. The PSUs were issued under the Company’s 2007 Omnibus Incentive Plan. PSU’s granted under the 2007 Omnibus Incentive Plan have dividend equivalent rights (which are subject to the same vesting and payment restrictions as the related shares), but do not have voting rights and the shares underlying the PSU’s are not considered issued and outstanding.

In connection with the Fortive Separation and pursuant to the anti-dilution provisions of the 2007 Omnibus Incentive Plan, the Company made certain adjustments to the exercise price and the number of shares underlying stock-based compensation awards with the intention of preserving the intrinsic value of the awards prior to the Fortive Separation. Accordingly, the number of shares underlying each stock-based award outstanding as of the date of the Fortive Separation was multiplied by a factor of 1.32 and the related exercise price for stock options was divided by a factor of 1.32 which resulted in no increase in the intrinsic value of awards outstanding. The stock-based compensation awards continue to vest over their original vesting period. These adjustments to the Company’s stock-based compensation awards did not result in additional compensation expense. Stock-based compensation awards that were held by employees who transferred to Fortive in connection with the Separation were canceled and replaced by awards issued by Fortive.

The equity compensation awards granted by the Company generally vest only if the employee is employed by the Company (or in the case of directors, the director continues to serve on the Company Board) on the vesting date or in other limited circumstances. To cover the exercise of options and vesting of RSUs and PSUs, the Company generally issues new shares from its authorized but unissued share pool, although it may instead issue treasury shares in certain circumstances.

The Company accounts for stock-based compensation by measuring the cost of employee services received in exchange for all equity awards granted based on the fair value of the award as of the grant date. The Company recognizes the compensation expense over the requisite service period (which is generally the vesting period but may be shorter than the vesting period if the employee becomes retirement eligible before the end of the vesting period). The fair value for RSU awards was calculated using the closing price of the Company’s common stock on the date of grant, adjusted for the fact that RSUs (other than certain RSUs granted under the Assumed Plans) do not accrue dividends. The fair value of the PSU awards was calculated using a Monte Carlo pricing model. The fair value of the options granted was calculated using a Black-Scholes Merton option pricing model (“Black-Scholes”).

The following summarizes the assumptions used in the Black-Scholes model to value options granted during the years ended December 31:



	2018		2017		2016
Risk-free interest rate	2.6 – 3.1%		1.8 – 2.2%		1.2 – 1.8%
Weighted average volatility	21.4	%	17.9	%	24.3	%
Dividend yield	0.6	%	0.7	%	0.6	%
Expected years until exercise	5.0 – 8.0		5.0 – 8.0		5.5 – 8.0

The Black-Scholes model incorporates assumptions to value stock-based awards. The risk-free rate of interest for periods within the contractual life of the option is based on a zero-coupon U.S. government instrument whose maturity period equals or approximates the option’s expected term. Expected volatility is based on implied volatility from traded options on the Company’s stock and historical volatility of the Company’s stock. The dividend yield is calculated by dividing the Company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. To estimate the option exercise timing used in the valuation model (which impacts the risk-free interest rate and the expected years until exercise), in addition to considering the vesting period and contractual term of the option, the Company analyzes and considers actual historical exercise experience for previously granted options. The Company stratifies its employee population into multiple groups for option valuation and attribution purposes based upon distinctive patterns of forfeiture rates and option holding periods, as indicated by the ranges set forth in the table above for the risk-free interest rate and the expected years until exercise.

The amount of stock-based compensation expense recognized during a period is also based on the portion of the awards that are ultimately expected to vest. The Company estimates pre-vesting forfeitures at the time of grant by analyzing historical data and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will equal the fair value of awards that actually vest.

The following summarizes the components of the Company’s continuing operations stock-based compensation expense for the years ended December 31 ($ in millions):



	2018			2017			2016
RSUs/PSUs:
Pretax compensation expense	$	94.7		$	90.2		$	85.9
Income tax benefit	(19.8		)	(27.7		)	(25.3		)
RSU/PSU expense, net of income taxes	74.9			62.5			60.6
Stock options:
Pretax compensation expense	56.7			49.2			43.9
Income tax benefit	(12.0		)	(15.6		)	(13.6		)
Stock option expense, net of income taxes	44.7			33.6			30.3
Total stock-based compensation:
Pretax compensation expense	151.4			139.4			129.8
Income tax benefit	(31.8		)	(43.3		)	(38.9		)
Total stock-based compensation expense, net of income taxes	$	119.6		$	96.1		$	90.9

Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings. As of December 31, 2018, $149 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years. As of December 31, 2018, $139 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately three years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.

The following summarizes option activity under the Company’s stock plans (in millions, except weighted exercise price and number of years):



	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding as of January 1, 2016	24.9		$	43.75
Granted	5.7		67.52
Exercised	(5.3	)	33.45
Cancelled/forfeited	(1.2	)	73.21
Adjustment due to Fortive Separation ^(a)	(5.2	)	50.44
Outstanding as of December 31, 2016	18.9		50.07
Granted	4.4		86.14
Exercised	(3.3	)	35.26
Cancelled/forfeited	(1.2	)	70.40
Outstanding as of December 31, 2017	18.8		59.84
Granted	4.1		99.51
Exercised	(3.4	)	41.88
Cancelled/forfeited	(0.9	)	80.14
Outstanding as of December 31, 2018	18.6		70.86		7	$	600.8
Vested and expected to vest as of December 31, 2018 ^(b)	18.0		$	70.24	7	$	592.8
Vested as of December 31, 2018	7.7		$	53.19	5	$	383.3


^(a)	The “Adjustment due to Fortive Separation” reflects the cancellation of options which were outstanding as of July 2, 2016 and held by Fortive employees, which have been converted to Fortive equity awards as part of the Fortive Separation.


^(b)	The “expected to vest” options are the net unvested options that remain after applying the forfeiture rate assumption to total unvested options.

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between the Company’s closing stock price on the last trading day of 2018 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2018. The amount of aggregate intrinsic value will change based on the price of the Company’s common stock.

Options outstanding as of December 31, 2018 are summarized below (in millions, except price per share and number of years):



	Outstanding				Exercisable
Exercise Price	Shares	Average Exercise Price		Average Remaining Life (in years)	Shares	Average Exercise Price
$19.89 to $39.60	2.1	$	34.15	2	2.0	$	34.13
$39.61 to $56.70	2.5	48.73		4	2.3	48.15
$56.71 to $70.75	6.1	64.58		6	2.6	63.64
$70.76 to $86.08	3.9	85.13		8	0.7	84.37
$86.09 to $101.65	4.0	99.23		9	0.1	95.44

The aggregate intrinsic value of options exercised during the years ended December 31, 2018, 2017 and 2016 was $202 million, $162 million and $210 million, respectively. Exercise of options during the years ended December 31, 2018, 2017 and 2016 resulted in cash receipts of $133 million, $117 million and $161 million, respectively. Upon exercise of the award by the employee, the Company derives a tax deduction measured by the excess of the market value over the grant price at the date of exercise. The Company realized a tax benefit of $40 million, $50 million and $61 million in 2018, 2017 and 2016, respectively, related to the exercise of employee stock options.

The following summarizes information on unvested RSU and PSU activity (in millions, except weighted average grant-date fair value):



	Number of RSUs/PSUs		Weighted Average Grant-Date Fair Value
Unvested as of January 1, 2016	6.1		$	53.93
Granted	1.9		66.15
Vested	(1.8	)	50.64
Adjustment due to Fortive Separation ^(a)	(1.2	)	58.24
Forfeited	(0.5	)	28.79
Unvested as of December 31, 2016	4.5		62.16
Granted	1.4		86.04
Vested	(1.5	)	58.48
Forfeited	(0.5	)	68.83
Unvested as of December 31, 2017	3.9		71.27
Granted	1.5		99.15
Vested	(1.2	)	68.37
Forfeited	(0.3	)	78.41
Unvested as of December 31, 2018	3.9		82.21


^(a)	The “Adjustment due to Fortive Separation” reflects the cancellation of RSUs and PSUs which were outstanding as of July 2, 2016 and held by Fortive employees which have been converted to Fortive equity awards as part of the Fortive Separation.

The Company realized a tax benefit of $17 million, $35 million and $38 million in the years ended December 31, 2018, 2017 and 2016, respectively, related to the vesting of RSUs.

Prior to the adoption of ASU 2016-09 in 2017, the difference between the actual tax benefit realized upon exercise and the tax benefit recorded based on the fair value of the stock award at the time of grant (the “excess tax benefits”) was recorded as an increase to additional paid-in capital and was reflected as a financing cash flow. For the year ended December 31, 2016, the Company recorded an increase to additional paid-in capital and a financing cash flow of $50 million for the excess tax benefit. As a result of the adoption of ASU 2016-09, the excess tax benefit of $38 million and $55 million related to the exercise of employee stock options and vesting of RSUs for the years ended December 31, 2018 and 2017, respectively, has been recorded as a reduction to the current income tax provision and is reflected as an operating cash inflow in the accompanying Consolidated Statements of Cash Flows.

In connection with the exercise of certain stock options and the vesting of RSUs previously issued by the Company, a number of shares sufficient to fund statutory minimum tax withholding requirements has been withheld from the total shares issued or released to the award holder (though under the terms of the applicable plan, the shares are considered to have been issued and are not added back to the pool of shares available for grant). During the year ended December 31, 2018, 400 thousand shares with an aggregate value of $41 million were withheld to satisfy the requirement. During the year ended December 31, 2017, 600 thousand shares with an aggregate value of $47 million were withheld to satisfy the requirement. The withholding is treated as a reduction in additional paid-in capital in the accompanying Consolidated Statements of Stockholders’ Equity.

Net Earnings Per Share From Continuing Operations

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Net Earnings Per Share From Continuing Operations

NET EARNINGS PER SHARE FROM CONTINUING OPERATIONS

Basic net earnings per share (“EPS”) from continuing operations is calculated by dividing net earnings from continuing operations by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS from continuing operations is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the years ended December 31, 2018, 2017 and 2016, 1 million, 4 million and 1 million options to purchase shares, respectively, were not included in the diluted earnings per share calculation as the impact of their inclusion would have been anti-dilutive.

Information related to the calculation of net earnings from continuing operations per share of common stock is summarized as follows ($ and shares in millions, except per share amounts):



	Net Earnings from Continuing Operations (Numerator)		Shares (Denominator)	Per Share Amount
For the year ended December 31, 2018
Basic EPS	$	2,650.9	700.6	$	3.78
Adjustment for interest on convertible debentures	2.2		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		7.2
Incremental shares from assumed conversion of the convertible debentures	—		2.4
Diluted EPS	$	2,653.1	710.2	$	3.74

For the year ended December 31, 2017
Basic EPS	$	2,469.8	695.8	$	3.55
Adjustment for interest on convertible debentures	2.1		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		7.5
Incremental shares from assumed conversion of the convertible debentures	—		2.8
Diluted EPS	$	2,471.9	706.1	$	3.50

For the year ended December 31, 2016
Basic EPS	$	2,153.4	691.2	$	3.12
Adjustment for interest on convertible debentures	1.8		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		6.0
Incremental shares from assumed conversion of the convertible debentures	—		2.6
Diluted EPS	$	2,155.2	699.8	$	3.08

Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting, Measurement Disclosures [Abstract]

Segment Information

SEGMENT INFORMATION

The Company operates and reports its results in four separate business segments consisting of the Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.

Detailed segment data for the years ended December 31 is as follows ($ in millions):



	2018			2017			2016
Sales:
Life Sciences	$	6,471.4		$	5,710.1		$	5,365.9
Diagnostics	6,257.6			5,839.9			5,038.3
Dental	2,844.5			2,810.9			2,785.4
Environmental & Applied Solutions	4,319.5			3,968.8			3,692.8
Total	$	19,893.0		$	18,329.7		$	16,882.4

Operating profit:
Life Sciences	$	1,229.3		$	1,004.3		$	818.9
Diagnostics	1,073.8			871.6			786.4
Dental	346.7			400.7			419.4
Environmental & Applied Solutions	988.0			914.6			870.0
Other	(234.0		)	(200.8		)	(159.5		)
Total	$	3,403.8		$	2,990.4		$	2,735.2

Identifiable assets:
Life Sciences	$	22,122.4		$	20,576.8		$	19,875.9
Diagnostics	14,031.1			14,359.2			14,159.6
Dental	5,897.3			6,026.8			5,772.2
Environmental & Applied Solutions	4,637.3			4,649.2			4,172.9
Other	1,144.4			1,036.6			1,314.7
Total	$	47,832.5		$	46,648.6		$	45,295.3

Depreciation and amortization:
Life Sciences	$	471.2		$	427.9		$	426.2
Diagnostics	589.0			581.5			481.5
Dental	130.0			121.4			127.2
Environmental & Applied Solutions	109.0			99.9			86.7
Other	8.5			7.6			6.5
Total	$	1,307.7		$	1,238.3		$	1,128.1



	2018		2017		2016
Capital expenditures, gross:
Life Sciences	$	140.1	$	130.6	$	109.7
Diagnostics	380.0		372.6		374.3
Dental	72.2		48.9		49.1
Environmental & Applied Solutions	57.1		60.9		51.0
Other	6.3		6.6		5.5
Total	$	655.7	$	619.6	$	589.6

Operations in Geographical Areas:



	Year Ended December 31
($ in millions)	2018		2017		2016
Sales:
United States	$	7,374.4	$	6,837.9	$	6,377.4
China	2,357.3		2,011.6		1,799.1
Germany	1,247.0		1,161.6		1,084.6
Japan	918.7		872.1		864.7
All other (each country individually less than 5% of total sales)	7,995.6		7,446.5		6,756.6
Total	$	19,893.0	$	18,329.7	$	16,882.4

Property, plant and equipment, net:
United States	$	1,224.4	$	1,126.2	$	1,198.4
Germany	198.3		212.4		190.8
United Kingdom	157.0		152.0		140.6
All other (each country individually less than 5% of total property, plant and equipment, net)	931.5		964.0		824.2
Total	$	2,511.2	$	2,454.6	$	2,354.0

Sales by Major Product Group:



	Year Ended December 31
($ in millions)	2018		2017		2016
Analytical and physical instrumentation	$	2,437.0	$	2,232.9	$	2,088.9
Research and medical products	12,686.0		11,512.4		10,366.7
Dental products	2,844.5		2,810.9		2,785.4
Product identification	1,925.5		1,773.5		1,641.4
Total	$	19,893.0	$	18,329.7	$	16,882.4

Quarterly Data-Unaudited

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Data-Unaudited

QUARTERLY DATA-UNAUDITED



($ in millions, except per share data)	1st Quarter		2nd Quarter		3rd Quarter		4th Quarter
2018:
Sales	$	4,695.4	$	4,981.0	$	4,853.1	$	5,363.5
Gross profit	2,643.6		2,817.1		2,690.5		2,955.9
Operating profit	743.0		867.5		830.7		962.6
Net earnings from continuing operations	566.6		673.8		663.7		746.8
Net earnings	566.6		673.8		663.7		746.8
Net earnings per share from continuing operations:
Basic	$	0.81	$	0.96	$	0.95	$	1.06
Diluted	$	0.80	$	0.95	$	0.93	$	1.05	*
Net earnings per share:
Basic	$	0.81	$	0.96	$	0.95	$	1.06
Diluted	$	0.80	$	0.95	$	0.93	$	1.05	*

2017:
Sales	$	4,205.7	$	4,510.1	$	4,528.2	$	5,085.7
Gross profit	2,334.3		2,482.3		2,536.8		2,839.1
Operating profit	617.0		676.7		759.2		937.5
Net earnings from continuing operations	483.8		557.3		572.1		856.6
Net earnings from discontinued operations	22.3		—		—		—
Net earnings	506.1		557.3		572.1		856.6
Net earnings per share from continuing operations:
Basic	$	0.70	$	0.80	$	0.82	$	1.23
Diluted	$	0.69	$	0.79	$	0.81	$	1.21
Net earnings per share from discontinued operations:
Basic	$	0.03	$	—	$	—	$	—
Diluted	$	0.03	$	—	$	—	$	—
Net earnings per share:
Basic	$	0.73	$	0.80	$	0.82	$	1.23
Diluted	$	0.72	$	0.79	$	0.81	$	1.21

* Net earnings per share amounts do not add across to the full year amount due to rounding.

Schedule II - Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation And Qualifying Accounts

DANAHER CORPORATION AND SUBSIDIARIES

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

($ in millions)



Classification	Balance at Beginning of Period ^(a)		Charged to Costs & Expenses		Impact of Currency			Charged to Other Accounts^(b)		Write-Offs, Write-Downs & Deductions			Balance at End of Period ^(a)
Year ended December 31, 2018:
Allowances deducted from asset account
Allowance for doubtful accounts	$	118.2	$	35.9	$	(4.5	)	$	1.3	$	(29.3	)	$	121.6
Year ended December 31, 2017:
Allowances deducted from asset account
Allowance for doubtful accounts	$	103.5	$	32.9	$	4.5		$	3.5	$	(26.2	)	$	118.2
Year ended December 31, 2016:
Allowances deducted from asset account
Allowance for doubtful accounts	$	89.7	$	32.5	$	(0.6	)	$	2.3	$	(20.4	)	$	103.5


^(a)	Amounts include allowance for doubtful accounts classified as current and noncurrent.


^(b)	Amounts related to businesses acquired, net of amounts related to businesses disposed not included in discontinued operations.

Business And Summary Of Significant Accounting Policies (Policy)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Business Description and Basis of Presentation

Refer to Notes 3 and 4 for a discussion of significant acquisitions and discontinued operations.

Accounting Principles

Use of Estimates

Cash and Equivalents

Cash and Equivalents—The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.

Accounts Receivable and Allowances for Doubtful Accounts

Inventory Valuation

Property, Plant and Equipment



Category		Useful Life
Buildings		30 years
Leased assets and leasehold improvements		Amortized over the lesser of the economic life of the asset or the term of the lease
Machinery and equipment		3 – 10 years
Customer-leased instruments		5 – 7 years

Estimated useful lives are periodically reviewed and, when appropriate, changes to estimates are made prospectively.

Investments

Other Assets

Other Assets—Other assets principally include noncurrent financing receivables, noncurrent deferred tax assets and other investments.

Fair Value of Financial Instruments

Goodwill and Other Intangible Assets

Revenue Recognition

Shipping and Handling

Shipping and Handling—Shipping and handling costs are included as a component of cost of sales. Revenue derived from shipping and handling costs billed to customers is included in sales.

Advertising

Advertising—Advertising costs are expensed as incurred.

Research and Development

Income Taxes

Productivity Improvement and Restructuring

Foreign Currency Translation

Derivative Financial Instruments

Accounting for Stock-Based Compensation

Pension and Postretirement Benefit Plans

New Accounting Standards

Business And Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Useful Lives Of Depreciable Assets

The provision for depreciation has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets as follows:



Category		Useful Life
Buildings		30 years
Leased assets and leasehold improvements		Amortized over the lesser of the economic life of the asset or the term of the lease
Machinery and equipment		3 – 10 years
Customer-leased instruments		5 – 7 years

The classes of property, plant and equipment as of December 31 are summarized as follows ($ in millions):



	2018			2017
Land and improvements	$	176.5		$	155.6
Buildings	1,047.8			1,009.5
Machinery and equipment	2,482.3			2,239.5
Customer-leased equipment	1,632.9			1,569.4
Gross property, plant and equipment	5,339.5			4,974.0
Less: accumulated depreciation	(2,828.3		)	(2,519.4		)
Property, plant and equipment, net	$	2,511.2		$	2,454.6

Schedule of Accumulated Other Comprehensive Income (Loss)



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments				Total
Balance, January 1, 2016	$	(1,797.4	)	$	(647.3	)		$	133.5			$	(2,311.2	)
Other comprehensive income (loss) before reclassifications:
(Decrease) increase	(517.3		)	(115.4		)		39.6				(593.1		)
Income tax impact	—			38.9				(14.8		)		24.1
Other comprehensive income (loss) before reclassifications, net of income taxes	(517.3		)	(76.5		)		24.8				(569.0		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	—			28.0			(a)	(223.4		)	(b)	(195.4		)
Income tax impact	—			(9.7		)		83.8				74.1
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			18.3				(139.6		)		(121.3		)
Net current period other comprehensive income (loss), net of income taxes	(517.3		)	(58.2		)		(114.8		)		(690.3		)
Distribution of Fortive Corporation	(83.5		)	63.3			(c)	—				(20.2		)
Balance, December 31, 2016	(2,398.2		)	(642.2		)		18.7				(3,021.7		)
Other comprehensive income (loss) before reclassifications:
Increase	976.1			62.4				41.7				1,080.2
Income tax impact	—			(13.4		)		(15.7		)		(29.1		)
Other comprehensive income (loss) before reclassifications, net of income taxes	976.1			49.0				26.0				1,051.1
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)	—			28.7			(a)	(72.8		)	(b)	(44.1		)
Income tax impact	—			(6.7		)		27.2				20.5
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			22.0				(45.6		)		(23.6		)
Net current period other comprehensive income (loss), net of income taxes	976.1			71.0				(19.6		)		1,027.5
Balance, December 31, 2017	(1,422.1		)	(571.2		)		(0.9		)		(1,994.2		)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)		(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)		(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Decrease	(632.2		)	(44.9		)		(1.1		)		(678.2		)
Income tax impact	—			9.2				0.3				9.5
Other comprehensive income (loss) before reclassifications, net of income taxes	(632.2		)	(35.7		)		(0.8		)		(668.7		)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			30.3			(a)	—				30.3
Income tax impact	—			(7.3		)		—				(7.3		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			23.0				—				23.0
Net current period other comprehensive income (loss), net of income taxes	(632.2		)	(12.7		)		(0.8		)		(645.7		)
Balance, December 31, 2018	$	(2,098.1	)	$	(691.1	)		$	(1.9	)		$	(2,791.1	)


^(a)	This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension and postretirement cost (refer to Notes 11 and 12 for additional details).


^(b)	Included in other income in the accompanying Consolidated Statements of Earnings (refer to Note 14 for additional details).


^(c)	This accumulated other comprehensive income (loss) component included an income tax impact of $21 million.

Revenue Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue



	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	2,295.6	$	2,403.4	$	1,350.4	$	1,770.7	$	7,820.1
Western Europe	1,846.7		1,155.4		659.6		1,059.1		4,720.8
Other developed markets	570.0		379.1		179.9		125.7		1,254.7
High-growth markets	1,759.1		2,319.7		654.6		1,364.0		6,097.4
Total	$	6,471.4	$	6,257.6	$	2,844.5	$	4,319.5	$	19,893.0

Revenue type:
Recurring	$	4,131.8	$	5,272.0	$	2,039.8	$	2,280.0	$	13,723.6
Nonrecurring	2,339.6		985.6		804.7		2,039.5		6,169.4
Total	$	6,471.4	$	6,257.6	$	2,844.5	$	4,319.5	$	19,893.0

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Fair Values Of The Assets Acquired And Liabilities Assumed

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition ($ in millions):



	2018			2017			2016
Trade accounts receivable	$	41.1		$	21.6		$	97.8
Inventories	14.8			21.3			204.8
Property, plant and equipment	88.4			9.1			161.8
Goodwill	1,275.4			267.6			3,061.8
Other intangible assets, primarily customer relationships, trade names and technology	850.7			155.1			1,867.0
In-process research and development	—			—			65.0
Trade accounts payable	(6.7		)	(9.9		)	(50.7		)
Other assets and liabilities, net	(66.5		)	(75.0		)	(518.0		)
Assumed debt	—			—			(1.0		)
Attributable to noncontrolling interest	—			(4.0		)	—
Net assets acquired	2,197.2			385.8			4,888.5
Less: noncash consideration	(23.9		)	—			(8.4		)
Net cash consideration	$	2,173.3		$	385.8		$	4,880.1



	IDT			Other			Total
Trade accounts receivable	$	36.0		$	5.1		$	41.1
Inventories	14.8			—			14.8
Property, plant and equipment	88.2			0.2			88.4
Goodwill	1,212.6			62.8			1,275.4
Other intangible assets, primarily customer relationships, trade names and technology	811.0			39.7			850.7
Trade accounts payable	(5.5		)	(1.2		)	(6.7		)
Other assets and liabilities, net	(55.0		)	(11.5		)	(66.5		)
Net assets acquired	2,102.1			95.1			2,197.2
Less: noncash consideration	(23.9		)	—			(23.9		)
Net cash consideration	$	2,078.2		$	95.1		$	2,173.3

The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2016 discussed above, and all of the other 2016 acquisitions as a group ($ in millions):



	Cepheid			Others			Total
Trade accounts receivable	$	61.4		$	36.4		$	97.8
Inventories	165.8			39.0			204.8
Property, plant and equipment	144.5			17.3			161.8
Goodwill	2,584.0			477.8			3,061.8
Other intangible assets, primarily customer relationships, trade names and technology	1,480.0			387.0			1,867.0
In-process research and development	65.0			—			65.0
Trade accounts payable	(41.2		)	(9.5		)	(50.7		)
Other assets and liabilities, net	(452.4		)	(65.6		)	(518.0		)
Assumed debt	(1.0		)	—			(1.0		)
Net assets acquired	4,006.1			882.4			4,888.5
Less: noncash consideration	(8.4		)	—			(8.4		)
Net cash consideration	$	3,997.7		$	882.4		$	4,880.1

Results Of Operations If Acquisition Was Consummated



	2018		2017
Sales	$	19,995.7	$	18,744.7
Net earnings from continuing operations	2,652.9		2,449.8
Diluted net earnings per share from continuing operations	3.74		3.47

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule Of Discontinued Operations

The key components of income from discontinued operations for the years ended December 31 were as follows ($ in millions):



	2017		2016
Sales	$	—	$	3,029.8
Cost of sales	—		(1,566.4		)
Selling, general and administrative expenses	—		(696.0		)
Research and development expenses	—		(190.4		)
Interest expense	—		(19.7		)
Income from discontinued operations before income taxes	—		557.3
Income taxes	22.3		(157.0		)
Earnings from discontinued operations, net of income taxes	$	22.3	$	400.3

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory, Net [Abstract]

Schedule Of Inventory

The classes of inventory as of December 31 are summarized as follows ($ in millions):



	2018		2017
Finished goods	$	1,031.2	$	982.5
Work in process	313.9		309.7
Raw materials	565.0		548.6
Total	$	1,910.1	$	1,840.8

Property, Plant And Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule Of Property, Plant And Equipment

The provision for depreciation has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets as follows:



Category		Useful Life
Buildings		30 years
Leased assets and leasehold improvements		Amortized over the lesser of the economic life of the asset or the term of the lease
Machinery and equipment		3 – 10 years
Customer-leased instruments		5 – 7 years

The classes of property, plant and equipment as of December 31 are summarized as follows ($ in millions):



	2018			2017
Land and improvements	$	176.5		$	155.6
Buildings	1,047.8			1,009.5
Machinery and equipment	2,482.3			2,239.5
Customer-leased equipment	1,632.9			1,569.4
Gross property, plant and equipment	5,339.5			4,974.0
Less: accumulated depreciation	(2,828.3		)	(2,519.4		)
Property, plant and equipment, net	$	2,511.2		$	2,454.6

Goodwill And Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Rollforward Of Goodwill

The following is a rollforward of the Company’s goodwill by segment ($ in millions):



	Life Sciences			Diagnostics				Dental			Environmental & Applied Solutions			Total
Balance, January 1, 2017	$	11,610.3		$	6,903.0			$	3,215.6		$	2,098.0		$	23,826.9
Attributable to 2017 acquisitions	95.5			—				2.8			169.3			267.6
Adjustments due to finalization of purchase price allocations	(19.1		)	(39.6		)	^(a)	8.8			—			(49.9		)
Foreign currency translation and other	648.8			216.1				142.8			86.3			1,094.0
Balance, December 31, 2017	12,335.5			7,079.5				3,370.0			2,353.6			25,138.6
Attributable to 2018 acquisitions	1,212.6			—				—			62.8			1,275.4
Adjustments due to finalization of purchase price allocations	2.8			—				—			4.7			7.5
Foreign currency translation and other	(239.9		)	(153.9		)		(44.5		)	(77.2		)	(515.5		)
Balance, December 31, 2018	$	13,311.0		$	6,925.6			$	3,325.5		$	2,343.9		$	25,906.0


^(a)	This adjustment is primarily related to finalization of the Cepheid purchase price allocations.

Schedule of Finite-lived Intangible Assets And Indefinite-lived Intangible Assets By Major Class

The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets as of December 31 ($ in millions):



	2018					2017
	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived intangibles:
Patents and technology	$	2,985.3	$	(945.2	)	$	2,363.5	$	(783.7	)
Customer relationships and other intangibles	7,302.8		(2,661.3		)	7,354.9		(2,203.6		)
Trademarks and trade names	190.7		(28.0		)	23.9		(14.0		)
Total finite-lived intangibles	10,478.8		(3,634.5		)	9,742.3		(3,001.3		)
Indefinite-lived intangibles:
Trademarks and trade names	4,828.8		—			4,926.1		—
Total intangibles	$	15,307.6	$	(3,634.5	)	$	14,668.4	$	(3,001.3	)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Carried At Fair Value

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
December 31, 2018:
Assets:
Available-for-sale debt securities	$	—	$	38.3	$	—	$	38.3
Investment in equity securities	—		—		148.9		148.9
Liabilities:
Deferred compensation plans	—		60.9		—		60.9
December 31, 2017:
Assets:
Available-for-sale debt securities	$	—	$	45.4	$	—	$	45.4
Liabilities:
Deferred compensation plans	—		62.9		—		62.9

Carrying Amounts And Fair Values Of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments as of December 31 were as follows ($ in millions):



	2018				2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	38.3	$	38.3	$	45.4	$	45.4
Investment in equity securities	148.9		148.9		—		—
Liabilities:
Notes payable and current portion of long-term debt	51.8		51.8		194.7		194.7
Long-term debt	9,688.5		9,990.6		10,327.4		10,847.1

Accrued Expenses And Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

Accrued Expenses And Other Liabilities

Accrued expenses and other liabilities as of December 31 were as follows ($ in millions):



	2018				2017
	Current		Noncurrent		Current		Noncurrent
Compensation and benefits	$	1,026.8	$	236.9	$	961.0	$	236.2
Pension and postretirement benefits	75.2		961.9		95.8		1,052.0
Taxes, income and other	292.4		3,577.7		386.4		3,543.6
Deferred revenue	685.2		113.8		666.0		104.9
Sales and product allowances	167.8		2.0		155.7		2.0
Other	829.5		183.5		822.8		222.4
Total	$	3,076.9	$	5,075.8	$	3,087.7	$	5,161.1

Financing (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt as of December 31 were as follows ($ in millions):



	2018		2017
U.S. dollar-denominated commercial paper	$	72.8	$	436.9
Euro-denominated commercial paper (€2.1 billion and €1.7 billion, respectively)	2,377.5		1,993.9
1.65% senior unsecured notes due 2018 (the “2018 U.S. Notes”)	—		499.2
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	687.0		718.4
2.4% senior unsecured notes due 2020 (the “2020 U.S. Notes”)	498.5		497.7
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	386.7		394.6
Zero-coupon LYONs due 2021	56.2		69.1
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	273.2		265.5
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	913.2		955.6
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the "Floating Rate 2022 Euronotes")	285.7		299.1
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	550.7		555.5
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	912.6		955.6
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	496.8		496.3
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	279.9		272.2
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	682.0		714.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	218.1		220.3
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	483.4		470.2
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.3		499.3
Other	66.7		208.6
Total debt	9,740.3		10,522.1
Less: currently payable	51.8		194.7
Long-term debt	$	9,688.5	$	10,327.4

The following summarizes the key terms for the Company’s long-term debt as of December 31, 2018:



	Outstanding Balance as of December 31, 2018		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Issue Date	Maturity Date	Interest Payment Dates (in arrears)
2019 Euronotes ⁽¹⁾	$	687.0	1.0	%	99.696	%	July 8, 2015	July 8, 2019	July 8
2020 U.S. Notes ⁽³⁾	498.5		2.4	%	99.757	%	September 15, 2015	September 15, 2020	March 15 and September 15
2020 Assumed Pall Notes ⁽⁵⁾	386.7		5.0	%	not applicable		not applicable	June 15, 2020	June 15 and December 15
2021 LYONs	56.2		see below		not applicable		January 22, 2001	January 22, 2021	January 22 and July 22
2021 Yen Notes ⁽⁴⁾	273.2		0.352	%	100	%	February 28, 2016	March 16, 2021	September 16
2022 Euronotes ⁽¹⁾	913.2		1.7	%	99.651	%	July 8, 2015	January 4, 2022	January 4
Floating Rate 2022 Euronotes ⁽⁶⁾	285.7		three-month EURIBOR + 0.3%		100.147	%	June 30, 2017	June 30, 2022	March 30, June 30, September 30 and December 31
2023 CHF Bonds⁽²⁾	550.7		0.5	%	100.924	%	December 8, 2015	December 8, 2023	December 8
2025 Euronotes ⁽¹⁾	912.6		2.5	%	99.878	%	July 8, 2015	July 8, 2025	July 8
2025 U.S. Notes ⁽³⁾	496.8		3.35	%	99.857	%	September 15, 2015	September 15, 2025	March 15 and September 15
2027 Yen Notes ⁽⁷⁾	279.9		0.3	%	100	%	May 11, 2017	May 11, 2027	May 11 and November 11
2027 Euronotes ⁽⁶⁾	682.0		1.2	%	99.682	%	June 30, 2017	June 30, 2027	June 30
2028 CHF Bonds⁽²⁾	218.1		1.125	%	102.870	%	December 8, 2015 and December 8, 2017	December 8, 2028	December 8
2032 Yen Notes ⁽⁷⁾	483.4		0.65	%	100	%	May 11, 2017	May 11, 2032	May 11 and November 11
2045 U.S. Notes ⁽³⁾	499.3		4.375	%	99.784	%	September 15, 2015	September 15, 2045	March 15 and September 15
U.S. dollar and euro-denominated commercial paper	2,450.3		various		various		various	various	various
Other	66.7		various		various		various	various	various
Total debt	$	9,740.3


⁽¹⁾	The net proceeds, after underwriting discounts and commissions and offering expenses, of approximately €2.2 billion (approximately $2.4 billion based on currency exchange rates as of the date of issuance) from these notes were used to pay a portion of the purchase price for the acquisition of Pall Corporation in 2015 (the “Pall Acquisition”).

⁽²⁾


⁽³⁾	The net proceeds, after underwriting discounts and commissions and offering expenses, of approximately $2.0 billion from these notes were used to repay a portion of the commercial paper issued to finance the Pall Acquisition.


⁽⁴⁾	The net proceeds, after offering expenses, of approximately ¥29.9 billion ($262 million based on currency exchange rates as of the date of issuance) from these notes were used to repay a portion of the commercial paper borrowings issued to finance the Pall Acquisition.

⁽⁵⁾


⁽⁶⁾	The net proceeds at issuance, after offering expenses, of €843 million ($940 million based on currency exchange rates as of the date of pricing) from these notes were used to partially repay commercial paper borrowings.


⁽⁷⁾	The net proceeds at issuance, after offering expenses, of approximately ¥83.6 billion ($744 million based on currency exchange rates as of the date of pricing) from these notes were used to partially repay commercial paper borrowings.

Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]

The Company’s minimum principal payments for the next five years are as follows ($ in millions):



2019	$	51.8
2020	4,021.8
2021	327.5
2022	1,211.9
2023	548.1
Thereafter	3,579.2

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Pension Benefit Plans (Tables) - Pension benefit plans

12 Months Ended

Dec. 31, 2018

Defined Benefit Plans and Other Post-Retirement Benefit Plans [Line Items]

Funded Status Of Pension Plans

The following sets forth the funded status of the U.S. and non-U.S. plans as of the most recent actuarial valuations using measurement dates of December 31 ($ in millions):



	U.S. Pension Benefits						Non-U.S. Pension Benefits
	2018			2017			2018			2017
Change in pension benefit obligation:
Benefit obligation at beginning of year	$	(2,612.9	)	$	(2,558.1	)	$	(1,571.8	)	$	(1,493.0	)
Service cost	(6.7		)	(7.3		)	(35.5		)	(32.7		)
Interest cost	(81.0		)	(82.3		)	(25.1		)	(25.5		)
Employee contributions	—			—			(9.3		)	(8.2		)
Benefits and other expenses paid	179.0			181.8			51.4			58.3
Acquisitions and other	—			—			(3.6		)	—
Actuarial gain (loss)	145.2			(139.9		)	68.9			51.4
Amendments, settlements and curtailments	31.4			(7.1		)	26.5			10.5
Foreign exchange rate impact	—			—			56.2			(132.6		)
Benefit obligation at end of year	(2,345.0		)	(2,612.9		)	(1,442.3		)	(1,571.8		)
Change in plan assets:
Fair value of plan assets at beginning of year	2,004.9			1,868.2			1,199.3			1,042.9
Actual (loss) return on plan assets	(72.1		)	265.3			(19.9		)	74.6
Employer contributions	55.1			53.2			52.4			44.7
Employee contributions	—			—			9.3			8.2
Amendments and settlements	(30.6		)	—			(28.2		)	(3.7		)
Benefits and other expenses paid	(179.0		)	(181.8		)	(51.4		)	(58.3		)
Acquisitions and other	—			—			1.9			—
Foreign exchange rate impact	—			—			(45.0		)	90.9
Fair value of plan assets at end of year	1,778.3			2,004.9			1,118.4			1,199.3
Funded status	$	(566.7	)	$	(608.0	)	$	(323.9	)	$	(372.5	)

Weighted Average Assumptions Used To Determine Benefit Obligations And Cost

Weighted average assumptions used to determine benefit obligations at date of measurement:



	U.S. Plans				Non-U.S. Plans
	2018		2017		2018		2017
Discount rate	4.3	%	3.6	%	2.0	%	1.8	%
Rate of compensation increase	4.0	%	4.0	%	2.3	%	2.2	%

Weighted average assumptions used to determine net periodic pension (cost) benefit at date of measurement:



	U.S. Plans				Non-U.S. Plans
	2018		2017		2018		2017
Discount rate	3.6	%	4.1	%	1.8	%	1.8	%
Expected long-term return on plan assets	7.0	%	7.0	%	3.9	%	3.9	%
Rate of compensation increase	4.0	%	4.0	%	2.3	%	2.9	%

Components of Net Periodic Pension Cost

Components of net periodic pension benefit (cost):



	U.S. Pension Benefits						Non-U.S. Pension Benefits
($ in millions)	2018			2017			2018			2017
Service cost	$	(6.7	)	$	(7.3	)	$	(35.5	)	$	(32.7	)
Interest cost	(81.0		)	(82.3		)	(25.1		)	(25.5		)
Expected return on plan assets	132.0			130.5			46.9			42.4
Amortization of prior service (cost) credit	(0.9		)	—			0.5			0.3
Amortization of net loss	(31.3		)	(24.9		)	(6.0		)	(7.8		)
Curtailment and settlement gains recognized	—			—			4.9			0.5
Net periodic pension benefit (cost)	$	12.1		$	16.0		$	(14.3	)	$	(22.8	)

Disaggregation of Service Cost

The net periodic benefit cost of the noncontributory defined benefit pension plans incurred during the years ended December 31, 2018 and 2017 are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):



	Year Ended December 31
	2018			2017			2016
Service cost:
Cost of sales	$	(11.4	)	$	(8.2	)	$	(9.8	)
Selling, general and administrative expenses	(30.8		)	(31.8		)	(35.6		)
Total service cost	(42.2		)	(40.0		)	(45.4		)
Other net periodic pension costs:
Nonoperating income (expense), net	40.0			33.2			19.2
Total	$	(2.2	)	$	(6.8	)	$	(26.2	)

Fair Values Of Pension Plan Assets

The fair values of the Company’s pension plan assets for both the U.S. and non-U.S. plans as of December 31, 2018, by asset category were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Cash and equivalents	$	29.7	$	—	$	—	$	29.7
Equity securities:
Common stock	355.7		—		—		355.7
Preferred stock	4.6		—		—		4.6
Fixed income securities:
Corporate bonds	—		76.8		—		76.8
Government issued	—		32.8		—		32.8
Mutual funds	284.6		205.2		—		489.8
Insurance contracts	—		168.7		—		168.7
Total	$	674.6	$	483.5	$	—	1,158.1
Investments measured at NAV ^(a):
Mutual funds							179.8
Insurance contracts							209.1
Common collective trusts							957.8
Venture capital, partnerships and other private investments							391.9
Total assets at fair value							$	2,896.7


^(a)	The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

The fair values of the Company’s pension plan assets for both the U.S. and non-U.S. plans as of December 31, 2017, by asset category were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Cash and equivalents	$	36.0	$	—	$	—	$	36.0
Equity securities:
Common stock	444.8		—		—		444.8
Preferred stock	6.7		—		—		6.7
Fixed income securities:
Corporate bonds	—		113.3		—		113.3
Government issued	—		37.5		—		37.5
Mutual funds	341.5		147.0		—		488.5
Insurance contracts	—		299.4		—		299.4
Total	$	829.0	$	597.2	$	—	1,426.2
Investments measured at NAV ^(a):
Mutual funds							232.4
Insurance contracts							72.1
Common collective trusts							1,089.8
Venture capital, partnerships and other private investments							383.7
Total assets at fair value							$	3,204.2


^(a)	The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

Benefit Payments That Reflect Expected Future Service

The following sets forth benefit payments, which reflect expected future service, as appropriate, expected to be paid by the plans in the periods indicated ($ in millions):



	U.S. Pension Plans		Non-U.S. Pension Plans		All Pension Plans
2019	$	172.3	$	50.2	$	222.5
2020	174.1		52.4		226.5
2021	174.8		51.1		225.9
2022	174.3		54.1		228.4
2023	174.2		56.3		230.5
2024 - 2028	814.7		308.7		1,123.4

Other Postretirement Employee Benefit Plans (Tables) - Other postretirement benefits

12 Months Ended

Dec. 31, 2018

Defined Benefit Plans and Other Post-Retirement Benefit Plans [Line Items]

Funded Status Of Pension Plans

The following sets forth the funded status of the domestic plans as of the most recent actuarial valuations using measurement dates of December 31 ($ in millions):



	2018			2017
Change in benefit obligation:
Benefit obligation at beginning of year	$	(167.3	)	$	(174.6	)
Service cost	(0.5		)	(0.7		)
Interest cost	(5.3		)	(5.6		)
Amendments, curtailments and other	1.1			(0.4		)
Actuarial gain (loss)	9.5			(1.5		)
Retiree contributions	(2.6		)	(2.9		)
Benefits paid	18.6			18.4
Benefit obligation at end of year	(146.5		)	(167.3		)
Change in plan assets:
Fair value of plan assets	—			—
Funded status	$	(146.5	)	$	(167.3	)

Weighted Average Assumptions Used To Determine Benefit Obligations And Cost

Weighted average assumptions used to determine benefit obligations at date of measurement:



	2018		2017
Discount rate	4.2	%	3.5	%
Medical trend rate – initial	6.0	%	6.3	%
Medical trend rate – grading period	19 years		20 years
Medical trend rate – ultimate	4.5	%	4.5	%

Effect Of One-Percentage-Point Change In Assumed Health Care Cost Trend Rates

Effect of a one-percentage-point change in assumed health care cost trend rates:



($ in millions)	1% Increase		1% Decrease
Effect on the total of service and interest cost components	$	0.3	$	(0.2	)
Effect on postretirement medical benefit obligation	4.4		(3.7		)

Components of Net Periodic Pension Cost

Components of net periodic benefit cost:



($ in millions)	2018			2017
Service cost	$	(0.5	)	$	(0.7	)
Interest cost	(5.3		)	(5.6		)
Amortization of net gain	—			0.1
Amortization of prior service credit	2.5			3.1
Net periodic benefit cost	$	(3.3	)	$	(3.1	)

Disaggregation of Service Cost

The net periodic benefit cost of the other postretirement employee benefit plans incurred during the years ended December 31, 2018 and 2017 are reflected in the following captions in the accompanying Consolidated Condensed Statements of Earnings ($ in millions):



	Year Ended December 31
	2018			2017			2016
Service cost:
Cost of sales	$	(0.1	)	$	(0.1	)	$	(0.2	)
Selling, general and administrative expenses	(0.4		)	(0.6		)	(0.5		)
Total service cost	(0.5		)	(0.7		)	(0.7		)
Other net periodic pension costs:
Nonoperating income (expense), net	(2.8		)	(2.4		)	(3.5		)
Total	$	(3.3	)	$	(3.1	)	$	(4.2	)

Benefit Payments That Reflect Expected Future Service

The following sets forth benefit payments, which reflect expected future service, as appropriate, expected to be paid in the periods indicated ($ in millions):



2019	$	15.2
2020	14.5
2021	13.8
2022	13.1
2023	12.3
2024 - 2028	54.1

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule Of Earnings From Continuing Operations Before Income Taxes

Earnings from continuing operations before income taxes for the years ended December 31 were as follows ($ in millions):



	2018		2017		2016
United States	$	914.2	$	927.2	$	647.7
International	2,378.6		2,011.6		1,963.6
Total	$	3,292.8	$	2,938.8	$	2,611.3

Schedule Of Provision For Income Taxes

The provision for income taxes from continuing operations for the years ended December 31 were as follows ($ in millions):



	2018			2017			2016
Current:
Federal U.S.	$	278.8		$	448.3		$	237.2
Non-U.S.	494.3			457.2			542.9
State and local	63.9			(9.6		)	61.7
Deferred:
Federal U.S.	(157.2		)	(424.7		)	(237.5		)
Non-U.S.	(6.8		)	(61.5		)	(104.2		)
State and local	(31.1		)	59.3			(42.2		)
Income tax provision	$	641.9		$	469.0		$	457.9

Schedule Of Deferred Income Tax

Deferred income tax assets and liabilities as of December 31 were as follows ($ in millions):



	2018			2017
Deferred tax assets:
Allowance for doubtful accounts	$	19.7		$	18.6
Inventories	81.2			95.9
Pension and postretirement benefits	222.7			250.6
Environmental and regulatory compliance	22.4			26.8
Other accruals and prepayments	223.7			345.8
Stock-based compensation expense	64.7			63.9
Tax credit and loss carryforwards	894.5			673.4
Valuation allowances	(389.6		)	(324.6		)
Total deferred tax asset	1,139.3			1,150.4
Deferred tax liabilities:
Property, plant and equipment	(90.0		)	(63.4		)
Insurance, including self-insurance	(564.0		)	(696.2		)
Basis difference in LYONs	(21.6		)	(12.9		)
Goodwill and other intangibles	(2,774.9		)	(2,711.2		)
Total deferred tax liability	(3,450.5		)	(3,483.7		)
Net deferred tax liability	$	(2,311.2	)	$	(2,333.3	)

Reconciliation Of The Statutory Federal Income Tax Rate To The Effective Tax Rate

The effective income tax rate from continuing operations for the years ended December 31 varies from the U.S. statutory federal income tax rate as follows:



	Percentage of Pretax Earnings
	2018		2017		2016
Statutory federal income tax rate	21.0	%	35.0	%	35.0	%
Increase (decrease) in tax rate resulting from:
State income taxes (net of federal income tax benefit)	0.9	%	0.8	%	0.6	%
Foreign rate differential	(0.3	)%	(11.6	)%	(10.2	)%
Resolution and expiration of statutes of limitation of uncertain tax positions	(1.7	)%	(6.5	)%	(3.1	)%
Permanent foreign exchange losses	—	%	(0.6	)%	(8.2	)%
Research credits, uncertain tax positions and other	(0.6	)%	(1.0	)%	3.4	%
TCJA - revaluation of U.S. deferred income taxes	(1.4	)%	(41.5	)%	—	%
TCJA - Transition Tax	1.6	%	41.4	%	—	%
Effective income tax rate	19.5	%	16.0	%	17.5	%

Reconciliation Of Unrecognized Tax Benefits



	2018			2017			2016
Unrecognized tax benefits, beginning of year	$	736.8		$	992.2		$	990.2
Additions based on tax positions related to the current year	43.1			53.0			80.0
Additions for tax positions of prior years	324.3			39.8			154.3
Reductions for tax positions of prior years	(21.9		)	(14.5		)	(7.0		)
Acquisitions, divestitures and other	9.4			13.4			(41.5		)
Lapse of statute of limitations	(52.9		)	(246.7		)	(124.0		)
Settlements	(41.8		)	(124.8		)	(45.3		)
Effect of foreign currency translation	(11.0		)	24.4			(14.5		)
Unrecognized tax benefits, end of year	$	986.0		$	736.8		$	992.2

Productivity Improvement And Restructuring Initiatives (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs



	2018		2017		2016
Life Sciences	$	11.4	$	25.4	$	40.5
Diagnostics	14.9		85.4		62.2
Dental	23.7		35.8		34.3
Environmental & Applied Solutions	20.0		12.5		15.4
Total	$	70.0	$	159.1	$	152.4

The table below summarizes the Company’s accrual balance and utilization by type of productivity improvement and restructuring costs associated with the 2018 and 2017 actions ($ in millions):



	Employee Severance & Related			Facility Exit & Related			Total
Balance, January 1, 2017	$	45.3		$	11.8		$	57.1
Costs incurred	77.7			81.4			159.1
Paid/settled	(74.0		)	(75.9		)	(149.9		)
Balance, December 31, 2017	49.0			17.3			66.3
Costs incurred	59.4			10.6			70.0
Paid/settled	(68.8		)	(20.3		)	(89.1		)
Balance, December 31, 2018	$	39.6		$	7.6		$	47.2

Schedule of Restructuring Reserve by Type of Cost

These charges are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):



	2018		2017		2016
Cost of sales	$	16.8	$	38.0	$	25.4
Selling, general and administrative expenses	53.2		121.1		127.0
Total	$	70.0	$	159.1	$	152.4

Leases And Commitments (Tables)

12 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Minimum Rental Payments For Operating Leases

The Company’s future minimum rental payments for all operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows ($ in millions):



2019	$	203.0
2020	167.7
2021	133.3
2022	116.8
2023	101.9
Thereafter	287.2

Warranty Accrual

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



	2018			2017
Balance, January 1	$	79.0		$	75.8
Accruals for warranties issued during the year	60.6			54.5
Settlements made	(60.0		)	(56.6		)
Additions due to acquisitions	—			1.7
Effect of foreign currency translation	(2.2		)	3.6
Balance, December 31	$	77.4		$	79.0

Stock Transactions And Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Share-based Compensation [Abstract]

Assumptions Used In The Black-Scholes Model To Value Options Granted

The following summarizes the assumptions used in the Black-Scholes model to value options granted during the years ended December 31:



	2018		2017		2016
Risk-free interest rate	2.6 – 3.1%		1.8 – 2.2%		1.2 – 1.8%
Weighted average volatility	21.4	%	17.9	%	24.3	%
Dividend yield	0.6	%	0.7	%	0.6	%
Expected years until exercise	5.0 – 8.0		5.0 – 8.0		5.5 – 8.0

Components Of Share-Based Compensation Program

The following summarizes the components of the Company’s continuing operations stock-based compensation expense for the years ended December 31 ($ in millions):



	2018			2017			2016
RSUs/PSUs:
Pretax compensation expense	$	94.7		$	90.2		$	85.9
Income tax benefit	(19.8		)	(27.7		)	(25.3		)
RSU/PSU expense, net of income taxes	74.9			62.5			60.6
Stock options:
Pretax compensation expense	56.7			49.2			43.9
Income tax benefit	(12.0		)	(15.6		)	(13.6		)
Stock option expense, net of income taxes	44.7			33.6			30.3
Total stock-based compensation:
Pretax compensation expense	151.4			139.4			129.8
Income tax benefit	(31.8		)	(43.3		)	(38.9		)
Total stock-based compensation expense, net of income taxes	$	119.6		$	96.1		$	90.9

Option Activity Under The Company's Stock Plans

The following summarizes option activity under the Company’s stock plans (in millions, except weighted exercise price and number of years):



	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding as of January 1, 2016	24.9		$	43.75
Granted	5.7		67.52
Exercised	(5.3	)	33.45
Cancelled/forfeited	(1.2	)	73.21
Adjustment due to Fortive Separation ^(a)	(5.2	)	50.44
Outstanding as of December 31, 2016	18.9		50.07
Granted	4.4		86.14
Exercised	(3.3	)	35.26
Cancelled/forfeited	(1.2	)	70.40
Outstanding as of December 31, 2017	18.8		59.84
Granted	4.1		99.51
Exercised	(3.4	)	41.88
Cancelled/forfeited	(0.9	)	80.14
Outstanding as of December 31, 2018	18.6		70.86		7	$	600.8
Vested and expected to vest as of December 31, 2018 ^(b)	18.0		$	70.24	7	$	592.8
Vested as of December 31, 2018	7.7		$	53.19	5	$	383.3


^(a)	The “Adjustment due to Fortive Separation” reflects the cancellation of options which were outstanding as of July 2, 2016 and held by Fortive employees, which have been converted to Fortive equity awards as part of the Fortive Separation.


^(b)	The “expected to vest” options are the net unvested options that remain after applying the forfeiture rate assumption to total unvested options.

Summary Of Options Outstanding

Options outstanding as of December 31, 2018 are summarized below (in millions, except price per share and number of years):



	Outstanding				Exercisable
Exercise Price	Shares	Average Exercise Price		Average Remaining Life (in years)	Shares	Average Exercise Price
$19.89 to $39.60	2.1	$	34.15	2	2.0	$	34.13
$39.61 to $56.70	2.5	48.73		4	2.3	48.15
$56.71 to $70.75	6.1	64.58		6	2.6	63.64
$70.76 to $86.08	3.9	85.13		8	0.7	84.37
$86.09 to $101.65	4.0	99.23		9	0.1	95.44

RSU And Restricted Stock Activity

The following summarizes information on unvested RSU and PSU activity (in millions, except weighted average grant-date fair value):



	Number of RSUs/PSUs		Weighted Average Grant-Date Fair Value
Unvested as of January 1, 2016	6.1		$	53.93
Granted	1.9		66.15
Vested	(1.8	)	50.64
Adjustment due to Fortive Separation ^(a)	(1.2	)	58.24
Forfeited	(0.5	)	28.79
Unvested as of December 31, 2016	4.5		62.16
Granted	1.4		86.04
Vested	(1.5	)	58.48
Forfeited	(0.5	)	68.83
Unvested as of December 31, 2017	3.9		71.27
Granted	1.5		99.15
Vested	(1.2	)	68.37
Forfeited	(0.3	)	78.41
Unvested as of December 31, 2018	3.9		82.21


^(a)	The “Adjustment due to Fortive Separation” reflects the cancellation of RSUs and PSUs which were outstanding as of July 2, 2016 and held by Fortive employees which have been converted to Fortive equity awards as part of the Fortive Separation.

Net Earnings Per Share From Continuing Operations (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Components Of Basic And Diluted Earnings Per Share

Information related to the calculation of net earnings from continuing operations per share of common stock is summarized as follows ($ and shares in millions, except per share amounts):



	Net Earnings from Continuing Operations (Numerator)		Shares (Denominator)	Per Share Amount
For the year ended December 31, 2018
Basic EPS	$	2,650.9	700.6	$	3.78
Adjustment for interest on convertible debentures	2.2		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		7.2
Incremental shares from assumed conversion of the convertible debentures	—		2.4
Diluted EPS	$	2,653.1	710.2	$	3.74

For the year ended December 31, 2017
Basic EPS	$	2,469.8	695.8	$	3.55
Adjustment for interest on convertible debentures	2.1		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		7.5
Incremental shares from assumed conversion of the convertible debentures	—		2.8
Diluted EPS	$	2,471.9	706.1	$	3.50

For the year ended December 31, 2016
Basic EPS	$	2,153.4	691.2	$	3.12
Adjustment for interest on convertible debentures	1.8		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		6.0
Incremental shares from assumed conversion of the convertible debentures	—		2.6
Diluted EPS	$	2,155.2	699.8	$	3.08

Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting, Measurement Disclosures [Abstract]

Segment Results

Detailed segment data for the years ended December 31 is as follows ($ in millions):



	2018			2017			2016
Sales:
Life Sciences	$	6,471.4		$	5,710.1		$	5,365.9
Diagnostics	6,257.6			5,839.9			5,038.3
Dental	2,844.5			2,810.9			2,785.4
Environmental & Applied Solutions	4,319.5			3,968.8			3,692.8
Total	$	19,893.0		$	18,329.7		$	16,882.4

Operating profit:
Life Sciences	$	1,229.3		$	1,004.3		$	818.9
Diagnostics	1,073.8			871.6			786.4
Dental	346.7			400.7			419.4
Environmental & Applied Solutions	988.0			914.6			870.0
Other	(234.0		)	(200.8		)	(159.5		)
Total	$	3,403.8		$	2,990.4		$	2,735.2

Identifiable assets:
Life Sciences	$	22,122.4		$	20,576.8		$	19,875.9
Diagnostics	14,031.1			14,359.2			14,159.6
Dental	5,897.3			6,026.8			5,772.2
Environmental & Applied Solutions	4,637.3			4,649.2			4,172.9
Other	1,144.4			1,036.6			1,314.7
Total	$	47,832.5		$	46,648.6		$	45,295.3

Depreciation and amortization:
Life Sciences	$	471.2		$	427.9		$	426.2
Diagnostics	589.0			581.5			481.5
Dental	130.0			121.4			127.2
Environmental & Applied Solutions	109.0			99.9			86.7
Other	8.5			7.6			6.5
Total	$	1,307.7		$	1,238.3		$	1,128.1



	2018		2017		2016
Capital expenditures, gross:
Life Sciences	$	140.1	$	130.6	$	109.7
Diagnostics	380.0		372.6		374.3
Dental	72.2		48.9		49.1
Environmental & Applied Solutions	57.1		60.9		51.0
Other	6.3		6.6		5.5
Total	$	655.7	$	619.6	$	589.6

Schedule Of Operations In Geographical Areas

Operations in Geographical Areas:



	Year Ended December 31
($ in millions)	2018		2017		2016
Sales:
United States	$	7,374.4	$	6,837.9	$	6,377.4
China	2,357.3		2,011.6		1,799.1
Germany	1,247.0		1,161.6		1,084.6
Japan	918.7		872.1		864.7
All other (each country individually less than 5% of total sales)	7,995.6		7,446.5		6,756.6
Total	$	19,893.0	$	18,329.7	$	16,882.4

Property, plant and equipment, net:
United States	$	1,224.4	$	1,126.2	$	1,198.4
Germany	198.3		212.4		190.8
United Kingdom	157.0		152.0		140.6
All other (each country individually less than 5% of total property, plant and equipment, net)	931.5		964.0		824.2
Total	$	2,511.2	$	2,454.6	$	2,354.0

Sales By Major Product Group

Sales by Major Product Group:



	Year Ended December 31
($ in millions)	2018		2017		2016
Analytical and physical instrumentation	$	2,437.0	$	2,232.9	$	2,088.9
Research and medical products	12,686.0		11,512.4		10,366.7
Dental products	2,844.5		2,810.9		2,785.4
Product identification	1,925.5		1,773.5		1,641.4
Total	$	19,893.0	$	18,329.7	$	16,882.4

Quarterly Data-Unaudited (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule Of Quarterly Data

QUARTERLY DATA-UNAUDITED



($ in millions, except per share data)	1st Quarter		2nd Quarter		3rd Quarter		4th Quarter
2018:
Sales	$	4,695.4	$	4,981.0	$	4,853.1	$	5,363.5
Gross profit	2,643.6		2,817.1		2,690.5		2,955.9
Operating profit	743.0		867.5		830.7		962.6
Net earnings from continuing operations	566.6		673.8		663.7		746.8
Net earnings	566.6		673.8		663.7		746.8
Net earnings per share from continuing operations:
Basic	$	0.81	$	0.96	$	0.95	$	1.06
Diluted	$	0.80	$	0.95	$	0.93	$	1.05	*
Net earnings per share:
Basic	$	0.81	$	0.96	$	0.95	$	1.06
Diluted	$	0.80	$	0.95	$	0.93	$	1.05	*

2017:
Sales	$	4,205.7	$	4,510.1	$	4,528.2	$	5,085.7
Gross profit	2,334.3		2,482.3		2,536.8		2,839.1
Operating profit	617.0		676.7		759.2		937.5
Net earnings from continuing operations	483.8		557.3		572.1		856.6
Net earnings from discontinued operations	22.3		—		—		—
Net earnings	506.1		557.3		572.1		856.6
Net earnings per share from continuing operations:
Basic	$	0.70	$	0.80	$	0.82	$	1.23
Diluted	$	0.69	$	0.79	$	0.81	$	1.21
Net earnings per share from discontinued operations:
Basic	$	0.03	$	—	$	—	$	—
Diluted	$	0.03	$	—	$	—	$	—
Net earnings per share:
Basic	$	0.73	$	0.80	$	0.82	$	1.23
Diluted	$	0.72	$	0.79	$	0.81	$	1.21

* Net earnings per share amounts do not add across to the full year amount due to rounding.

Schedule II - Valuation And Qualifying Accounts Schedule II - Valuation And Qualifying Accounts (Tables)

12 Months Ended

Dec. 31, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Summary of Valuation Allowance [Table Text Block]

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

($ in millions)



Classification	Balance at Beginning of Period ^(a)		Charged to Costs & Expenses		Impact of Currency			Charged to Other Accounts^(b)		Write-Offs, Write-Downs & Deductions			Balance at End of Period ^(a)
Year ended December 31, 2018:
Allowances deducted from asset account
Allowance for doubtful accounts	$	118.2	$	35.9	$	(4.5	)	$	1.3	$	(29.3	)	$	121.6
Year ended December 31, 2017:
Allowances deducted from asset account
Allowance for doubtful accounts	$	103.5	$	32.9	$	4.5		$	3.5	$	(26.2	)	$	118.2
Year ended December 31, 2016:
Allowances deducted from asset account
Allowance for doubtful accounts	$	89.7	$	32.5	$	(0.6	)	$	2.3	$	(20.4	)	$	103.5


^(a)	Amounts include allowance for doubtful accounts classified as current and noncurrent.


^(b)	Amounts related to businesses acquired, net of amounts related to businesses disposed not included in discontinued operations.

Business And Summary Of Significant Accounting Policies (Narrative) (Details) $ in Millions		12 Months Ended
	Jan. 01, 2018 USD ($)	Dec. 31, 2018 USD ($) Reporting_Unit	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Reporting_Unit	Jan. 31, 2019 USD ($)	Jan. 01, 2019 USD ($)
Number of segments \| Reporting_Unit		4		4
Charges associated with doubtful accounts		$ 36.0	$ 33.0	$ 33.0
Net aggregate financing receivables		219.0	213.0
Investment in equity securities		$ 148.9
Effect of change in accounting principle on net other income, increase (decrease) to AOCI	$ (151.2)
Foreign exchange forward
Derivative, term of contract		12 months
ASU No. 2014-09
Effect of change in accounting principle on retained earnings	3.0
ASU No. 2018-02
Effect of change in accounting principle on retained earnings	151.0
Effect of change in accounting principle on net other income, increase (decrease) to AOCI	$ (151.0)
ASU No. 2017-07
Effect of change in accounting principle on operating profit			(31.0)	(16.0)
Effect of change in accounting principle on net other income			$ 31.0	$ 16.0
Subsequent event
Operating lease, ROU asset						$ 1,000.0
Operating lease, liability						$ 1,000.0
Subsequent event \| Currency swap
Derivative, notional amount					$ 1,900.0

Business And Summary Of Significant Accounting Policies (Useful Lives Of Depreciable Assets) (Details)	12 Months Ended
	Dec. 31, 2018
Buildings
Property, Plant and Equipment [Line Items]
Useful life (in years)	30 years
Leased assets and leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life	Amortized over the lesser of the economic life of the asset or the term of the lease
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Customer-leased instruments \| Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Customer-leased instruments \| Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years

Business And Summary Of Significant Accounting Policies (Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		12 Months Ended
	Jan. 01, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income Loss [Roll Forward]
Balance at beginning of year	$ (1,994.2)	$ (1,994.2)	$ (3,021.7)	$ (2,311.2)
Adoption of accounting standards	151.2
Increase (decrease)		(678.2)	1,080.2	(593.1)
Income tax impact		9.5	(29.1)	24.1
Other comprehensive income (loss), before reclassifications, net of income taxes		(668.7)	1,051.1	(569.0)
Increase (decrease)		30.3	(44.1)	(195.4)
Income tax impact		(7.3)	20.5	74.1
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		23.0	(23.6)	(121.3)
Total other comprehensive income (loss), net of income taxes		(645.7)	1,027.5	(690.3)
Distribution of Fortive Corporation				(20.2)
Balance at end of year	(2,145.4)	(2,791.1)	(1,994.2)	(3,021.7)
AOCI, distribution to Fortive Corporation, tax			21.0
Foreign currency translation adjustments
Accumulated Other Comprehensive Income Loss [Roll Forward]
Balance at beginning of year	(1,422.1)	(1,422.1)	(2,398.2)	(1,797.4)
Adoption of accounting standards	43.8
Increase (decrease)		(632.2)	976.1	(517.3)
Income tax impact		0.0	0.0	0.0
Other comprehensive income (loss), before reclassifications, net of income taxes		(632.2)	976.1	(517.3)
Increase (decrease)		0.0	0.0	0.0
Income tax impact		0.0	0.0	0.0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	0.0	0.0
Total other comprehensive income (loss), net of income taxes		(632.2)	976.1	(517.3)
Distribution of Fortive Corporation				(83.5)
Balance at end of year	(1,465.9)	(2,098.1)	(1,422.1)	(2,398.2)
Pension and postretirement plan benefit adjustments
Accumulated Other Comprehensive Income Loss [Roll Forward]
Balance at beginning of year	(571.2)	(571.2)	(642.2)	(647.3)
Adoption of accounting standards	107.2
Increase (decrease)		(44.9)	62.4	(115.4)
Income tax impact		9.2	(13.4)	38.9
Other comprehensive income (loss), before reclassifications, net of income taxes		(35.7)	49.0	(76.5)
Increase (decrease)		30.3	28.7	28.0
Income tax impact		(7.3)	(6.7)	(9.7)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		23.0	22.0	18.3
Total other comprehensive income (loss), net of income taxes		(12.7)	71.0	(58.2)
Distribution of Fortive Corporation				63.3
Balance at end of year	(678.4)	(691.1)	(571.2)	(642.2)
Unrealized gain (loss) on available-for-sale securities
Accumulated Other Comprehensive Income Loss [Roll Forward]
Balance at beginning of year	(0.9)	(0.9)	18.7	133.5
Adoption of accounting standards	0.2
Increase (decrease)		(1.1)	41.7	39.6
Income tax impact		0.3	(15.7)	(14.8)
Other comprehensive income (loss), before reclassifications, net of income taxes		(0.8)	26.0	24.8
Increase (decrease)		0.0	(72.8)	(223.4)
Income tax impact		0.0	27.2	83.8
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	(45.6)	(139.6)
Total other comprehensive income (loss), net of income taxes		(0.8)	(19.6)	(114.8)
Distribution of Fortive Corporation				0.0
Balance at end of year	$ (1.1)	$ (1.9)	$ (0.9)	$ 18.7

Revenue Revenue (Details) - USD ($) $ in Millions	12 Months Ended
Revenue Revenue (Details) - USD ($) $ in Millions	Dec. 31, 2018	Jan. 01, 2018
Revenue from Contract with Customer [Abstract]
Operating-type lease and sales-type lease, revenues	$ 402
Revenue, remaining performance obligation	$ 1,900
Revenue, remaining performance obligation, expected satisfaction in the next 12 months, percent	43.00%
Revenue, remaining performance obligation, expected satisfaction in year two, percent	27.00%
Contract with customer, asset, net	$ 82	$ 114
Contract with customer, liability	799	$ 783
Contract with customer, liability, revenue recognized	$ 657

Acquisitions (Narrative) (Details) $ / shares in Units, $ in Millions			3 Months Ended	12 Months Ended
	Apr. 13, 2018 USD ($)	Nov. 04, 2016 USD ($) $ / shares	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) Businesses Reporting_Unit	Dec. 31, 2017 USD ($) Business	Dec. 31, 2016 USD ($) Reporting_Unit Business
Business Acquisition [Line Items]
Goodwill				$ 1,275.4	$ 267.6	$ 3,061.8
Net cash consideration				$ 2,173.3	385.8	$ 4,880.1
Number of segments \| Reporting_Unit				4		4
Payment for purchase of noncontrolling interest			$ (64.0)	$ 0.0	(64.4)	$ 0.0
Change in noncontrolling interests			(63.0)
Adjustments to additional paid in capital, other			$ (1.0)
IDT
Business Acquisition [Line Items]
Revenue reported by acquired entity for last annual period	$ 260.0
Goodwill	1,200.0			1,212.6
Net cash consideration	$ 2,100.0			2,078.2
Transaction costs				15.0	15.0
Others
Business Acquisition [Line Items]
Revenue reported by acquired entity for last annual period				53.0	160.0	237.0
Goodwill				$ 62.8	$ 268.0	$ 477.8
Number of businesses acquired				1	10	7
Net cash consideration				$ 95.1	$ 386.0	$ 882.4
Cepheid
Business Acquisition [Line Items]
Revenue reported by acquired entity for last annual period		$ 539.0
Goodwill						2,584.0
Net cash consideration						3,997.7
Business acquisition, share price \| $ / shares		$ 53.00
Consideration transferred		$ 4,000.0
Transaction costs						61.0
Fair value adjustment to inventory \| IDT
Business Acquisition [Line Items]
Fair value adjustments to inventory				$ 1.0	$ (1.0)
Fair value adjustment to inventory \| Cepheid
Business Acquisition [Line Items]
Fair value adjustments to inventory						$ 23.0

Acquisitions (Fair Values Of The Assets Acquired And Liabilities) (Details) - USD ($) $ in Millions		12 Months Ended
	Apr. 13, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Trade accounts receivable		$ 41.1	$ 21.6	$ 97.8
Inventories		14.8	21.3	204.8
Property, plant and equipment		88.4	9.1	161.8
Goodwill		1,275.4	267.6	3,061.8
Other intangible assets, primarily customer relationships, trade names and technology		850.7	155.1	1,867.0
In-process research and development		0.0	0.0	65.0
Trade accounts payable		(6.7)	(9.9)	(50.7)
Other assets and liabilities, net		(66.5)	(75.0)	(518.0)
Assumed debt		0.0	0.0	(1.0)
Attributable to noncontrolling interest		0.0	(4.0)	0.0
Net assets acquired		2,197.2	385.8	4,888.5
Less: noncash consideration		(23.9)	0.0	(8.4)
Net cash consideration		2,173.3	385.8	4,880.1
IDT
Business Acquisition [Line Items]
Trade accounts receivable		36.0
Inventories		14.8
Property, plant and equipment		88.2
Goodwill	$ 1,200.0	1,212.6
Other intangible assets, primarily customer relationships, trade names and technology		811.0
Trade accounts payable		(5.5)
Other assets and liabilities, net		(55.0)
Net assets acquired		2,102.1
Less: noncash consideration		(23.9)
Net cash consideration	$ 2,100.0	2,078.2
Others
Business Acquisition [Line Items]
Trade accounts receivable		5.1		36.4
Inventories		0.0		39.0
Property, plant and equipment		0.2		17.3
Goodwill		62.8	268.0	477.8
Other intangible assets, primarily customer relationships, trade names and technology		39.7		387.0
In-process research and development				0.0
Trade accounts payable		(1.2)		(9.5)
Other assets and liabilities, net		(11.5)		(65.6)
Assumed debt				0.0
Net assets acquired		95.1		882.4
Less: noncash consideration		0.0		0.0
Net cash consideration		$ 95.1	$ 386.0	882.4
Cepheid
Business Acquisition [Line Items]
Trade accounts receivable				61.4
Inventories				165.8
Property, plant and equipment				144.5
Goodwill				2,584.0
Other intangible assets, primarily customer relationships, trade names and technology				1,480.0
In-process research and development				65.0
Trade accounts payable				(41.2)
Other assets and liabilities, net				(452.4)
Assumed debt				(1.0)
Net assets acquired				4,006.1
Less: noncash consideration				(8.4)
Net cash consideration				$ 3,997.7

Acquisitions (Results Of Operations If Acquisition Was Consummated) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition, Pro Forma Information [Abstract]
Sales	$ 19,995.7	$ 18,744.7
Net earnings from continuing operations	$ 2,652.9	$ 2,449.8
Diluted net earnings per share from continuing operations (in dollars per share)	$ 3.74	$ 3.47

Discontinued Operations (Narrative) (Details) $ in Millions	1 Months Ended		3 Months Ended								6 Months Ended	12 Months Ended
Discontinued Operations (Narrative) (Details) $ in Millions	Aug. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2018 USD ($)	Sep. 28, 2018 USD ($)	Jun. 29, 2018 USD ($)	Mar. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 29, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jul. 01, 2016 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jun. 15, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Separation, Fortive shares distributed per Danaher share, ratio															0.5
Long-term debt			$ 9,740.3				$ 10,522.1					$ 9,740.3	$ 10,522.1
Payments of debt extinguishment costs												0.0	0.0	$ 188.1
Discontinued operation, revenues prior Separation													0.0	3,029.8
Discontinued operation, income tax benefit													(22.3)	157.0
Sales			$ 5,363.5	$ 4,853.1	$ 4,981.0	$ 4,695.4	$ 5,085.7	$ 4,528.2	$ 4,510.1	$ 4,205.7		19,893.0	18,329.7	16,882.4
Fortive
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Long-term debt		$ 3,400.0
Fortive's cash payments to Danaher prior to distribution date		3,000.0
Senior notes \| 2.3% senior unsecured notes due 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, face amount		$ 500.0
Interest rate of debt instrument		2.30%
Senior notes \| 5.625% senior unsecured notes due 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate of debt instrument		5.625%
Senior notes \| 5.4% senior unsecured notes due 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate of debt instrument		5.40%
Senior notes \| 3.9% senior unsecured notes due 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate of debt instrument		3.90%
Discontinued operations, spin-off \| Fortive
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Extinguishment of debt, amount	$ 1,900.0
Discontinued operation, revenues prior Separation											$ 3,000.0
Separation-related costs														48.0
Dental \| Operating segments
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales												$ 2,844.5	$ 2,810.9	$ 2,785.4

Discontinued Operations (Components Of Income Related To Discontinued Operations) (Details) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Dec. 31, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures
Sales						$ 0.0	$ 3,029.8
Cost of sales						0.0	(1,566.4)
Selling, general and administrative expenses						0.0	(696.0)
Research and development expenses						0.0	(190.4)
Interest expense						0.0	(19.7)
Income from discontinued operations before income taxes						0.0	557.3
Income taxes						22.3	(157.0)
Earnings from discontinued operations, net of income taxes	$ 0.0	$ 0.0	$ 0.0	$ 22.3	$ 0.0	$ 22.3	$ 400.3

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Inventories (Schedule Of Inventory) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Inventory, Net [Abstract]
Finished goods	$ 1,031.2	$ 982.5
Work in process	313.9	309.7
Raw materials	565.0	548.6
Total	$ 1,910.1	$ 1,840.8

Property, Plant And Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 5,339.5	$ 4,974.0
Less: accumulated depreciation	(2,828.3)	(2,519.4)
Property, plant and equipment, net	2,511.2	2,454.6	$ 2,354.0
Land and improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	176.5	155.6
Buildings
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	1,047.8	1,009.5
Machinery and equipment
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	2,482.3	2,239.5
Customer-leased instruments
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 1,632.9	$ 1,569.4

Goodwill And Other Intangible Assets (Narrative) (Details) $ in Millions		12 Months Ended
	Dec. 31, 2018 USD ($) Reporting_Unit	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Goodwill [Line Items]
Reporting units for goodwill impairment testing \| Reporting_Unit	8
Goodwill	$ 25,906.0	$ 25,906.0	$ 25,138.6	$ 23,826.9
Impairment loss		$ 0.0	$ 0.0	0.0
Finite-lived intangible assets, weighted-average life (in years)		18 years	9 years
Total intangible amortization expense		$ 706.0	$ 661.0	$ 583.0
Future amortization expense, year one	720.0	720.0
Future amortization expense, year two	709.0	709.0
Future amortization expense, year three	694.0	694.0
Future amortization expense, year four	673.0	673.0
Future amortization expense, year five	665.0	665.0
Minimum
Goodwill [Line Items]
Goodwill	511.0	511.0
Maximum
Goodwill [Line Items]
Goodwill	$ 13,300.0	$ 13,300.0

Goodwill And Other Intangible Assets (Rollforward Of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Roll Forward]
Balance at beginning of year	$ 25,138.6	$ 23,826.9
Attributable to acquisitions	1,275.4	267.6	$ 3,061.8
Adjustments due to finalization of purchase price adjustments	7.5	(49.9)
Foreign currency translation and other	(515.5)	1,094.0
Balance at end of year	25,906.0	25,138.6	23,826.9
Operating segments \| Life Sciences
Goodwill [Roll Forward]
Balance at beginning of year	12,335.5	11,610.3
Attributable to acquisitions	1,212.6	95.5
Adjustments due to finalization of purchase price adjustments	2.8	(19.1)
Foreign currency translation and other	(239.9)	648.8
Balance at end of year	13,311.0	12,335.5	11,610.3
Operating segments \| Diagnostics
Goodwill [Roll Forward]
Balance at beginning of year	7,079.5	6,903.0
Attributable to acquisitions	0.0	0.0
Adjustments due to finalization of purchase price adjustments	0.0	(39.6)
Foreign currency translation and other	(153.9)	216.1
Balance at end of year	6,925.6	7,079.5	6,903.0
Operating segments \| Dental
Goodwill [Roll Forward]
Balance at beginning of year	3,370.0	3,215.6
Attributable to acquisitions	0.0	2.8
Adjustments due to finalization of purchase price adjustments	0.0	8.8
Foreign currency translation and other	(44.5)	142.8
Balance at end of year	3,325.5	3,370.0	3,215.6
Operating segments \| Environmental & Applied Solutions
Goodwill [Roll Forward]
Balance at beginning of year	2,353.6	2,098.0
Attributable to acquisitions	62.8	169.3
Adjustments due to finalization of purchase price adjustments	4.7	0.0
Foreign currency translation and other	(77.2)	86.3
Balance at end of year	$ 2,343.9	$ 2,353.6	$ 2,098.0

Goodwill And Other Intangible Assets (Schedule of Finite-lived Intangible Assets And Indefinite-lived Intangible Assets By Major Class) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Intangible Assets, Gross (Excluding Goodwill) [Abstract]
Finite-lived intangibles, gross carrying amount	$ 10,478.8	$ 9,742.3
Total intangibles, gross carrying amount	15,307.6	14,668.4
Finite-lived intangibles, accumulated amortization	(3,634.5)	(3,001.3)
Trademarks and trade names
Intangible Assets, Gross (Excluding Goodwill) [Abstract]
Indefinite-lived intangibles, gross carrying amount	4,828.8	4,926.1
Patents and technology
Intangible Assets, Gross (Excluding Goodwill) [Abstract]
Finite-lived intangibles, gross carrying amount	2,985.3	2,363.5
Finite-lived intangibles, accumulated amortization	(945.2)	(783.7)
Customer relationships and other intangibles
Intangible Assets, Gross (Excluding Goodwill) [Abstract]
Finite-lived intangibles, gross carrying amount	7,302.8	7,354.9
Finite-lived intangibles, accumulated amortization	(2,661.3)	(2,203.6)
Trademarks and trade names
Intangible Assets, Gross (Excluding Goodwill) [Abstract]
Finite-lived intangibles, gross carrying amount	190.7	23.9
Finite-lived intangibles, accumulated amortization	$ (28.0)	$ (14.0)

Fair Value Measurements (Financial Assets And Liabilities Carried At Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Assets:
Available-for-sale debt securities	$ 38.3	$ 45.4
Investment in equity securities	148.9
Liabilities:
Deferred compensation plans	60.9	62.9
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale debt securities	0.0	0.0
Investment in equity securities	0.0
Liabilities:
Deferred compensation plans	0.0	0.0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale debt securities	38.3	45.4
Investment in equity securities	0.0
Liabilities:
Deferred compensation plans	60.9	62.9
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale debt securities	0.0	0.0
Investment in equity securities	148.9
Liabilities:
Deferred compensation plans	$ 0.0	$ 0.0

Fair Value Measurements Fair Value Measurements (Carrying Amounts And Fair Values Of Financial Instruments) (Details) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale debt securities	$ 38.3	$ 45.4
Investment in equity securities	148.9
Carrying Amount
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale debt securities	38.3	45.4
Investment in equity securities	148.9	0.0
Notes payable and current portion of long-term debt	51.8	194.7
Long-term debt	9,688.5	10,327.4
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale debt securities	38.3	45.4
Investment in equity securities	148.9	0.0
Notes payable and current portion of long-term debt	51.8	194.7
Long-term debt	$ 9,990.6	$ 10,847.1

Accrued Expenses And Other Liabilities (Accrued Expenses And Other Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current
Compensation and benefits	$ 1,026.8	$ 961.0
Pension and postretirement benefits	75.2	95.8
Taxes, income and other	292.4	386.4
Contract liabilities	685.2	666.0
Sales and product allowances	167.8	155.7
Other	829.5	822.8
Total	3,076.9	3,087.7
Noncurrent
Compensation and benefits	236.9	236.2
Pension and postretirement benefits	961.9	1,052.0
Taxes, income and other	3,577.7	3,543.6
Contract liabilities	113.8	104.9
Sales and product allowances	2.0	2.0
Other	183.5	222.4
Total	$ 5,075.8	$ 5,161.1

Financing (Commercial Paper Programs And Credit Facilities) (Narrative) (Details) - USD ($)		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2015	Nov. 06, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Debt discounts, premiums and debt issuance costs	$ 19,000,000	$ 19,000,000			$ 25,000,000
Long-term debt	$ 9,740,300,000	$ 9,740,300,000			$ 10,522,100,000
Commercial paper
Line of Credit Facility [Line Items]
Debt, weighted average annual interest rate, basis points	(0.20%)	(0.20%)
Long-term debt weighted average maturity	37 days
U.S. dollar denominated and euro-denominated commercial paper \| Commercial paper
Line of Credit Facility [Line Items]
Long-term debt	$ 2,450,300,000	$ 2,450,300,000
Revolving credit facility \| Federal funds rate
Line of Credit Facility [Line Items]
Basis spread percentage to determine floating interest rate	0.50%
Revolving credit facility \| Credit Facility
Line of Credit Facility [Line Items]
Consolidated leverage ratio	0.65	0.65
Credit facility, borrowings outstanding	$ 0	$ 0
Revolving credit facility \| Credit Facility \| Federal funds rate
Line of Credit Facility [Line Items]
Basis spread percentage to determine floating interest rate	0.50%
Revolving credit facility \| Credit Facility \| LIBOR-based rate
Line of Credit Facility [Line Items]
Basis spread percentage to determine floating interest rate	1.00%
Revolving credit facility \| Credit Facility \| Long-term debt
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity			$ 4,000,000,000
Debt instrument, extension option, term			1 year
Line of credit facility, maximum amount outstanding during period		0
Credit facility, borrowings outstanding	$ 0	0
Revolving credit facility \| 364-Day Facility \| Short-term debt
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity				$ 1,000,000,000
Line of credit facility, maximum amount outstanding during period		$ 0

Financing (LYONS) (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended				216 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2001	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from borrowings (maturities longer than 90 days)	$ 0.0	$ 1,782.1	$ 3,240.9
Common stock par value	$ 0.01	$ 0.01			$ 0.01
Convertible debt \| Zero-coupon LYONS due 2021
Debt Instrument [Line Items]
Debt instrument, face amount				$ 830.0
Proceeds from borrowings (maturities longer than 90 days)				505.0
Repayments of long-term lines of credit				$ 100.0
Interest rate of debt instrument	0.00%			2.375%	0.00%
Debt instrument, convertible, conversion ratio				0.0381998
Debt conversion, converted instrument, shares issued	585				22,000
Debt conversion, converted instrument, tax benefit (expense)	$ 5.0
Average market price percentage for measurement period resulting in payment of contingent interest to debt instrument holders				120.00%
Debt instrument percentage				0.0315%
Debt Instrument, periodic payment, interest	$ 2.0	$ 2.0	$ 1.0

Financing (Long-Term Debt Repayments) (Narrative) (Details) - Senior notes € in Millions, $ in Millions	Sep. 30, 2018 USD ($)	Jun. 30, 2017 EUR (€)
1.65% senior unsecured notes due 2018
Debt Instrument [Line Items]
Debt instrument, face amount \| $	$ 500
Floating rate senior unsecured notes due 2017
Debt Instrument [Line Items]
Debt instrument, face amount \| €		€ 500

Financing (Covenants and Redemption Provisions Applicable to Notes) (Narrative) (Details)	Dec. 31, 2018
Bonds \| Swiss franc-denominated senior unsecured bonds
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount redeemed, threshold	85.00%
Senior notes
Debt Instrument [Line Items]
Percentage of notes' principal in addition to accrued interest that redemption price must equal or be greater than if a credit downgrade or change in control occurs	101.00%
Senior notes \| 2027 and 2032 Yen notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%

Financing (Other) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Interest paid	$ 140	$ 130	$ 212

Financing (Components Of Debt) (Table) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Dec. 31, 2018 USD ($)	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 JPY (¥)	Sep. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 CHF (SFr)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 JPY (¥)	Dec. 31, 2001 USD ($)
Debt Instrument [Line Items]
Total debt	$ 9,740.3					$ 10,522.1
Less: currently payable	51.8					194.7
Long-term debt	9,688.5					10,327.4
U.S. dollar-denominated commercial paper \| Commercial paper
Debt Instrument [Line Items]
Total debt	72.8					436.9
Euro-denominated commercial paper \| Commercial paper
Debt Instrument [Line Items]
Total debt	2,377.5		€ 2,100			1,993.9		€ 1,700
1.65% senior unsecured notes due 2018 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 0.0					499.2
Interest rate of debt instrument	1.65%	1.65%	1.65%	1.65%
Debt instrument, face amount					$ 500.0
1.0% senior unsecured notes due 2019 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 687.0					718.4
Interest rate of debt instrument	1.00%	1.00%	1.00%	1.00%
Debt instrument, face amount \| €			€ 600					600
2.4% senior unsecured notes due 2020 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 498.5					497.7
Interest rate of debt instrument	2.40%	2.40%	2.40%	2.40%
5.0% senior unsecured notes due 2020 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 386.7					394.6
Interest rate of debt instrument	5.00%	5.00%	5.00%	5.00%
Zero-coupon LYONS due 2021 \| Convertible debt
Debt Instrument [Line Items]
Total debt	$ 56.2					69.1
Interest rate of debt instrument	0.00%	0.00%	0.00%	0.00%						2.375%
Debt instrument, face amount										$ 830.0
0.352% senior unsecured notes due 2021 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 273.2					265.5
Interest rate of debt instrument	0.352%	0.352%	0.352%	0.352%
Debt instrument, face amount \| ¥				¥ 30.0					¥ 30.0
1.7% senior unsecured notes due 2022 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 913.2					955.6
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%
Debt instrument, face amount \| €			€ 800					800
Floating rate senior unsecured notes due 2022 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 285.7					299.1
Debt instrument, face amount \| €			€ 250					250
0.5% senior unsecured bonds due 2023 \| Bonds
Debt Instrument [Line Items]
Total debt	$ 550.7					555.5
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%
Debt instrument, face amount \| SFr		SFr 540					SFr 540
2.5% senior unsecured notes due 2025 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 912.6					955.6
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%
Debt instrument, face amount \| €			€ 800					800
3.35% senior unsecured notes due 2025 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 496.8					496.3
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%
0.3% senior unsecured notes due 2027 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 279.9					272.2
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%
Debt instrument, face amount \| ¥				¥ 30.8					30.8
1.2% senior unsecured notes due 2027 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 682.0					714.1
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%
Debt instrument, face amount \| €			€ 600					€ 600
1.125% senior unsecured bonds due 2028 \| Bonds
Debt Instrument [Line Items]
Total debt	$ 218.1					220.3
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%
Debt instrument, face amount \| SFr		SFr 210					SFr 210
0.65% senior unsecured notes due 2032 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 483.4					470.2
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%
Debt instrument, face amount \| ¥				¥ 53.2					¥ 53.2
4.375% senior unsecured notes due 2045 \| Senior notes
Debt Instrument [Line Items]
Total debt	$ 499.3					499.3
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%
Other
Debt Instrument [Line Items]
Total debt	$ 66.7					$ 208.6

Financing (Long-Term Indebtedness) (Table) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Dec. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	May 11, 2017 USD ($)	May 11, 2017 JPY (¥)	Feb. 28, 2016 USD ($)	Feb. 28, 2016 JPY (¥)	Dec. 08, 2015 USD ($)	Dec. 08, 2015 CHF (SFr)	Sep. 15, 2015 USD ($)	Jul. 08, 2015 USD ($)	Jul. 08, 2015 EUR (€)	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 JPY (¥)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 CHF (SFr)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 JPY (¥)	Aug. 31, 2015 USD ($)	Dec. 31, 2001 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 9,740.3															$ 10,522.1
Other
Debt Instrument [Line Items]
Long-term debt	66.7															208.6
Senior notes \| 1.0% senior unsecured notes due 2019
Debt Instrument [Line Items]
Long-term debt	$ 687.0															718.4
Interest rate of debt instrument	1.00%												1.00%	1.00%	1.00%
Debt instrument, redemption price, percentage	99.696%
Debt instrument, face amount \| €														€ 600				€ 600
Senior notes \| 2.4% senior unsecured notes due 2020
Debt Instrument [Line Items]
Long-term debt	$ 498.5															497.7
Interest rate of debt instrument	2.40%												2.40%	2.40%	2.40%
Debt instrument, redemption price, percentage	99.757%
Senior notes \| 5.0% senior unsecured notes due 2020
Debt Instrument [Line Items]
Long-term debt	$ 386.7															394.6
Interest rate of debt instrument	5.00%												5.00%	5.00%	5.00%
Senior notes \| 0.352% senior unsecured notes due 2021
Debt Instrument [Line Items]
Long-term debt	$ 273.2															265.5
Interest rate of debt instrument	0.352%												0.352%	0.352%	0.352%
Debt instrument, redemption price, percentage	100.00%
Net proceeds from debt						$ 262.0	¥ 29.9
Debt instrument, face amount \| ¥															¥ 30.0				¥ 30.0
Senior notes \| 1.7% senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt	$ 913.2															955.6
Interest rate of debt instrument	1.70%												1.70%	1.70%	1.70%
Debt instrument, redemption price, percentage	99.651%
Debt instrument, face amount \| €														€ 800				800
Senior notes \| Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt	$ 285.7															299.1
Debt instrument, redemption price, percentage	100.147%
Basis spread percentage to determine floating interest rate	0.30%
Debt instrument, face amount \| €														€ 250				250
Senior notes \| 2.5% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt	$ 912.6															955.6
Interest rate of debt instrument	2.50%												2.50%	2.50%	2.50%
Debt instrument, redemption price, percentage	99.878%
Debt instrument, face amount \| €														€ 800				800
Senior notes \| 3.35% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt	$ 496.8															496.3
Interest rate of debt instrument	3.35%												3.35%	3.35%	3.35%
Debt instrument, redemption price, percentage	99.857%
Senior notes \| 0.3% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt	$ 279.9															272.2
Interest rate of debt instrument	0.30%												0.30%	0.30%	0.30%
Debt instrument, redemption price, percentage	100.00%
Debt instrument, face amount \| ¥															¥ 30.8				30.8
Senior notes \| 1.2% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt	$ 682.0															714.1
Interest rate of debt instrument	1.20%												1.20%	1.20%	1.20%
Debt instrument, redemption price, percentage	99.682%
Debt instrument, face amount \| €														€ 600				€ 600
Senior notes \| 0.65% senior unsecured notes due 2032
Debt Instrument [Line Items]
Long-term debt	$ 483.4															470.2
Interest rate of debt instrument	0.65%												0.65%	0.65%	0.65%
Debt instrument, redemption price, percentage	100.00%
Debt instrument, face amount \| ¥															¥ 53.2				¥ 53.2
Senior notes \| 4.375% senior unsecured notes due 2045
Debt Instrument [Line Items]
Long-term debt	$ 499.3															499.3
Interest rate of debt instrument	4.375%												4.375%	4.375%	4.375%
Debt instrument, redemption price, percentage	99.784%
Senior notes \| Euro-denominated senior unsecured notes, 2019, 2022 and 2025 tranches
Debt Instrument [Line Items]
Net proceeds from debt											$ 2,400.0	€ 2,200
Senior notes \| U.S. dollar-denominated senior unsecured notes
Debt Instrument [Line Items]
Net proceeds from debt										$ 2,000.0
Senior notes \| Euronotes
Debt Instrument [Line Items]
Net proceeds from debt		$ 940.0	€ 843
Senior notes \| 2027 and 2032 Yen notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Net proceeds from debt				$ 744.0	¥ 83.6
Convertible debt \| Zero-coupon LYONS due 2021
Debt Instrument [Line Items]
Long-term debt	$ 56.2															69.1
Interest rate of debt instrument	0.00%												0.00%	0.00%	0.00%						2.375%
Debt instrument, face amount																					$ 830.0
Bonds \| 0.5% senior unsecured bonds due 2023
Debt Instrument [Line Items]
Long-term debt	$ 550.7															555.5
Interest rate of debt instrument	0.50%												0.50%	0.50%	0.50%
Debt instrument, redemption price, percentage	100.924%
Debt instrument, face amount \| SFr													SFr 540				SFr 540
Bonds \| 0.0% senior unsecured bonds due 2017
Debt Instrument [Line Items]
Interest rate of debt instrument	0.00%												0.00%	0.00%	0.00%
Bonds \| 1.125% senior unsecured bonds due 2028
Debt Instrument [Line Items]
Long-term debt	$ 218.1															$ 220.3
Interest rate of debt instrument	1.125%												1.125%	1.125%	1.125%
Debt instrument, redemption price, percentage	102.87%
Debt instrument, face amount \| SFr													SFr 210				SFr 210
Bonds \| Swiss franc-denominated senior unsecured bonds
Debt Instrument [Line Items]
Net proceeds from debt								$ 739.0	SFr 758
Debt instrument, face amount \| SFr									SFr 100
Commercial paper \| U.S. dollar denominated and euro-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt	$ 2,450.3
Pall Corporation \| Senior notes \| 5.0% senior unsecured notes due 2020
Debt Instrument [Line Items]
Debt instrument, face amount																				$ 375.0
Long-term debt, fair value																				$ 417.0
Interest rate, effective percentage																				2.90%

Financing (Schedule of Future Minimum Lease Payments for Capital Leases) (Table) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Debt Disclosure [Abstract]
Long-term debt, maturities, repayments of principal in next twelve months	$ 51.8
Long-term debt, maturities, repayments of principal in year two	4,021.8
Long-term debt, maturities, repayments of principal in year three	327.5
Long-term debt, maturities, repayments of principal in year four	1,211.9
Long-term debt, maturities, repayments of principal in year five	548.1
Long-term debt, maturities, repayments of principal after year five	$ 3,579.2

Pension Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
NAV per share, investment redemption, notice period		90 days
Expense for all defined benefit and defined contributions pension plans		$ 187.0	$ 177.0	$ 177.0
Pension benefit plans
Defined Benefit Plan Disclosure [Line Items]
Unrecognized prior service credits, before tax		7.0
Unrecognized net prior service credits, net of tax		5.0
Unrecognized actuarial losses, before tax		(919.0)
Unrecognized actuarial losses, net of tax		(695.0)
Future amortization of prior service cost (credit)		0.7
Future amortization of prior service cost (credit), net of tax		0.5
Future amortization of gain (loss)		(30.0)
Future amortization of gain (loss), net of tax		$ (23.0)
Non-U.S. plan \| Pension benefit plans
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions		3.90%	3.90%
Employer contributions		$ 52.4	$ 44.7
Expected employer contributions within the next year		$ 50.0
Non-U.S. plan \| Pension benefit plans \| Minimum
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions		1.00%	1.00%
Non-U.S. plan \| Pension benefit plans \| Maximum
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions		5.80%	5.80%
Non-U.S. plan \| Pension benefit plans \| Weighted average
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions		3.90%	3.90%
United States \| Domestic plan \| Pension benefit plans
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions		7.00%	7.00%
Employer contributions		$ 55.1	$ 53.2
Expected employer contributions within the next year		$ 10.0
United States \| Domestic plan \| Pension benefit plans \| Minimum
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, target allocation, percentage		60.00%
United States \| Domestic plan \| Pension benefit plans \| Maximum
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, target allocation, percentage		70.00%
Scenario, forecast \| United States \| Domestic plan \| Pension benefit plans
Defined Benefit Plan Disclosure [Line Items]
Long-term rate of return on asset assumptions	7.00%
ASU No. 2017-07
Defined Benefit Plan Disclosure [Line Items]
Effect of change in accounting principle on operating profit			(31.0)	(16.0)
Effect of change in accounting principle on net other income			31.0	16.0
ASU No. 2017-07 \| Pension benefit plans
Defined Benefit Plan Disclosure [Line Items]
Effect of change in accounting principle on operating profit			(33.0)	(19.0)
Effect of change in accounting principle on net other income			$ 33.0	$ 19.0

Pension Benefit Plans (Funded Status Of Pension Plans) (Details) - Pension benefit plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Change in benefit obligation:
Service cost	$ (42.2)	$ (40.0)	$ (45.4)
Change in plan assets:
Fair value of plan assets at beginning of year	3,204.2
Fair value of plan assets at end of year	2,896.7	3,204.2
Non-U.S. plan
Change in benefit obligation:
Benefit obligation at beginning of year	(1,571.8)	(1,493.0)
Service cost	(35.5)	(32.7)
Interest cost	(25.1)	(25.5)
Employee contributions	(9.3)	(8.2)
Benefits and other expenses paid	51.4	58.3
Acquisitions and other	(3.6)	0.0
Actuarial gain (loss)	68.9	51.4
Amendments, settlements and curtailments	26.5	10.5
Foreign exchange rate impact	56.2	(132.6)
Benefit obligation at end of year	(1,442.3)	(1,571.8)	(1,493.0)
Change in plan assets:
Fair value of plan assets at beginning of year	1,199.3	1,042.9
Actual return (loss) on plan assets	(19.9)	74.6
Employer contributions	52.4	44.7
Employee contributions	9.3	8.2
Amendments and settlements	(28.2)	(3.7)
Benefits and other expenses paid	(51.4)	(58.3)
Acquisitions and other	1.9	0.0
Foreign exchange rate impact	(45.0)	90.9
Fair value of plan assets at end of year	1,118.4	1,199.3	1,042.9
Funded status	(323.9)	(372.5)
United States \| Domestic plan
Change in benefit obligation:
Benefit obligation at beginning of year	(2,612.9)	(2,558.1)
Service cost	(6.7)	(7.3)
Interest cost	(81.0)	(82.3)
Employee contributions	0.0	0.0
Benefits and other expenses paid	179.0	181.8
Acquisitions and other	0.0	0.0
Actuarial gain (loss)	145.2	(139.9)
Amendments, settlements and curtailments	31.4	(7.1)
Foreign exchange rate impact	0.0	0.0
Benefit obligation at end of year	(2,345.0)	(2,612.9)	(2,558.1)
Change in plan assets:
Fair value of plan assets at beginning of year	2,004.9	1,868.2
Actual return (loss) on plan assets	(72.1)	265.3
Employer contributions	55.1	53.2
Employee contributions	0.0	0.0
Amendments and settlements	(30.6)	0.0
Benefits and other expenses paid	(179.0)	(181.8)
Acquisitions and other	0.0	0.0
Foreign exchange rate impact	0.0	0.0
Fair value of plan assets at end of year	1,778.3	2,004.9	$ 1,868.2
Funded status	$ (566.7)	$ (608.0)

Pension Benefit Plans (Weighted Average Assumptions Used To Determine Benefit Obligations) (Details) - Pension benefit plans	Dec. 31, 2018	Dec. 31, 2017
Non-U.S. plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.00%	1.80%
Rate of compensation increase	2.30%	2.20%
United States \| Domestic plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	4.30%	3.60%
Rate of compensation increase	4.00%	4.00%

Pension Benefit Plans (Components Of Net Periodic Pension Costs) (Details) - Pension benefit plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (42.2)	$ (40.0)	$ (45.4)
Net periodic pension benefit (cost)	(2.2)	(6.8)	$ (26.2)
Non-U.S. plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	(35.5)	(32.7)
Interest cost	(25.1)	(25.5)
Expected return on plan assets	46.9	42.4
Amortization of prior service (cost) credit	0.5	0.3
Amortization of net loss	(6.0)	(7.8)
Curtailment and settlement gains recognized	4.9	0.5
Net periodic pension benefit (cost)	(14.3)	(22.8)
United States \| Domestic plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	(6.7)	(7.3)
Interest cost	(81.0)	(82.3)
Expected return on plan assets	132.0	130.5
Amortization of prior service (cost) credit	(0.9)	0.0
Amortization of net loss	(31.3)	(24.9)
Curtailment and settlement gains recognized	0.0	0.0
Net periodic pension benefit (cost)	$ 12.1	$ 16.0

Pension Benefit Plans Pension Benefit Plans (Disaggregation of Service Costs) (Details) - Pension benefit plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (42.2)	$ (40.0)	$ (45.4)
Nonoperating income (expense), net	40.0	33.2	19.2
Net periodic pension benefit (cost)	(2.2)	(6.8)	(26.2)
Cost of sales
Defined Benefit Plan Disclosure [Line Items]
Service cost	(11.4)	(8.2)	(9.8)
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (30.8)	$ (31.8)	$ (35.6)

Pension Benefit Plans (Weighted Average Assumptions Used To Determine Net Periodic Pension Cost) (Details) - Pension benefit plans	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Non-U.S. plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	1.80%	1.80%
Expected long-term return on plan assets	3.90%	3.90%
Rate of compensation increase	2.30%	2.90%
United States \| Domestic plan
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.60%	4.10%
Expected long-term return on plan assets	7.00%	7.00%
Rate of compensation increase	4.00%	4.00%

Pension Benefit Plans (Fair Values Of Pension Plan Assets) (Details) - Pension benefit plans - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,896.7	$ 3,204.2
Quoted Prices in Active Market (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	674.6	829.0
Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	483.5	597.2
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,158.1	1,426.2
Cash and cash equivalents \| Quoted Prices in Active Market (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29.7	36.0
Cash and cash equivalents \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	29.7	36.0
Common stock \| Quoted Prices in Active Market (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	355.7	444.8
Common stock \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	355.7	444.8
Preferred stock \| Quoted Prices in Active Market (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4.6	6.7
Preferred stock \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4.6	6.7
Corporate bonds \| Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	76.8	113.3
Corporate bonds \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	76.8	113.3
Government issued \| Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32.8	37.5
Government issued \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	32.8	37.5
Mutual funds \| Quoted Prices in Active Market (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	284.6	341.5
Mutual funds \| Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	205.2	147.0
Mutual funds \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	489.8	488.5
Mutual funds \| Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	179.8	232.4
Insurance contracts \| Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	168.7	299.4
Insurance contracts \| Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	168.7	299.4
Insurance contracts \| Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	209.1	72.1
Common collective trusts \| Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	957.8	1,089.8
Venture capital, partnerships and other private investments \| Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 391.9	$ 383.7

Pension Benefit Plans (Benefit Payments That Reflect Expected Future Service) (Details) - Pension benefit plans $ in Millions	Dec. 31, 2018 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Expected future benefit payments, next 12 months	$ 222.5
Expected future benefit payments, in year two	226.5
Expected future benefit payments, in year three	225.9
Expected future benefit payments, in year four	228.4
Expected future benefit payments, in year five	230.5
Expected future benefit payments, thereafter	1,123.4
Non-U.S. plan
Defined Benefit Plan Disclosure [Line Items]
Expected future benefit payments, next 12 months	50.2
Expected future benefit payments, in year two	52.4
Expected future benefit payments, in year three	51.1
Expected future benefit payments, in year four	54.1
Expected future benefit payments, in year five	56.3
Expected future benefit payments, thereafter	308.7
United States \| Domestic plan
Defined Benefit Plan Disclosure [Line Items]
Expected future benefit payments, next 12 months	172.3
Expected future benefit payments, in year two	174.1
Expected future benefit payments, in year three	174.8
Expected future benefit payments, in year four	174.3
Expected future benefit payments, in year five	174.2
Expected future benefit payments, thereafter	$ 814.7

Other Postretirement Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018
Other postretirement benefits
Defined Benefit Plan Disclosure [Line Items]
Postretirement liability, noncurrent	$ (152)		$ (131)
Medical trend rate - initial	6.30%		6.00%
Medical trend rate - ultimate	4.50%		4.50%
Unrecognized prior service credits, before tax			$ 19
Unrecognized net prior service credits, net of tax			14
Unrecognized actuarial losses, before tax			(6)
Unrecognized actuarial losses, net of tax			(5)
Future amortization of prior service cost (credit)			(2)
Future amortization of prior service cost (credit), net of tax			$ (2)
ASU No. 2017-07
Defined Benefit Plan Disclosure [Line Items]
Effect of change in accounting principle on operating profit	$ (31)	$ (16)
Effect of change in accounting principle on net other income	31	16
ASU No. 2017-07 \| Other postretirement benefits
Defined Benefit Plan Disclosure [Line Items]
Effect of change in accounting principle on operating profit	2	3
Effect of change in accounting principle on net other income	$ (2)	$ (3)

Other Postretirement Employee Benefit Plans (Funded Status Of The Domestic Plans) (Details) - Other postretirement benefits - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Change in benefit obligation:
Benefit obligation at beginning of year	$ (167.3)	$ (174.6)
Service cost	(0.5)	(0.7)	$ (0.7)
Interest cost	(5.3)	(5.6)
Amendments, curtailments and other	1.1	(0.4)
Actuarial gain (loss)	9.5	(1.5)
Retiree contributions	(2.6)	(2.9)
Benefits paid	18.6	18.4
Benefit obligation at end of year	(146.5)	(167.3)	$ (174.6)
Change in plan assets:
Fair value of plan assets	0.0	0.0
Funded status	$ (146.5)	$ (167.3)

Other Postretirement Employee Benefit Plans (Weighted Average Assumptions Used To Determine Benefit Obligations) (Details) - Other postretirement benefits	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Discount rate	4.20%	3.50%
Medical trend rate - initial	6.00%	6.30%
Medical trend rate - grading period	19 years	20 years
Medical trend rate - ultimate	4.50%	4.50%

Other Postretirement Employee Benefit Plans (Effect Of One-Percentage-Point Change In Assumed Health Care Cost Trend Rates) (Details) - Other postretirement benefits $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Effect on the total of service and interest cost components, 1% increase	$ 0.3
Effect on the total of service and interest cost components, 1% decrease	(0.2)
Effect on postretirement medical benefit obligation, 1% increase	4.4
Effect on postretirement medical benefit obligation, 1% decrease	$ (3.7)

Other Postretirement Employee Benefit Plans (Components Of Net Periodic Benefit Cost) (Details) - Other postretirement benefits - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (0.5)	$ (0.7)	$ (0.7)
Interest cost	(5.3)	(5.6)
Amortization of net gain	0.0	0.1
Amortization of prior service (cost) credit	2.5	3.1
Net periodic pension benefit (cost)	$ (3.3)	$ (3.1)	$ (4.2)

Other Postretirement Employee Benefit Plans Other Postretirement Employee Benefit Plans (Disaggregation of Service Cost) (Details) - Other postretirement benefits - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (0.5)	$ (0.7)	$ (0.7)
Nonoperating income (expense), net	(2.8)	(2.4)	(3.5)
Net periodic pension benefit (cost)	(3.3)	(3.1)	(4.2)
Cost of sales
Defined Benefit Plan Disclosure [Line Items]
Service cost	(0.1)	(0.1)	(0.2)
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (0.4)	$ (0.6)	$ (0.5)

Other Postretirement Employee Benefit Plans (Benefit Payments That Reflect Expected Future Service) (Details) - Other postretirement benefits $ in Millions	Dec. 31, 2018 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Expected future benefit payments, next 12 months	$ 15.2
Expected future benefit payments, in year two	14.5
Expected future benefit payments, in year three	13.8
Expected future benefit payments, in year four	13.1
Expected future benefit payments, in year five	12.3
Expected future benefit payments, thereafter	$ 54.1

Income Taxes (Narrative) (Details) kr in Millions, $ in Millions			3 Months Ended	12 Months Ended			36 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2012 DKK (kr)	Dec. 31, 2015 USD ($)	Dec. 10, 2013 DKK (kr)
Net deferred tax liabilities	$ 2,311.2	$ 2,333.3	$ 2,311.2	$ 2,311.2	$ 2,333.3
Valuation allowance, deferred tax asset, change in amount				65.0
Basis differences in investments outside the U.S.	9,500.0		9,500.0	$ 9,500.0
Statutory federal income tax rate		21.00%		21.00%	35.00%	35.00%
TCJA, effect on income tax expense, transition tax				$ 40.0	$ 1,200.0
TCJA, effect on income tax expense, transition tax payable, term				7 years	8 years
TCJA, effect on income tax expense, transition tax payable, amount	180.0		180.0	$ 180.0
TCJA, effect on income tax expense, transition tax, provision of unrealizable credits				13.0
TCJA, effect on income tax expense, remeasured deferred tax assets and liabilities				$ 47.0	$ 1,200.0
Effective income tax rate				19.50%	16.00%	17.50%
Effective income tax rate reconciliation, other reconciling items, percent				(0.70%)	(5.00%)	(3.50%)
Income tax payments				$ 673.0	$ 689.0	$ 767.0
Employee service share-based compensation, tax benefit from exercise of stock options				57.0	85.0	99.0
Excess tax benefit from share-based compensation, operating activities				38.0	55.0
Adjustments to additional paid in capital, income tax benefit from share-based compensation						50.0
Excess tax benefit from share-based compensation, financing activities						50.0
Net operating loss carryforwards	653.0		653.0	653.0
Operating loss carryforwards, valuation allowances	252.0		252.0	252.0
Deferred tax assets, valuation allowances	389.6	$ 324.6	389.6	389.6	324.6
Gross unrecognized tax benefits	986.0	736.8	986.0	986.0	736.8	992.2		$ 990.2
Recognized potential interest and penalties				41.0	41.0	47.0
Unrecognized tax benefits that would impact effective tax rate	936.0		936.0	936.0
Entity \| United States
Net deferred tax liabilities	2,000.0	2,000.0	2,000.0	2,000.0	2,000.0
Entity \| International
Net deferred tax liabilities	277.0	301.0	277.0	277.0	301.0
Foreign tax authority
Income tax examination, amount of tax assessments	247.0		247.0	247.0					kr 1,600
Income tax examination, amount of potential additional tax assessments	146.0						kr 954
Income tax holiday, aggregate dollar amount				70.0	62.0	$ 61.0
Deferred tax asset, other
Deferred tax assets, valuation allowances	49.0		49.0	49.0
Continuing operations
Gross unrecognized tax benefits	986.0	737.0	986.0	986.0	737.0
Unrecognized tax benefits, net of offsetting indirect tax benefits	988.0	736.0	988.0	988.0	736.0
Unrecognized tax benefits, indirect tax benefits	117.0	104.0	117.0	117.0	104.0
Potential interest and penalties	(119.0)	$ (103.0)	(119.0)	(119.0)	$ (103.0)
Estimated reduction in unrecognized tax benefits within twelve months	(134.0)		(134.0)	(134.0)
Continuing operations \| General business and foreign tax credit
Tax credit carryforwards	241.0		241.0	241.0
Tax credit carryforward, valuation allowance	89.0		89.0	$ 89.0
IRS \| Domestic tax authority
Proposed adjustments to taxable income, self-insurance			$ 960.0
Proposed adjustments to taxable income, self-insurance, other	$ 1,700.0

Income Taxes (Earnings From Continuing Operations Before Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings from continuing operations before income taxes	$ 3,292.8	$ 2,938.8	$ 2,611.3
United States
Earnings from continuing operations before income taxes	914.2	927.2	647.7
International
Earnings from continuing operations before income taxes	$ 2,378.6	$ 2,011.6	$ 1,963.6

Income Taxes (Provision For Income Taxes From Continuing Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]
Federal U.S., current	$ 278.8	$ 448.3	$ 237.2
Non-U.S., current	494.3	457.2	542.9
State and local, current	63.9	(9.6)	61.7
Federal U.S., deferred	(157.2)	(424.7)	(237.5)
Non-U.S., deferred	(6.8)	(61.5)	(104.2)
State and local, deferred	(31.1)	59.3	(42.2)
Income tax provision	$ 641.9	$ 469.0	$ 457.9

Income Taxes (Deferred Income Tax Assets And Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Allowance for doubtful accounts	$ 19.7	$ 18.6
Inventories	81.2	95.9
Pension and postretirement benefits	222.7	250.6
Environmental and regulatory compliance	22.4	26.8
Other accruals and prepayments	223.7	345.8
Stock-based compensation expense	64.7	63.9
Tax credit and loss carryforwards	894.5	673.4
Valuation allowances	(389.6)	(324.6)
Total deferred tax asset	1,139.3	1,150.4
Deferred tax liabilities:
Property, plant and equipment	(90.0)	(63.4)
Insurance, including self-insurance	(564.0)	(696.2)
Basis difference in LYONs	(21.6)	(12.9)
Goodwill and other intangibles	(2,774.9)	(2,711.2)
Total deferred tax liability	(3,450.5)	(3,483.7)
Net deferred tax liability	$ (2,311.2)	$ (2,333.3)

Income Taxes (Reconciliation Of The Statutory Federal Income Tax Rate To The Effective Tax Rate) (Details)		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	21.00%	35.00%	35.00%
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes (net of federal income tax benefit)		0.90%	0.80%	0.60%
Foreign rate differential		(0.30%)	(11.60%)	(10.20%)
Resolution and expiration of statutes of limitation of uncertain tax positions		(1.70%)	(6.50%)	(3.10%)
Permanent foreign exchange losses		0.00%	(0.60%)	(8.20%)
Research credits, uncertain tax positions and other		(0.60%)	(1.00%)	3.40%
TCJA - revaluation of U.S. deferred income taxes		(1.40%)	(41.50%)	0.00%
TCJA - Transition Tax		1.60%	41.40%	0.00%
Effective income tax rate		19.50%	16.00%	17.50%

Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of year	$ 736.8	$ 992.2	$ 990.2
Additions based on tax positions related to the current year	43.1	53.0	80.0
Additions for tax positions of prior years	324.3	39.8	154.3
Reductions for tax positions of prior years	(21.9)	(14.5)	(7.0)
Acquisitions, divestitures and other	9.4	13.4	(41.5)
Lapse of statute of limitations	(52.9)	(246.7)	(124.0)
Settlements	(41.8)	(124.8)	(45.3)
Effect of foreign currency translation	(11.0)	24.4	(14.5)
Unrecognized tax benefits, end of year	$ 986.0	$ 736.8	$ 992.2

Nonoperating Income (Expense) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Income and Expenses [Abstract]
Other nonoperating income, net pension and postretirement benefits	$ 37.0	$ (31.0)	$ (16.0)
Proceeds from sales of investments	22.2	137.9	264.8
Receivable from sale of marketable securities		22.0
Marketable securities, realized gain		73.0	223.0
Marketable securities, after tax realized gain		$ 46.0	$ 140.0
Marketable securities, after-tax gain, per diluted share		$ 0.06	$ 0.20
Payments of debt extinguishment costs	0.0	$ 0.0	$ 188.1
Loss on early extinguishment of borrowings	$ 0.0	$ 0.0	(178.8)
Extinguishment of debt, gain, net of tax			$ (112.0)
Extinguishment of debt, gain, per share, net of tax			$ (0.16)

Productivity Improvement And Restructuring Initiatives (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges	$ 70.0	$ 159.1	$ 152.4
Employee severance and related charges	59.0	78.0	111.0
Facility exit and other related charges	11.0	81.0	30.0
Cash charges
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges	68.0	103.0	140.0
Noncash charges
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges	2.0	56.0	12.0
Operating segments \| Diagnostics
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges	14.9	85.4	62.2
Operating segments \| Diagnostics \| Molecular diagnostic product line
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges		76.0
Productivity improvement and restructuring related charges, after-tax		$ 51.0
Productivity improvement and restructuring related charges, after-tax, per diluted share		$ 0.07
Operating segments \| Diagnostics \| Molecular diagnostic product line \| Cash charges
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges		$ 27.0
Operating segments \| Diagnostics \| Molecular diagnostic product line \| Noncash charges
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges		49.0
Operating segments \| Excluding molecular diagnostic product line
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges		83.0
Operating segments \| Dental
Restructuring Cost and Reserve [Line Items]
Productivity improvement and restructuring related charges	$ 23.7	$ 35.8	34.3
Operating segments \| Dental \| Trade names
Restructuring Cost and Reserve [Line Items]
Impairment of trade name			$ 11.0

Productivity Improvement And Restructuring Initiatives (Schedule Of Restructuring And Other Related Charges By Segment) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 70.0	$ 159.1	$ 152.4
Operating segments \| Life Sciences
Restructuring Cost and Reserve [Line Items]
Costs incurred	11.4	25.4	40.5
Operating segments \| Diagnostics
Restructuring Cost and Reserve [Line Items]
Costs incurred	14.9	85.4	62.2
Operating segments \| Dental
Restructuring Cost and Reserve [Line Items]
Costs incurred	23.7	35.8	34.3
Operating segments \| Environmental & Applied Solutions
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 20.0	$ 12.5	$ 15.4

Productivity Improvement And Restructuring Initiatives (Schedule Of Restructuring And Related Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Reserve [Roll Forward]
Balance at beginning of year	$ 66.3	$ 57.1
Costs incurred	70.0	159.1	$ 152.4
Paid/settled	(89.1)	(149.9)
Balance at end of year	47.2	66.3	57.1
Employee severance and related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	49.0	45.3
Costs incurred	59.4	77.7
Paid/settled	(68.8)	(74.0)
Balance at end of year	39.6	49.0	45.3
Facility exit and related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	17.3	11.8
Costs incurred	10.6	81.4
Paid/settled	(20.3)	(75.9)
Balance at end of year	$ 7.6	$ 17.3	$ 11.8

Productivity Improvement And Restructuring Initiatives (Schedule Of Restructuring Reserve By Type Of Cost) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Costs incurred	$ 70.0	$ 159.1	$ 152.4
Cost of sales
Costs incurred	16.8	38.0	25.4
Selling, general and administrative expenses
Costs incurred	$ 53.2	$ 121.1	$ 127.0

Leases And Commitments (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Rent expense for operating leases	$ 282	$ 249	$ 220
Maximum
Lessee leasing arrangements, operating leases, term of contract (in years)	20 years

Leases And Commitments Leases And Commitments (Future Minimum Rental Payments) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating leases, future minimum rental payments, due in one year	$ 203.0
Operating leases, future minimum rental payments, due in two years	167.7
Operating leases, future minimum rental payments, due in three years	133.3
Operating leases, future minimum rental payments, due in four years	116.8
Operating leases, future minimum rental payments, due in five years	101.9
Operating leases, future minimum rental payments, due thereafter	$ 287.2

Leases And Commitments (Warranty Accrual) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at beginning of year	$ 79.0	$ 75.8
Accruals for warranties issued during the year	60.6	54.5
Settlements made	(60.0)	(56.6)
Additions due to acquisitions	0.0	1.7
Effect of foreign currency translation	(2.2)	3.6
Balance at end of year	$ 77.4	$ 79.0

Litigation And Contingencies (Narrative) (Details) $ in Millions	Dec. 31, 2018 USD ($)
Loss Contingency [Abstract]
Reserve for environmental matters	$ 147
Reserve for environmental matters, noncurrent	110
Guarantees	$ 668

Stock Transactions And Stock-Based Compensation (Narrative) (Details) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($)	Jul. 02, 2016	Jul. 16, 2013 shares
Repurchase of common stock authorized, shares \| shares					20,000
Stock repurchase program, remaining number of shares authorized to be repurchased, shares \| shares	20,000
Total number of authorized shares to be issued under the 2007 Omnibus Incentive Plan, shares \| shares	127,000
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan, shares \| shares	58,000
Aggregate intrinsic value of options exercised	$ 202	$ 162	$ 210
Cash receipts due to exercise of options	133	117	161
Employee service share-based compensation, tax benefit from exercise of stock options	57	85	99
Adjustments to additional paid in capital, income tax benefit from share-based compensation			50
Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount	$ 38	$ 55
Excess tax benefit from share-based compensation, financing activities			50
Aggregate number of shares withheld to satisfy tax requirement \| shares	400	600
Aggregate value of shares withheld to satisfy tax requirement	$ 41	$ 47
Fortive
Separation conversion factor				1.32
Stock options
Vesting period of shares (in years)	5 years
Stock option term (in years)	10 years
Total unrecognized compensation cost	$ 139
Weighted average period for cost to be recognized (in years)	3 years
Employee service share-based compensation, tax benefit from exercise of stock options	$ 40	50	61
RSUs/PSUs:
Vesting period of shares (in years)	5 years
Total unrecognized compensation cost	$ 149
Weighted average period for cost to be recognized (in years)	2 years
Employee service share-based compensation, tax benefit from exercise of stock options	$ 17	$ 35	$ 38
PSUs
Vesting period of shares (in years)	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Additional Holding Period	2 years

Stock Transactions And Stock-Based Compensation (Assumptions Used In The Black-Scholes Model To Value Options Granted) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average volatility	21.40%	17.90%	24.30%
Dividend yield	0.60%	0.70%	0.60%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.60%	1.80%	1.20%
Expected years until exercise	5 years	5 years	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.10%	2.20%	1.80%
Expected years until exercise	8 years	8 years	8 years

Stock Transactions And Stock-Based Compensation (Components Of Share-Based Compensation Program) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pretax compensation expense	$ 151.4	$ 139.4	$ 129.8
Income tax benefit	(31.8)	(43.3)	(38.9)
Total stock-based compensation expense, net of income taxes	119.6	96.1	90.9
RSUs/PSUs:
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pretax compensation expense	94.7	90.2	85.9
Income tax benefit	(19.8)	(27.7)	(25.3)
Total stock-based compensation expense, net of income taxes	74.9	62.5	60.6
Stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Pretax compensation expense	56.7	49.2	43.9
Income tax benefit	(12.0)	(15.6)	(13.6)
Total stock-based compensation expense, net of income taxes	$ 44.7	$ 33.6	$ 30.3

Stock Transactions And Stock-Based Compensation (Option Activity Under The Company's Stock Plans) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Options, Outstanding [Roll Forward]
Outstanding at beginning of year, options	18.8	18.9	24.9
Granted, options	4.1	4.4	5.7
Exercised, options	(3.4)	(3.3)	(5.3)
Cancelled/forfeited, options	(0.9)	(1.2)	(1.2)
Adjustment due to Fortive Separation, options			(5.2)
Outstanding at end of year, options	18.6	18.8	18.9
Weighted Average Exercise Price, Outstanding [Roll Forward]
Outstanding as of beginning of year, weighted average exercise price	$ 59.84	$ 50.07	$ 43.75
Granted, weighted average exercise price	99.51	86.14	67.52
Exercised, weighted average exercise price	41.88	35.26	33.45
Cancelled/forfeited, weighted average exercise price	80.14	70.40	73.21
Adjustment due to Fortive Separation, weighted average exercise price			50.44
Outstanding as of end of year, weighted average exercise price	$ 70.86	$ 59.84	$ 50.07
Vested and expected to vest at end of year, options	18.0
Vested at end of year, options	7.7
Vested and expected to vest at end of year, weighted average exercise price	$ 70.24
Vested at end of year, weighted average exercise price	$ 53.19
Outstanding at end of year, weighted average remaining contractual term (in years)	7 years
Vested and expected to vest at end of year, weighted average remaining contractual term (in years)	7 years
Vested at end of year, weighted average remaining contractual term (in years)	5 years
Outstanding at end of year, aggregate intrinsic value	$ 600.8
Vested and expected to vest at end of year, aggregate intrinsic value	592.8
Vested at end of year, aggregate intrinsic value	$ 383.3

Stock Transactions And Stock-Based Compensation (Summary Of Options Outstanding) (Details) shares in Millions	12 Months Ended
	Dec. 31, 2018 $ / shares shares
$19.89 to $39.60
Options, exercise price, lower range limit	$ 19.89
Options, exercise price, upper range limit	$ 39.60
Outstanding, shares (in millions) \| shares	2.1
Outstanding, average exercise price	$ 34.15
Outstanding, average remaining life (in years)	2 years
Exercisable, shares (in millions) \| shares	2.0
Exercisable, average exercise price	$ 34.13
$39.61 to $56.70
Options, exercise price, lower range limit	39.61
Options, exercise price, upper range limit	$ 56.70
Outstanding, shares (in millions) \| shares	2.5
Outstanding, average exercise price	$ 48.73
Outstanding, average remaining life (in years)	4 years
Exercisable, shares (in millions) \| shares	2.3
Exercisable, average exercise price	$ 48.15
$56.71 to $70.75
Options, exercise price, lower range limit	56.71
Options, exercise price, upper range limit	$ 70.75
Outstanding, shares (in millions) \| shares	6.1
Outstanding, average exercise price	$ 64.58
Outstanding, average remaining life (in years)	6 years
Exercisable, shares (in millions) \| shares	2.6
Exercisable, average exercise price	$ 63.64
$70.76 to $86.08
Options, exercise price, lower range limit	70.76
Options, exercise price, upper range limit	$ 86.08
Outstanding, shares (in millions) \| shares	3.9
Outstanding, average exercise price	$ 85.13
Outstanding, average remaining life (in years)	8 years
Exercisable, shares (in millions) \| shares	0.7
Exercisable, average exercise price	$ 84.37
$86.09 to $101.65
Options, exercise price, lower range limit	86.09
Options, exercise price, upper range limit	$ 101.65
Outstanding, shares (in millions) \| shares	4.0
Outstanding, average exercise price	$ 99.23
Outstanding, average remaining life (in years)	9 years
Exercisable, shares (in millions) \| shares	0.1
Exercisable, average exercise price	$ 95.44

Stock Transactions And Stock-Based Compensation (Summary Of Unvested RSU And PSU Activity) (Details) - RSUs/PSUs: - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested at beginning of year, number of RSUs/PSUs	3.9	4.5	6.1
Granted, number of RSUs/PSUs	1.5	1.4	1.9
Vested, number of RSUs/PSUs	(1.2)	(1.5)	(1.8)
Adjustment due to Fortive Separation, number of RSUs/PSUs			(1.2)
Forfeited, number of RSUs/PSUs	(0.3)	(0.5)	(0.5)
Unvested at end of year, number of RSUs/PSUs	3.9	3.9	4.5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Unvested at beginning of year, weighted average grant-date fair value	$ 71.27	$ 62.16	$ 53.93
Granted, weighted average grant-date fair value	99.15	86.04	66.15
Vested, weighted average grant-date fair value	68.37	58.48	50.64
Adjustment due to Fortive Separation, weighted average grant-date fair value			58.24
Forfeited, weighted average grant-date fair value	78.41	68.83	28.79
Unvested at end of year, weighted average grant-date fair value	$ 82.21	$ 71.27	$ 62.16

Net Earnings Per Share From Continuing Operations (Narrative) (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Options excluded from diluted earnings per share calculation (anti-dilutive)	1	4	1

Net Earnings Per Share From Continuing Operations (Components Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 31, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share Reconciliation [Abstract]
Basic EPS, net earnings from continuing operations, numerator	$ 746.8	$ 663.7	$ 673.8	$ 566.6	$ 856.6	$ 572.1	$ 557.3	$ 483.8	$ 2,650.9	$ 2,469.8	$ 2,153.4
Adjustment for interest on convertible debentures, net earnings from continuing operations (numerator)									2.2	2.1	1.8
Diluted EPS, net earnings from continuing operations (numerator)									$ 2,653.1	$ 2,471.9	$ 2,155.2
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic EPS, shares (denominator)									700.6	695.8	691.2
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs, shares (denominator)									7.2	7.5	6.0
Incremental shares from assumed conversion of the convertible debentures, shares (denominator)									2.4	2.8	2.6
Diluted EPS, shares (denominator)									710.2	706.1	699.8
Basic EPS	$ 1.06	$ 0.95	$ 0.96	$ 0.81	$ 1.23	$ 0.82	$ 0.80	$ 0.70	$ 3.78	$ 3.55	$ 3.12
Diluted EPS	$ 1.05	$ 0.93	$ 0.95	$ 0.80	$ 1.21	$ 0.81	$ 0.79	$ 0.69	$ 3.74	$ 3.50	$ 3.08

Segment Information (Narrative) (Details) - Reporting_Unit	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2016
Segment Reporting [Abstract]
Number of segments	4	4

Segment Information (Segment Results) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 31, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Sales	$ 5,363.5	$ 4,853.1	$ 4,981.0	$ 4,695.4	$ 5,085.7	$ 4,528.2	$ 4,510.1	$ 4,205.7	$ 19,893.0	$ 18,329.7	$ 16,882.4
Operating profit	962.6	$ 830.7	$ 867.5	$ 743.0	937.5	$ 759.2	$ 676.7	$ 617.0	3,403.8	2,990.4	2,735.2
Identifiable assets	47,832.5				46,648.6				47,832.5	46,648.6	45,295.3
Depreciation and amortization									1,307.7	1,238.3	1,128.1
Capital expenditures, gross									655.7	619.6	589.6
Operating segments \| Life Sciences
Segment Reporting Information [Line Items]
Sales									6,471.4	5,710.1	5,365.9
Operating profit									1,229.3	1,004.3	818.9
Identifiable assets	22,122.4				20,576.8				22,122.4	20,576.8	19,875.9
Depreciation and amortization									471.2	427.9	426.2
Capital expenditures, gross									140.1	130.6	109.7
Operating segments \| Diagnostics
Segment Reporting Information [Line Items]
Sales									6,257.6	5,839.9	5,038.3
Operating profit									1,073.8	871.6	786.4
Identifiable assets	14,031.1				14,359.2				14,031.1	14,359.2	14,159.6
Depreciation and amortization									589.0	581.5	481.5
Capital expenditures, gross									380.0	372.6	374.3
Operating segments \| Dental
Segment Reporting Information [Line Items]
Sales									2,844.5	2,810.9	2,785.4
Operating profit									346.7	400.7	419.4
Identifiable assets	5,897.3				6,026.8				5,897.3	6,026.8	5,772.2
Depreciation and amortization									130.0	121.4	127.2
Capital expenditures, gross									72.2	48.9	49.1
Operating segments \| Environmental & Applied Solutions
Segment Reporting Information [Line Items]
Sales									4,319.5	3,968.8	3,692.8
Operating profit									988.0	914.6	870.0
Identifiable assets	4,637.3				4,649.2				4,637.3	4,649.2	4,172.9
Depreciation and amortization									109.0	99.9	86.7
Capital expenditures, gross									57.1	60.9	51.0
Other
Segment Reporting Information [Line Items]
Operating profit									(234.0)	(200.8)	(159.5)
Identifiable assets	$ 1,144.4				$ 1,036.6				1,144.4	1,036.6	1,314.7
Depreciation and amortization									8.5	7.6	6.5
Capital expenditures, gross									$ 6.3	$ 6.6	$ 5.5

Segment Information (Schedule Of Operations In Geographical Areas) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 31, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales	$ 5,363.5	$ 4,853.1	$ 4,981.0	$ 4,695.4	$ 5,085.7	$ 4,528.2	$ 4,510.1	$ 4,205.7	$ 19,893.0	$ 18,329.7	$ 16,882.4
Property, plant and equipment, net	2,511.2				2,454.6				2,511.2	2,454.6	2,354.0
Reportable geographical components \| United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales									7,374.4	6,837.9	6,377.4
Property, plant and equipment, net	1,224.4				1,126.2				1,224.4	1,126.2	1,198.4
Reportable geographical components \| China
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales									2,357.3	2,011.6	1,799.1
Reportable geographical components \| Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales									1,247.0	1,161.6	1,084.6
Property, plant and equipment, net	198.3				212.4				198.3	212.4	190.8
Reportable geographical components \| Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales									918.7	872.1	864.7
Reportable geographical components \| United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	157.0				152.0				157.0	152.0	140.6
Reportable geographical components \| All other (each country individually less than 5% of total)
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales									7,995.6	7,446.5	6,756.6
Property, plant and equipment, net	$ 931.5				$ 964.0				$ 931.5	$ 964.0	$ 824.2
Geographic concentration risk \| Reportable geographical components \| Total sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage									5.00%	5.00%	5.00%
Geographic concentration risk \| Reportable geographical components \| Total property, plant and equipment
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage									5.00%	5.00%	5.00%

Segment Information (Sales By Major Product Group) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 31, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Sales	$ 5,363.5	$ 4,853.1	$ 4,981.0	$ 4,695.4	$ 5,085.7	$ 4,528.2	$ 4,510.1	$ 4,205.7	$ 19,893.0	$ 18,329.7	$ 16,882.4
Analytical and physical instrumentation
Sales									2,437.0	2,232.9	2,088.9
Research and medical products
Sales									12,686.0	11,512.4	10,366.7
Dental products
Sales									2,844.5	2,810.9	2,785.4
Product Identification
Sales									$ 1,925.5	$ 1,773.5	$ 1,641.4

Quarterly Data-Unaudited (Schedule Of Quarterly Data) (Details) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 31, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Sales

$ 5,363.5

$ 4,853.1

$ 4,981.0

$ 4,695.4

$ 5,085.7

$ 4,528.2

$ 4,510.1

$ 4,205.7

$ 19,893.0

$ 18,329.7

$ 16,882.4

Gross profit

2,955.9

2,690.5

2,817.1

2,643.6

2,839.1

2,536.8

2,482.3

2,334.3

11,107.1

10,192.5

9,334.6

Operating profit

962.6

830.7

867.5

743.0

937.5

759.2

676.7

617.0

3,403.8

2,990.4

2,735.2

Net earnings from continuing operations

746.8

663.7

673.8

566.6

856.6

572.1

557.3

483.8

2,650.9

2,469.8

2,153.4

Earnings from discontinued operations, net of income taxes

0.0

22.3

0.0

22.3

400.3

Net earnings

$ 746.8

$ 663.7

$ 673.8

$ 566.6

$ 856.6

$ 572.1

$ 557.3

$ 506.1

$ 2,650.9

$ 2,492.1

$ 2,553.7

Net earnings per share:

Net earnings per share from continuing operations, basic

$ 1.06

$ 0.95

$ 0.96

$ 0.81

$ 1.23

$ 0.82

$ 0.80

$ 0.70

$ 3.78

$ 3.55

$ 3.12

Net earnings per share from continuing operations, diluted

1.05

0.93

0.95

0.80

1.21

0.81

0.79

0.69

3.74

3.50

3.08

Net earnings per share from discontinued operations, basic

0.00

0.03

0.00

0.03

0.58

Net earnings per share from discontinued operations, diluted

0.00

0.03

0.00

0.03

0.57

Basic

1.06

0.95

0.96

0.81

1.23

0.82

0.80

0.73

3.78

3.58

3.69

^[1]

Diluted

$ 1.05

$ 0.93

$ 0.95

$ 0.80

$ 1.21

$ 0.81

$ 0.79

$ 0.72

$ 3.74

$ 3.53

$ 3.65

[1]	*Net earnings per share amount does not add due to rounding.

Schedule II - Valuation And Qualifying Accounts (Details) - Allowance for Doubtful Accounts - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 118.2	$ 103.5	$ 89.7
Charged to costs & expenses	35.9	32.9	32.5
Impact of Currency	(4.5)	4.5	(0.6)
Charged to other accounts	1.3	3.5	2.3
Write-offs, write-downs & deductions	(29.3)	(26.2)	(20.4)
Balance at end of period	$ 121.6	$ 118.2	$ 103.5

Revenue Revenue (Revenue Disaggregation by Geographical Region and Revenue Type) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 19,893.0
North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	7,820.1
Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	4,720.8
Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,254.7
High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	6,097.4
Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	13,723.6
Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	6,169.4
Operating segments \| Life Sciences
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	6,471.4
Operating segments \| Life Sciences \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,295.6
Operating segments \| Life Sciences \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,846.7
Operating segments \| Life Sciences \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	570.0
Operating segments \| Life Sciences \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,759.1
Operating segments \| Life Sciences \| Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	4,131.8
Operating segments \| Life Sciences \| Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,339.6
Operating segments \| Diagnostics
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	6,257.6
Operating segments \| Diagnostics \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,403.4
Operating segments \| Diagnostics \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,155.4
Operating segments \| Diagnostics \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	379.1
Operating segments \| Diagnostics \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,319.7
Operating segments \| Diagnostics \| Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	5,272.0
Operating segments \| Diagnostics \| Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	985.6
Operating segments \| Dental
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,844.5
Operating segments \| Dental \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,350.4
Operating segments \| Dental \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	659.6
Operating segments \| Dental \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	179.9
Operating segments \| Dental \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	654.6
Operating segments \| Dental \| Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,039.8
Operating segments \| Dental \| Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	804.7
Operating segments \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	4,319.5
Operating segments \| Environmental & Applied Solutions \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,770.7
Operating segments \| Environmental & Applied Solutions \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,059.1
Operating segments \| Environmental & Applied Solutions \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	125.7
Operating segments \| Environmental & Applied Solutions \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,364.0
Operating segments \| Environmental & Applied Solutions \| Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	2,280.0
Operating segments \| Environmental & Applied Solutions \| Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 2,039.5